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ABSTRACT
Introduction: Osteoporosis is a common disease with a strong genetic component
and the collagen type I alpha I gene (COL1A1) is an important candidate for
susceptibility. Three single nucleotide polymorphisms (SNP) have been identified in
the 5' flank of the COLIA1 gene (-1997G/T; -1663IndelT and +1245G/T) which have
been associated with osteoporosis in various populations. The mechanisms by which
these SNP predispose to osteoporosis are unclear however.
Methods: I analyzed the effects of the individual SNPs and associated haplotypes on
bone mineral density (BMD) and risk of osteoporotic fracture in women in association
studies. I also studied associations between the SNPs, haplotypes and bone strength
ex-vivo by biomechanical testing of bone cores obtained from femoral heads of
patients undergoing surgery for hip fracture. The effects of the SNPs and haplotypes
on gene expression were studied using promoter-reporter assays and gel shift assays
were performed to investigate whether the SNPs were situated at transcription factor
binding sites and whether the polymorphic variants affected DNA protein binding. In
order to investigate the possible effects of the polymorphisms in vivo, gene targeting
constructs were prepared containing two common haplotypes and these were
transfected into ES cells.
Results: The individual polymorphisms were all associated with BMD, but the
haplotypes defined by all three SNPs showed a stronger association with BMD,
biomechanical strength of bone and hip fracture. Two haplotypes increased in
frequency with age suggesting an effect on survival. However these haplotypes were
particularly enriched in hip fracture patients. Biomechanical testing showed that all
three SNPs were strongly associated with reduced bone strength, independently of
BMD. Gel shift assays showed that the region surrounding the -1663insdelT
polymorphism recognized the nuclear binding proteins Spl, Nmp4 and Osterix and
the -1663delT allele had greater binding affinities for Nmp4 and Osterix than
-1663insT allele. The region surrounding the -1997 G/T polymorphism also
recognized DNA binding proteins but the polymorphism did not affect DNA protein
binding significantly. Reporter assays showed significant differences between the
ability of different haplotypes to drive gene expression and constructs containing
haplotype2 (G-delT-T) had the highest transcriptional activity (pO.OOl). Transgenic
constructs containing different 5' COL1A1 haplotypes were completed and
transformed into mouse embryonic stem cells by electroporation in an attempt to
iv
generate a disease model of osteoporosis associated with common variants in the
COLIA1 gene
Conclusion: The studies suggest that haplotypes, rather than individual
polymorphisms in the 5' flank of COL1A1 predispose to osteoporosis, by affecting
DNA protein interactions and gene expression.
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Bones provide structural support to the body; protect many internal organs from
injury and act as an important reservoir for calcium and phosphate in the regulation of
mineral homeostasis. The skeleton is made up of two different types of bone tissue
called cortical bone and trabecular bone. The cortical bone is a dense layer of
calcified tissue which covers the external surface of long bones. Within cortical bone
there are neurovascular channels known as "Haversian canals", each one of which
contains blood vessels and nerve fibres surrounded by concentric rings (lamellae) of
bone matrix. Trabecular bone is metabolically more active than cortical bone and it is
found mainly in the vertebrae, pelvis, flat bones and the end of long bones. It is made
up of an interconnecting network of bone tissue interspaced with irregular cavities
that contain red and yellow marrow, bone cells and other cell types. The most
abundant protein in bone is type I collagen, a fibrillar protein composed of two
identical alphal polypeptides and one alpha2 polypeptide bound to form a triple helix.
Collagen comprises 90% of the protein in bone matrix and the fibres are organized in
a preferential orientation to give a high density of collagen per unit of bone. The
remaining 10% of bone matrix proteins consist of various non-col lagenous proteins
and glycoproteins which are thought to play an important role in bone mineralization
and in regulating bone cell activity. The inorganic content of bone is composed
mostly of calcium hydroxyapatite crystals (Caio(PC>4)6(OH)2) which confer properties
of hardness and rigidity. The main cellular components of bone are osteoblasts (bone-




1.1.2 Osteoclasts and Bone Resorption
Osteoclasts are giant multinucleated cells derived from cells of the monocyte-
macrophase lineage. Differentiation of osteoclasts from heamatopoietic precursor
cells requires many key factors (Figure 1.1). The transcription factor PU-1 is
necessary to commit the precursors into the myeloid lineage at early stage by binding
to the promoter region of Csflr (encoding M-CSF receptor) and positively regulating
transcription (Zhang DE et al, 1994). Mice deficient in PU-1 display an osteopetrosis
(op) phenotype similar to the op/op mice (Tondravi MM et al, 1997). Further
differentiation of the osteoclast progenitor cells is controlled by macrophage colony
stimulating factor (M-CSF). M-CSF binds to its receptor, c-fms, to simulate
differentiation and proliferation of haematopoietic precursor cells to macrophage
colony-forming units (CFU-M) which are the common precursors of macrophages
and osteoclasts. At this stage, these factors are essential for stimulating differentiation
and activation of mature osteoclasts including the Nuclear factor Kappa B (NF-kB,
Franzoso G et al, 1997 & Iotsova V et al, 1997), the Receptor for Activation of NF-
kB (RANK, Dougall WC et al, 1999 & Li J et al, 2000)), the RANK Ligand (RANKL,
Kong YY et al, 1999), Tumor Necrosis Factor (TNF) receptor associated factor 6
(TRAF6, Lomaga MA et al, 1999 &Kobayashi T et al, 2003), Nuclear Factor of
Activated T-cell, cytoplasmic, calcineurin-dependent 1 (NFATcl, Asagiri M et al,
2005), c-fos (Johnson RS et al, 1992 & Wang ZQ et al, 1992), and Fc receptor
common y subunit (FcRy) / DNAX-activating protein (DAP) 12 (Koga T et al, 2004
& Mocasai A et al, 2004). The deficiency of any of these factors leads to the loss of
multinucleated osteoclasts causing severe osteopetrosis despite a normal or increased
number of monocyte/macrophages. For example, Koga T et al (2004) showed that
mice lacking FcRy and DAP 12 exhibited severe osteopetrosis due to impaired
3
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osteoclast differentiation. FcRy and DAP12 are required for the induction ofNFATcl,
which is the crucial step in the RANKL-induced osteoclast differentiation through
activation of calcium signaling.
Figure 1.1 Mechanism of osteoclast differentiation and osteoclastic bone resorption.
The close contact between osteoclast precursors and stromal cells or osteoblasts is
also important in osteoclastogenesis. The osteoblasts express RANKL, M-CSF and a
decoy RANK receptor, osteoprotegerin (OPG). OPG blocks the interaction of RANK
(expressed on the membrane of osteoclast) and RANKL by competitively binding to
RANKL resulting in inhibition of osteoclast formation (Figure 1.1). It was found that
mice lacking OPG have accelerated osteoclastogenesis and develop severe
osteoporosis (Simonet et al, 1997). RANKL is also expressed in abundance by
activated T lymphocytes, which can directly trigger osteoclastogenesis and are
probably pivotal to the joint destruction in rheumatoid arthritis (Kong YY et aL 1999).
Therefore, the balance between the expression of the stimulator of osteoclastogenesis
(RANKL) and of the inhibitor (OPG), influences osteoclast formation and hence bone
4
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resorption (Teitelbaum SL, 2000). In fact, most osteoclastogenic factors such as
parathyroid hormone (PTH), tumour necrosis factor (TNF), and Interleukin-1 (IL-1)
exert their effects mainly by regulating the expression of RANK, RANKL, OPG and
M-CFS. It is clear that PTH stimulates osteoclastogenesis and the activity of mature
osteoclasts by increasing M-CSF (Suda T et al, 1999) and RANKL (Yasuda H et al,
1998) and inhibiting OPG (Horwood NJ et al, 1998). TNF-a and IL-1 also stimulate
bone resorption primarily by stimulating M-CSF production and by directly
increasing RANKL expression (Walsh MC & Choi Y, 2003).
The mature osteoclasts exert their effects on bone resorption. Osteoclasts attach to the
mineralized bone surface by forming a tight seal which creates an isolated
extracellular microenvironment known as Howship's lacuna (Figure 1.1). A ruffled
border with dense patches on each site (sealing zone) also forms along the plasma
membrane facing the mineralized surface of bone (Figure 1.1). The importance of the
ruffled border was demonstrated in mice with a targeted disruption of the c-Src proto-
oncogene, which developed osteopetrosis due to non-functional osteoclasts (Soriano P
et al, 1991). Subsequent experiments showed that Src-deficient mice have
multinuclear osteoclasts which attach to bone via a normal sealing zone, but the
osteoclasts lack a ruffle border (Boyce BF et al, 1992 & Lowe C et al, 1993).
Demineralization of bone matrix is initiated by acidification of the isolated
extracellular microenvironment via a vacuolar H+ -adenosine triphosphatase (H+ -
ATPase) and CF channel in the cell's ruffled membrane. This acidic milieu first
mobilizes bone matrix by digestion and dissolving the hydroxyapatite crystals. Then,
the demineralized organic component of bone is degraded by collagenase or a
lysosomal protease, Cathepsin K at low pH.
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The matrix-degradation products are endocytosed by the osteoclast and transported to
and released at the cell surface opposite to the ruffled border (Nesbitt & Horton,
1997). Therefore, bone resorption helps to maintain calcium and inorganic phosphate
levels in the plasma and the concentration of hydroxyproline and N-terminal or C-
terminal collagen peptide fragments in the serum or urine can be used as indirect
measurements of bone resorption.
Several proteins are directly involved in the regulation of this resorption process, such
as CLC-7 (iCLCN7, Kornak U et al, 2001), Atp6i (TCIRG1, Li YP et al, 1999 &
Frattini A et al, 2000) and Cathepsin K (Saftig P et al, 1998; Gowen M et al, 1999 &
Kiviranta R et al, 2005). Mice deficient in these molecules have osteoclasts with no or




1.1.3 Osteoblasts and Bone Formation
Osteoblasts are cuboidal bone cells responsible for the production of the bone matrix
and they are derived from mesenchymal stem cells. Undifferentiated mesenchymal
stem cells are capable of differentiating into many cell types including chondrocytes,
adipocytes, myoblasts, stromal cells and fibroblasts. As shown in figure 1.2, these
precursors also undergo proliferation and differentiation into preosteoblasts and
mature osteoblasts under the influence of local growth factors such as Wnt pathway
proteins, and essential transcription factors such as runt-related transcription factor 2
(Runx2) and Osterix (Ducy P et al, 1997; Nakashima K et al, 2002).
The critical role of Runx2, also known as Cbfal (Core-binding factor a 1), in
osteoblast differentiation was revealed by in vivo studies ofRunx2 null-mutant mice
that had a cartilaginous skeleton with complete absence of osteoblasts (Komori, T et
al, 1997 & Otto F et al, 1997). Runx2 regulates the expression of genes that are
specific to the osteoblast phenotype such as osteocalcin and alkaline phosphatase
(Ducy P et al, 1997). Thus, Runx2 is the earliest and most specific marker of
osteogenesis. Osterix acts downstream of Runx2 during osteoblastic differentiation.
Osx-null mice develop a perfectly patterned skeleton composed of normal cartilage,
lacking osteoblasts and mineralized bone matrix (Nakashima K et al, 2002).
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High levels of canonical Wnt signaling (as determined by levels of P-catenin) with the
presence of transcription factors Runx2 and Osterix are essential for
osteoblastogenesis (adapted from Glass DA 2nd & Karsenty G, 2007).
Mature osteoblasts synthesize the various organic components of bone matrix,
including the major product, type I collagen and a variety of noncollagenous proteins.
Two of these noncollagenous proteins are useful serum markers of osteoblastic
activity, and hence, bone formation in metabolic disease. One product is alkaline
phosphatase (ALP), a metalloprotein essential for mineralization. ALP deficiency, as
in the disease hypophosphatasia, results in defective mineralization of bone and teeth
(Whyte MP, 1994). Osteocalcin is another noncollagenous protein and widely
accepted as a clinical marker of bone turnover, as osteocalcin is incorporated into the
bone matrix and released into the circulation during bone resorption. Osteocalcin is
thought to inhibit the mineral deposition, as osteocalcin-deficient mice are shown to
have increased BMD compared with normal mice (Ducy P et al, 1996). However, the
precise role of osteocalcin remains unclear. Regarding the major synthetic product of
osteoblasts, type I collagen, its degradation products are used as markers of bone
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resorption, whereas levels of collagen propeptides are used as markers of bone
formation.
Importantly, the osteoblast has receptors for parathyroid hormone (Karaplis AC &
Goltzman D, 2000), prostaglandins, estrogen, vitamin D3 and several cytokines.
Steroid and polypeptide hormones regulate the growth of osteoprogenitors and/or
their progression to mature osteoblasts. PTH increases bone formation in vivo by
increasing the number of the osteoprogenitor cells (Aubin JE & Heersche JNM, 2001),
decreasing apoptosis of preosetoblasts and osetoblasts (Jilka RL et al, 1999), and
increasing osteoblast proliferation (Canalis E et al, 1989), whereas in vitro
experiments showed that PTE! stops preosteoblasts from becoming mature osteoblasts
and inhibits the production of collagen and other matrix proteins (Tintut Y et al,
1999).
Osteoblasts are also a major source of the Colony Stimulating Factor 1 (CSF-1) and
secrete some cytokines, such as RANKL and OPG, which regulate osteoclastogenesis.
Mature osteoblasts form new bone by secreting unmineralized bone matrix (called
osteoid) which subsequently undergoes calcification (the osteoid maturation period)
by deposition of hydroxyapatite crystals (Baron R, 1999). Osteoblasts do not function
individually, but form a group of cells at the uncalcified bone matrix that they are
producing. Behind the osteoblasts one or two layers of cells can usually be found:
activated mesenchymal cells and preosteoblasts. Once osteoblasts become surrounded
by bone matrix, some of these cells differentiate into osteocytes, whereas others
differentiate into flat lining cells which cover the bone surface. Osteocytes are the
most abundant cell type in bone and are thought to act as sensors ofmechanical strain
in bone (Ehrlich PJ & Lanyon LE, 2002).
9
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1.1.4 Bone Remodelling and its regulation
Bone is constantly undergoing a process of bone removal and repair termed bone
remodelling which is mediated by complex interactions between osteoclasts,
osteoblasts and their precursors. This process is essential in maintaining the
mechanical integrity of the skeleton by which damaged or weak bone is replaced by
new bone. There are four sequential events involved in this bone remodelling process:
quiescence, resorption, reversal, and formation which are shown in Figure 1.3 (Baron
R, 1999).


















Bone formation and bone resorption are tightly coupled, and the total amount of bone
in the skeleton is determined by the balance between these two processes. During
early stages of skeletal growth until peak bone mass is achieved in early adulthood,
the rate of bone remodelling is high with bone formation exceeding resorption.
Between the age of 20-40 peak bone mass is achieved and resorption equals formation.
Following this, bone is removed more rapidly than new bone tissue is laid down,
resulting in a steady decrement in bone mass with age and an increased risk for
osteoporosis. This process occurs in both sexes, but men and women are affected
differently. At the time of the menopause women lose bone more rapidly due to
estrogen deficiency, which causes uncoupling of bone formation and resorption. After
that, the loss slows down, but continues. In men the loss of bone mass is slower. But
by age 65 or 70 men and women are losing bone at the same rate.
However, in diseases such as primary hyperparathyroidism, hyperthyroidism and
Paget's disease, osteoclast-mediated bone resorption is activated with subsequent
compensatory increased new bone formation, resulting in a disorganized mosaic of
woven and lamellar bone, which is more susceptible to deformity or fracture than
normal bone. Therefore, the balance between bone formation and resorption in the
remodeling process is very important in maintaining skeletal integrity.
Bone remodeling is under the control of several systemic hormones, locally produced
cytokines and growth factors. IL-6, a pleiotropic cytokine, is expressed and secreted
by osteoblast, osteoclast and stromal cells in response to osteotropic hormones such as
PTH, l,25(OH)2-D3, and IL-1. IL-6 has important effects on bone remodeling by
stimulating bone resorption (Moonga BS et al, 2002) but also by promoting osteoblast
generation in conditions of high bone turnover (Sims NA et al, 2004).
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TGF-P inhibits osteoblast differentiation yet stimulates the proliferation of
mesenchymal progenitors, thereby expanding the cell population that will differentiate
into osteoblasts (Alliston TN & Derynck R, 2000). TGF-P also has a fundamental role
in the control of bone resorption, because it directly enables osteoclast formation by
antagonising inflammatory signalling (Fox SW et al, 2000a; Fox SW et al, 2003 &
Lovibond AC et al, 2003), and indirectly suppresses osteoclast formation thorough its
ability to regulate RANKL/OPG expression (Murakami et al, 1998; Thirunavukkarasu
et al, 2001 & Quinn et al, 2001). During bone remodelling, low levels of TGF-p
stimulate osteoclast formation. But with continuous release of TGF-P from bone
matrix during the resorption process, TGF-P inhibits osteoclast activity and stimulates
the proliferation of osteoblasts to initiate formation of new bone. Therefore, TGF-P
acts as a central component coupling bone formation prior to resorption during bone
remodeling.
Mechanical stimuli are also thought to have an effect on initiation of bone remodeling
and determining the site at which remodeling occurs. It has been proposed that not
only the mechanical stimuli directly deform bone matrix and cells, but also the
changes in interstitial fluid flow stimulate osteocytes, which occurs when a load is




The strength of bone depends on its mass but also on the structure and material
properties of the bone tissue. Currently, the most commonly used tool for diagnosing
osteoporosis is measurement ofBMD by dual-energy X-ray absorptiometry (DXA) at
the spine, wrist, or proximal femur. However, BMD in itself is not sufficient to
accurately predict fracture risk or monitor treatment effects of an anti-osteoporosis
drug, as it does not measure variations in bone quality (structure and material
properties) which may alter bone strength independently of its mass.
There are a number of biomechanical parameters used to describe bone quality. The
key relationship between these parameters is the force-displacement curve resulting
from a mechanical test of loading a bone specimen until it breaks (Turner CH & Burr
DB, 1993; Turner CH, 2002; Figure 1.4). Each of these parameters reflects a different
property of bone: ultimate force reflects the general integrity of the bone structure;
stiffness is the primary property of bone and closely related to the mineralization of
the bone; toughness is the amount of energy necessary to break the bone and
determined by the collagen phase of bone matrix; and ultimate displacement is
inversely related to the brittleness of the bone (Felsenberg D & Boonen S, 2005).
Therefore, the material properties of bone play an important role in improving the
overall bone strength. The most obvious clinical example of the mechanical effects of
a collagen defect is osteogenesis imperfecta (01). OI is a family of heritable disorders
caused by mutations in the type I collagen genes (COL1A1 & COL1A2 genes) (Byers
PH, 2001; Byers PH & Cole WG, 2002; Rowe DW, 1991). People with OI have a
markedly increased risk of multi-fractures at a young age, which results from a
combination of poor material properties of bone (abnormal quantity and structure of
type I collagen), with low bone density and thin long bone cortices.
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The height of the curve represents strength (the maximum load the material can
sustain); the area under the curve is toughness (the energy required to break the
material) and resilience (stored elastic energy); and the maximum slope of the curve is
stiffness (initial reaction to a load, a factor important for bending and buckling),
(adapted from Felsenberg D & Boonen S, 2005)
In addition to the bone mass and material properties, structural properties of bone also
contribute to bone strength. In general, the size of bone appears to have an effect on
overall fragility. Large, dense bones are less susceptible to osteoporosis and fractures
than small bones. Smaller vertebral bone size has been found in patients with spine
fracture who had the same area BMD as matched controls (Silva M.1 & Gibson LJ,
1997). Whereas in patients with high bone mass (about 5SDs above normal) caused
by mutations in the LPR5 gene, individuals are protected from osteoporotic fractures
(Little RD et al, 2002).
In long bones, the differences in the extent of periosteal apposition and endocortical
resorption during growth and aging contribute to differences in bone strength, because
these differences in the long bone structure lead to variations in the diameter and
cortical thickness of bone and to the distance of cortical mass from the neutral axis.
14
Chapter 1: Introduction
For example, mechanical loading preferentially increases periosteal bone formation in
the region where mechanical stresses are highest to increase the bone mechanical
strength. Moreover, the increased periosteal bone formation also could compensate by
increasing bone rigidity when endosteal resoption is stimulated by the effect of aging
(Turner CH, 2006).
Differences in bone dimensions also contribute to sex-based and race-based
differences in bone strength. For instance, men and women generally have similar
vertebral trabecular volumetric density and similar vertebral heights, but men have
larger vertebral cross-sectional area which correlates with higher bone strength.
Therefore, bone strength is not only determined by its mass, but also bone quality
such as material and structural properties. All these properties can be altered by the
bone remodeling process to adapt to the prevailing loads. When the adaptation fails,




Osteoporosis is a complex disease characterized by loss of bone mass, micro¬
architectural deterioration of bone tissue, enhanced bone fragility and an increased
fracture risk. Clinically, osteoporosis is recognized by the occurrence of low trauma
fractures, most commonly at the hip, spine, and distal forearm. It is an important
public health issue because about 50% ofwomen and 20% ofmen older than 50 years
in the white population will have a fragility fracture in their remaining lifetime
(Department of Health and Human Services, 2004). The combined annual costs of all
osteoporotic fractures have been estimated to be $20 billion in the USA and about $30
billion in the European ETnion (Cummings SR & Melton LJ, 2002). In the UK, the
lifetime risk of symptomatic fracture for a 50 year old white woman has been
estimated as 13% for the forearm, 11% for the vertebrae and 14% for the femoral
neck. The annual cost to the NHS of managing osteoporotic fractures is £1.7 billion,
with over 90% of this figure attributable to hip fracture (http://www.mrc.soton.ac.uk/).
Osteoporotic fractures result from a combination of decreased BMD and deterioration
in bone microarchitecture. There is a strong relationship between bone mass and
fracture risk: for every standard deviation (SD) decrease in BMD, the risk of
osteoporotic fracture increases by a factor of 1.5-2. The causes of osteoporosis include
low peak bone mass, rapid bone loss at the menopause and accelerated bone loss due
to diseases or drugs. Other factors such as diet (calcium intake and alcohol
consumption), life style (smoking, physical activity and mechanical loading) also
influence the risk of osteoporosis.
As described in section 1.1.4, bone mass increases during childhood and puberty and
achieves its peak by the age of 20-30 years old. After that, bone mass remains static
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between the ages of 20 to 45, but then bone loss occurs because the rate of bone
turnover increases and the imbalance between bone formation and resorption widens.
In addition, bone architectural change also occurs along with bone loss, which impairs




1.3 Evidence for a Genetic Contribution to the Pathogenesis of
Osteoporosis
Whilst osteoporosis is a multi-factorial disease with several environmental influences,
genetic factors play an important role in its pathogenesis. Twin and family studies
have shown the importance of genetics in determination of BMD and other
osteoporosis-related phenotypes including biochemical markers of bone turnover,
skeletal geometry, ultrasound properties of bone, body mass index (BMI), and muscle
strength (Table 1.1).
The genetic contribution to the osteoporotic fracture has also been studied. Family
history of hip fracture has been consistently shown to be a risk factor for fracture,
independent of BMD in population-based studies. For example, Seeman E et al have
shown that daughters of women with hip fractures have an increased risk for hip
fractures (Seeman E et al, 1994). This was supported by a longitudinal study on 9516
white women aged 65 years or older, which found that a maternal history of hip
fracture doubles the risk of hip fracture independently of BMD (Cummings SR et al,
1995). In keeping with this, the heritability of wrist fracture was estimated to be 25%
and 54%, respectively, on the basis of family and twin studies and this was found to
be largely independent of BMD (Deng HW et al, 2000a; Andrew T et al, 2005). This
indicates that the predisposition may have been mediated through genetic influences
on bone turnover, and bone geometry or other factors such as the risk of falling.
The study on a large cohort of 6021 Swedish twins has shown that the heritability of
overall age-adjusted fracture was less than 20%, but it was greater for first hip
fractures before the age of 69 years (0.68; 95% CI, 0.41-0.78) and between 69 and 79
years (0.47; 95% CI, 0.04-0.62). But the heritability of hip fracture dropped off
rapidly with age to almost zero after 79 years old (0.03; 95% CI, 0.00-0.26)
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(Michaelsson K et al, 2005). This suggested that genetic factors play an important
role in the pathogenesis of osteoporotic fractures, but environmental factors become
more important with age. This could explain why another elderly twin study from
Finland showed little evidence to suggest that fractures were heritable (Kannus P et al,
1999).






Biochemical markers of bone turnover 0.59-0.75
(in women)
Skeletal genometry (HAL) 0.62




Age at natural menopause





Pocock NA et al, 1987; Smith DM et al, 1973
Krall EA & Dawson-Hughes B, 1993
Deng HW et al, 2000
Andrew T et al, 2005
Garnero P et al, 1996
Hunter D et al, 2001
Arden NK et al, 1996
Arden NK et al, 1996
Kaprio J et al, 1995
Carmichael CM & McGue M, 1995
Arden NK & Spector TD, 1997
Kaprio J et al, 1995
Snieder H et al, 1998
Genetic factors are the main determinant of peak bone mass. Evidence from twin and
family studies have indicated that between 50% - 85% of the variance in peak bone
mass is genetically determined, depending on skeletal site and the age of the subjects
studied (Smith DM et al, 1973; Pocock NA et al, 1987; Krall EA & Dawson-Hughes
B, 1993; Gueguen R et al, 1995). It is clear that several genes regulate bone mass,
each with a modest effect, and likely candidate genes include type I collagen genes
(COL1A1 & COL1A2), vitamin D receptor, LRP5 gene and others, which will be
described in the 'candidate gene' section (sectionl.4.3.4, page 39). Therefore, peak
bone mass is determined by the combined effects of heritability and various
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environmental factors including nutrition (especially calcium and caloric intake),
physical activity and sex steroid status. However the overall contribution of genetic
factors to age-related bone loss is less clear. One of the reasons for these difficulties is
that non-genetic factors, such as changes in hormone levels, nutritional intake and co¬
existing diseases, may interact with genetic variations to eventually modulate bone
loss.
In summary, it is currently believed that in the general population, genetic influences
on BMD and the other phenotypes mentioned above are polygenic in nature and are
mediated by the influence of several genetic variants each of modest effect size and
their interaction with environmental factors. However, osteoporosis, fragility fractures
or unusually high bone mass are features of several rare monogenic diseases including
osteopetrosis, sclerosing bone dysplasias, osteogenesis imperfecta (01), the
osteoporosis-pseudoglioma syndrome (OPS) and osteoporotic syndromes associated
with inactivating mutations of the estrogen receptor alpha and aromatase genes
(Bilezikian JP et al, 1998; Janssens K & Van Hul W, 2002; Van Wesenbeeck L et al,
2003; Balemans W et al, 2005). These diseases are rare, but some of the subtle
polymorphic variations in genes that are mutated in these diseases may also contribute
to regulation of BMD in the general population. For example, the inactivating
mutations and activating mutations in low density lipoprotein-related receptor-5 gene
(.LRP5) are responsible for OPS and autosomal dominant high bone mass, respectively.
The LRP5 gene polymorphisms have recently been shown to be associated with BMD,
bone area and stature particularly in men (Ferrari SL et al, 2004a).
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1.4 Approaches to Identify Osteoporosis Genes
1.4.1 Linkage Analysis
Linkage analysis can be used to identify regions of genome that might contain disease
genes. The method follows the segregation of chromosomal regions marked by
genetic variants in affected family associated with the disease or phenotype. Linkage
analysis can be applied to both monogenic diseases with major gene effects and
complex diseases with polygenic effects.
Linkage analysis is a well validated method to identify the responsible genes for rare
monogenic bone diseases which are segregating according to Mendelian laws. From
1996 onward, a number of linkage studies suggested the presence of at least one
important genetic locus for the regulation of bone mass on chromosome 1 lq 12—13
because different types of monogenic bone conditions were assigned to this
chromosomal region, including autosomal recessive osteoporosis pseudoglioma
(OPPG) syndrome (Gong Y et al, 1996), the autosomal dominant high bone mass
phenotype (Johnson ML et al, 1997) and autosomal dominant osteopetrosis type I
(Van Hul E et al, 2002). Follow-up genetic studies revealed that mutations in the gene
encoding low-density lipoprotein receptor-related protein 5 (LRP5), a coreceptor for
Wnt molecules, are at the basis of all the above mentioned conditions (Gong Y et al,
2001; Boyden LM et al, 2002; Little RD et al, 2002). Following studies reported that
various missense mutation of the LRP5 gene also cause endosteal hyperostosis, Worth
disease, van Buchem disease, autosomal dominant osteosclerosis, and autosomal
dominant osteopetrosis type I (Boyden LM et al, 2004; Whyte MP et al, 2005; Kwee
ML et al, 2005; Rickels MR et al, 2005; Balemans W et al, 2006).
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Linkage analysis also has been used to detect chromosome regions which harbour
genes regulating quantitative traits such as BMD in sib-pairs and families. The
advantage of this method is that it has the potential to detect new genes and new
molecular pathways that regulate bone metabolism. Some quantitative trait loci (QTL)
regulating BMD have been found in genome-wide linkage mapping (Table 1.2),
which gives valuable information about the likely chromosomal locations for genes
involved in the regulation of BMD. However, linkage analysis can only identify large
regions that are typically tens of cM containing hundreds of genes. So far it has been
difficult to narrow down the region to map the specific gene contributing to the
linkage peak at the majority of the QTL. This is because few QTL have been
replicated between different genome searches in different studies, perhaps because of
limited small sample size and limited statistical power to find genes or genetic
variants having modest effects on BMD. There are only a few genome-wide linkage
mapping studies for osteoporosis- related traits in large or extended multigenerational
families (Styrkarsdottir et al, 2003; Kammerer et al, 2003).
Moreover, the involvement of the numerous environmental factors makes it more
difficult to detect the small effects contributed by some biologically important genes
to osteoporosis in the general population by standard linkage mapping approaches.
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Table 1.2 Chromosome regions implicated by genome-wide linkage scans of BMD
(adapted from Zmuda JM et al, 2006)
Region Locus Phenotype LOD Ethnicity Comments
lp36 Femoral neck BMD 3.53 Caucasian (US) 42 families (N=254)
lp36 Whole body BMD 2.40 Caucasian (US) 1094 female twin pairs (N=2188)
iq Spine BMD 4.3 Caucasian (US) 938 sisters
1q21-23 Spine BMD 3.64 Caucasian (US) 464 sister pairs (N=706)
2q23-24 Hip BMD 2.25 Caucasian (US) 7 pedigrees (N=149)
2q23-24 Forearm BMD 2.15 Chinese 96 nuclear families (N=218)
2q25 Femoral neck BMD 3.98 Mexican American 29 pedigrees (N=664)
3p21 Spine BMD 2.1-2.7 Caucasian (US) 1094 female twin pairs (N=2188)
4p Forearm BMD 4.33 Mexican American 29 extended pedigrees (N=664)
4q31 Spine BMD 3.08 Caucasian (US) 53 extended pedigrees (N=630)
4q32 Wrist BMD 2.26 Caucasian (US) 53 extended pedigrees (N=630)
4q34 Hip BMD 2.95 Caucasian (US) 7 pedigrees (N=149)
5q33-35 Femoral neck BMD 2.23 Caucasian (US) 464 sister pairs (N=706)
6pl 1-12 Spine BMD 2.13 Caucasian (US) 464 sister pairs (N=706)
6p21 Femoral neck BMD 2.93 Caucasian (US) 330 extended pedigrees (N=1557)
8q24 Wards BMD 2.13 Caucasian (US) 330 extended pedigrees (N=1557)
10q26 Hip BMD 2.29 Caucasian (US) 53 extended pedigrees (N=630)
1 lpter-14 Whole body BMD 2.08 Caucasian (US) 1094 female twin pairs (N=2188)
11 q 12- 3 LRP5 Spine BMD 5.74 Caucasian (US) Single extended kindred
1 lq24 Spine BMD 2.08 Caucasian (US) 7 pedigrees (N=149)
12q23 Spine BMD 2.08 Caucasian (US) 330 extended pedigrees (N=1557)
12q24 Forearm BMD 2.53 Mexican American 29 extended pedigrees (N=664)
12q24 Spine BMD 2.96 Caucasian (US) 53 extended pedigrees (N=630)
13q Femoral neck BMD 2.51 Mexican American 29 extended pedigrees (N=664)
13q 14-22 Trachanter BMD 3.46 Mexican American 29 extended pedigrees (N=664)
13q33-34 Spine BMD 2.43 Caucasian (US) 53 extended pedigrees (N=630)
14q Trachanter BMD 3.5 Caucasian (US) 774 sister pairs
14q31 Spine BMD 2.08 Caucasian (US) 330 extended pedigrees (N=1557
15q Femoral neck BMD 4.3 Caucasian (US) 774 sister pairs
16pl2-q23 Spine BMD 2.11 Caucasian (US) 1094 female twin pairs (N=2188)
20pl2.3 BMP2 Spine+Hip BMD 4.93 Icelandic 207 extended pedigrees (N=1323)
21 q Trachanter BMD 3.14 Caucasian (US) 330 extended pedigrees (N=!557)
22ql2-13 Spine BMD 2.13 Caucasian (US) 464 sister pairs (N=706)
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So far only one candidate gene for BMD has emerged from a genome-wide linkage
study and this is the bone morphogenetic protein 2 (BMP2) gene (Styrkarsdottir et al,
2003). An initial linkage study linked spine and hip BMD to chromosome 20pl2.
Subsequent work showed that BMP2 contributed to part of the linkage peak due to an
association between osteoporotic fracture and a serine - alanine amino acid change at
codon 37 in the BMP2 gene in Icelandic pedigrees and a Danish cohort of
postmenopausal women. Further analysis showed that the Ser37Ala polymorphism
was in LD with a polymorphism in a conserved cA-acting regulatory element in the
3'- untranslated region (UTRs) ofBMP2 gene (Fritz et al, 2004). It was suggested that
this may cause subtle alterations in BMP2 protein level (Fritz et al, 2006). However,
in a large population-based cohort study of 6353 men and women from the Rotterdam
Study, there was no association of the BMP2 polymorphisms Ser37Ala and
Argl90Ser with various osteoporosis related phenotypes including BMD, bone loss,
hip structure analysis and fracture risk (Medici M et al, 2006). Therefore, the BMP2
gene can be considered the first osteoporosis gene identified by genome-wide linkage
analysis, but more research will be needed to determine if it is associated with
osteoporosis in other populations.
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1.4.2 Genome-wide Association Analysis
Genome-wide association studies have been proposed as a potentially powerful
strategy for detecting genes in complex diseases and may be a promising strategy for
identifying osteoporosis susceptibility genes. This method involves mapping hundreds
of thousands of single nucleotide polymorphisms (SNPs) throughout the whole
genome in either a case-control study or a population based study to find variants that
are associated with a disease-related phenotype. It has greater power to detect smaller
effects than linkage analysis, but requires many more markers to be examined.
There are an estimated 10 million common SNPs in the human genome. It will be
extremely expensive to screen all the common variants in a large sample. Fortunately
evidence based on the international HapMap project (www.hapmap.org) suggests that
a carefully chosen 300,000 to 500,000 SNPs should be sufficient to represent most
common variants across the entire human genome, because recently it has been
revealed that much of the genome may fall into segments of strong linkage
disequilibrium (LD), where variants within these segments are strongly associated
with each other (Reich et al, 2001; Daly et al, 2001; Gabriel et al, 2002). Therefore
common variants are either genotyped directly or are assessed by analysis of an allele
of single "tagging" SNP or a combination of alleles at several "tagging" SNPs.
Another strategy for reducing the number of SNPs to be tested is based on direct
association and the genotyping of all potentially functional SNPs across the genome
(Peltonen & McMkusick, 2001; Bonstein & Risch, 2003). This method decreases the
number of SNPs that need to be genotyped to 50,000 to 100,000, though additional
efforts will be needed to validate all these SNPs (ie, non-synonomous, non-
conservative coding changes). Very recently, the platforms for genotyping such large
set of SNPs throughout the genome simultaneously have become available now. For
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example, the new Affymetrix® Genome-Wide Human SNP Array 6.0 features more
than 1.8 million markers for genetic variation, including more than 906,600 SNPs and
more than 946,000 probes for the detection of copy number variation (CNV)
(www.affymetrix.com). Similarly, the new Human 1M BeadChip features over one
million markers of SNPs and copy number variation (CNV) (www.illumina.com).
These and the advances in the international HapMap project have made genome-wide
association analysis feasible.
The first genome-wide association study was reported by Ozaki K el al (2002). In this
study 92,788 gene-based SNPs were screened in a case (n=94) and control (n=658)
population and 2 SNPs in the lymphotoxin-alpha (LTA) gene were found to be
significantly associated with myocardial infarction. One SNP changed an amino-acid
residue from threonine to asparagine (Thr26Asn) while another SNP in intronl
influenced the transcription level ofLTA.
Recently, in a genome-wide association study conducted by Klein et al (2005), a
polymorphism in the complement factor H gene (CFH) was found to be associated
with age-related macular degeneration (AMD) among 116,204 SNPs genotyped. This
polymorphism changed an amino-acid from tyrosine to histidine (T402H) in a region
that binds heparin and C-reactive protein, while this gene is located on chromosome 1
in a region repeatedly linked to AMD in family-based studies.
Furthermore, a joint genome-wide association study has also been successfully
performed by the Wellcome trust Case Control Consortium for seven common
diseases using the Affymetrix GeneChip 500K Mapping Array Set. This study has
examined -2000 individuals for each of seven major diseases and a shared set of
-3000 controls. Case-control comparisons identified 25 independent association
signals at p<5x 10"7: 1 in bipolar, 1 in coronary artery disease, 9 in Crohn's disease, 3
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in rheumatoid arthritis, 7 in type 1 diabetes and 3 in type 2 diabetes (Wellcome Trust
Case Control Consortium, 2007). The following replication studies have confirmed
that almost all of these signals reflect genuine susceptibility-effects (Zeggini E et al,
2007; Parkes M et al, 2007;Samani NJ et al, 2007; Frayling TM et al, 2007; Todd JA
et al, 2007). The importance of appropriately large samples was confirmed by the
modest effect sizes observed at most loci identified. This study thus represents a
thorough validation of the genome-wide association approach.
So far genome-wide association analysis has not yet been completed for osteoporosis
related traits. With the advances in high-throughput genotyping methods and the
increases in the number of validated SNPs in the human genome, genome-wide
association analysis will be cheaper, faster and more accessible in the near future.
More gene regions are expected to be detected by this analysis with higher density
SNP arrays and larger number of cases-controls.
It is also important to note, however, multifactorial genetic susceptibility may also
often be due to the independent cumulative effects of a set of relatively low frequency
variants at several different loci. Each of these will contribute only a small amount to
the overall genetic determination of a trait, but the cumulative contribution of such
variants may be quite substantial (Fearnhead NS et al, 2004). However, these "rare
variants" will not be detected by association studies based on linkage disequilibrium
with linked common SNPs, such as the genome-wide association analysis. The only
productive approach to find such rare variants is to search for DNA variation in
carefully chosen candidate genes in selected disease groups and compare variant
frequencies, individually and in aggregate, between disease and control population.
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1.4.3 Candidate Gene Association Analysis
It has become clear that genetic susceptibility to common complex diseases such as
osteoporosis involves many genes, most of which have small effects. Candidate gene
association studies are relatively easy to perform, have greater power to detect small
allelic effects than linkage studies, and have been widely used to identify osteoporosis
susceptibility genes. The classical candidate gene association study involves
identifying polymorphisms of a particular candidate gene and relating alleles to BMD
or osteoporotic fractures in a population based study or a case control study.
Candidate genes include those that regulate calcium metabolism, those that are
mutated in rare monogenic bone diseases or those that have been mutated, over-
expressed or deleted in animal models and resulted in abnormal bone phenotypes.
However the major shortcoming of most association studies in the osteoporosis field
is lack of power due to the small sample size. Other limitations and potential
confounding factors include the genetic and population heterogeneity, multiple
comparisons and population stratification. Family-based tests such as the transmission
disequilibrium test (TDT) can help to avoid the false positive association due to the
unrecognized population admixture (Risch N & Teng J 1998; Guo W & Fung WK,
2005), but it may be impractical to collect large families with late-onset diseases such
as osteoporosis or fracture to carry out such studies.
Another approach is meta-analysis. Meta-analysis is a statistical technique for
combining the findings across independent studies. It is a powerful tool for
quantifying the true effect size of candidate genes on complex disease and addressing
the unexpected diversity in genetic association studies, for example, by investigating
heterogeneity (Fang Y et al, 2006; Uitterlinden A et al, 2006). Given the fact that
candidate genes for osteoporosis have small effects, thousands of subjects are required
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to achieve a satisfactory power. Although a single laboratory might not be able to
obtain such numbers and many association studies with small sample size were not
reproductive due to the low power, meta-analysis has the potential to overcome this
problem. For example, the GENOMOS (Genetic Markers for Osteoporosis) project
involves analyzing several candidate gene polymorphisms in relation to osteoporotic
fractures and BMD in a large-scale study. The GENOMOS meta-analysis showed no
associations between three polymorphisms of the estrogen receptor gene and BMD
but a modest effect on fracture risk independent ofBMD in 18,917 subjects (Ioannidis
et al, 2004). Another GENOMOS meta-analysis of five common polymorphisms of
vitamin D receptor gene in 26,242 subjects reported one observed association between
Cdx2 polymorphism and the risk for vertebral fracture, but no effect on BMD
(Uitterlinden A et al, 2006). The GENOMOS meta-analysis demonstrated that the
Spl polymorphism of the type I collagen gene (COL1A1) was associated with reduced
BMD and could predispose to incident vertebral fracture in women, independent of
BMD, which is the largest study ever performed for the COL1A1 Spl polymorphism
with over 20,000 subjects (Ralston SH et al, 2006). In addition to being a very- large
study of genetics of osteoporosis, the GENOMOS meta-analysis also successfully
avoids publication bias, selective reporting bias and between-study heterogeneity.
Thus, such a meta-analysis approach might be able to identify the true effect size of
individual genetic risk factors for complex disease.
It is important to remember that the gene polymorphisms associated with the disease
might not have a causal role but instead be in LD with a nearby causal variant. Recent
advances in the HapMap project provide a valuable resource for the design of
candidate gene association studies which allows genotyping higher density of markers
to improve the chances of detecting the true causal associations. These linked variants,
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which tend to be inherited together on a region of a chromosome, are so called
haplotypes. Once the common haplotype alleles within a candidate gene have been
established, the causal variant can be located in the haplotype block within the gene.
However, like mentioned previously, haplotype analysis has limitations in detecting
the rare variants that might cause disease.
Numerous candidate genes have been associated with BMD or osteoporotic fracture
(Table 1.3) including genes encoding hormones and receptors, cytokines and
receptors, bone matrix components and degradative enzymes, osteoblast regulatory
factors and osteoclast related genes. The most widely studied candidate genes such as
collagen type I gene, the vitamin D receptor gene, the estrogen receptor genes and
LRP5 are discussed below in details.
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Table 1.3 Candidate genes for regulation of susceptibility to osteoporosis (adapted from
Ralston SH & Crombrugghe B, 2006)
Hormones and receptors Bone matrix components & degradative
Androgen receptor Alpha HS2 glycoprotein
Aromatase Collagen type I alpha I
Calcium sensing receptor Osteocalcin
Calcitonin receptor Proline lysine oxidase dehydrogenase type




Cytokines and receptors Osteoblast regulatory factors
lnterleukin-1 alpha and beta Aloxl2 and Aloxl5
Interleukin-1 receptor antagonist Bone morphogenic protein 2
Interleukin-6 Bone morphogenic protein 4
Tumour necrosis factor receptor 2 Core binding factor A1
Tumour necrosis factor Insulin like growth factor 1
Sclerostin
Transforming growth factor beta
Lipoprotein related receptor 5 and 6
Peroxisome proliferators activated receptor gamma
Miscellaneous Osteoclast related genes
Apolipoprotein E Cathepin K
Methylene tetrahydrofolate reductase Chloride channel 7
Klotho Vacuolar proton pump a3 subunit
HLA class II Osteoprotegerin
Receptor activator ofNF k B
Receptor activator of nuclear factor kappa B ligand
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1.4.3.1 Type I Collagen Gene (COL1A1)
Type I collagen is the major protein of bone. It is a heterotrimer formed from two
collagen al (I) and one collagen a2(I) polypeptides that are encoded by the genes
COL1A1 and COL1A2 respectively. Mutations within the exons of these genes are
thought to be the major cause of osteogenesis imperfecta (01), a hereditary disease
characterized by increased bone fragility and premature osteoporosis (Row DW,
1991). These mutations lead to structural or quantitative defects of type I collagen.
Many mutations affect the conserved glycine residues in either COL1A1 or COL1A2,
which results in a mixture of normal and abnormal collagen fibrils being produced.
Such mutations result in excessive brittleness of bone. Mutations altering a splice site
creating a premature stop code within COL1A1 gene result in the reduced rate of
collagen production, because the abnormal transcription products are destroyed due to
nonsense mediated RNA decay, and only normal collagen chains are produced (Rauch
F & Glorieux FH, 2004). There is a mouse model of osteogenesis imperfecta (OI) that
was developed as a model of severe human OI and affected animals suffered from
fragility fractures, and were shown to have abnormal orientation of collagen fibers
and altered size ofmineral crystals (Viguet-Carrin S et al, 2006).
In view of this, the collagen genes are strong candidate genes for osteoporosis. Grant
et al described a common polymorphism affecting the transcription factor Spl
binding site in the first intron of COL1A1 gene that was associated with low bone
mass and an increased risk of fracture (1996). Positive associations between the Spl
polymorphism and BMD, fractures and postmenopausal bone loss were subsequently
reported in several populations reviewed by Raslton SH & de Crombrugghe B (2006).
Retrospective meta-analyses of published studies concluded that carriage of the T
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allele is associated with reduced BMD at the lumbar spine and femoral neck and with
vertebral fractures (Mann V et aI, 2001, Efstathiadou Z et al, 2001, Mann V &
Ralston SH, 2003),
Moreover, homozygote for the T allele of the Spl polymorphism was recently found
to be associated with BMD and incident vertebral fractures in the GENOMOS study,
which is the largest ever meta-analysis performed to study genetics of osteoporosis
with over 20,000 subjects (Ralston SH et al, 2006). Although the GENOMOS study
only detected a modest association between the Spl polymorphism, BMD and
fractures, it demonstrated the importance of conducting studies that have adequate
power to detect modest effects of common genetic variants on complex diseases. In
addition, the GENOMOS study also found that the association between vertebral
fracture and the Spl polymorphism was not fully explained on the basis of reduced
BMD, which indicated that the Spl may act as a marker for bone quality. This is
consistent with previous findings that the Spl predicts fractures independent of BMD
and interacts with BMD to enhance fracture prediction (McGuigan EF et al, 2001).
Furthermore, the Spl polymorphism has also been associated with other phenotypes
relevant to osteoporosis, including femoral neck geometry (Qureshi AM et al, 2001),
bone quality (Mann V et al, 2001), bone mineralization (Stewart TL et al, 2005) and
the therapeutic response to etidronate therapy (Qureshi AM et al, 2002).
The frequency of the Spl polymorphism differs between ethnic groups. In Caucasian
populations where osteoporosis is a common disease, the Spl polymorphism was
found to be relatively common with an allele frequency of 22%, whereas it is rare in
Africans and Asians, where the incidence of osteoporosis is lower than in Caucasian




The mechanism by which the Spl polymorphism predisposes to osteoporosis has been
investigated by in vitro functional studies. Mann V el al (2001) reported that the risk
allele 'T' of the Spl polymorphism had increased affinity for Spl protein binding and
was associated with elevated allele-specific transcription in heterozygotes, which
abnormally increased production of collagen type I alpha 1 mRNA and al chain of
collagen by osteoblasts. This abnormality led to an increased ratio of the al to a2
chains and reflected the presence of al homotrimer formation which is mechanically
weaker than normal al (I)/ a2 (I) heterotrimers because of altered inter-molecular
cross-linking (Misof K et al, 1997). The al homotrimer was observed in a mouse
model of osteogenesis imperfecta with a mutation in the COL1A2 gene which caused
a conformational change in the a2 chain and prevented a2 chain associating with al
chain. The homozygotes for this mutation had severe bone fragility where bones are
composed completely of al homotrimers, whereas heterozygotes had a mild
phenotype because the bones consist of a mixture of al homotrimers and normal al
(I)/ a2 (I) heterotrimers (Chipman SD et al, 1993). In keeping with this,
biomechanical testing of bone samples from heterozygotes for the Spl alleles showed
reduced bone strength compared with homozygotes for 'G' allele and a slight
reduction of mineralization of bone (Mann V et al, 2001). Taken together, these data
suggest that the Spl polymorphism is a functional variant that has adverse effects on
bone composition and mechanical strength.
Recently, two polymorphisms were identified in the promoter of the COL1A1 gene
that are in LD with the Spl polymorphism. These are a G/T polymorphism at position
-1997 relative to the transcription start site (-1997G/T; rs 1107946) and an
insertion/deletion polymorphism at position -1663 (-1663indelT; rs2412298). These
polymorphisms were found to interact with each other and with the Spl
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polymorphism to regulate BMD in a small study of Spanish postmenopausal women
(Garcia-Giralt N et al, 2002). The -1997G/T promoter polymorphism has been studied
in relation to BMD in other populations and family based studied with mixed results
although most of these studies have been of limited sample size (Stewart TL et al,
2006). Haplotype analysis has shown that an extended haplotype defined by the Spl
polymorphism and two promoter polymorphisms may exert stronger effects on BMD
than the individual polymorphism (Garcia-Giralt N et al, 2005; Stewart TL et al,
2006). Subsequent work found these two promoter polymorphisms influence COL1A1
transcription in a promoter-reporter assay and the -1663indelT polymorphism
interacts with the transcription factor Nmp4 which plays a role in osteoblast
differentiation by interacting with BMP/Smad signaling (Garcia-Giralt N et al, 2005).
Whilst a functional interaction has been reported between these two promoter
polymorphisms in regulating COL1A1 transcription (Garci'a-Giralta N et al, 2005),
future work will be required to establish them as functional variants and determine
whether they interact with Spl polymorphism to regulate BMD and gene transcription.
1.4.3.2 Vitamin D Receptor Gene (VDR)
Vitamin D, through its biologically active metabolite 1, 25-Dihydroxyvitamin D3
[l,25-(OH)2D3], plays a crucial role in calcium homeostasis by interacting with its
receptor to regulate bone cell growth and differentiation, intestinal calcium absorption
and parathyroid hormone secretion. The vitamin D receptor (VDR) was the first
candidate gene to be associated with bone-related phenotype (serum osteocalcin levels,
Morrison NA & Eisman JA, 1992). Since then, a number of studies have focused on
three polymorphisms in the 3' untranslated region (UTR) of the VDR gene recognized
by restriction enzymes Bsml, Apal and Taql, which were associated with
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postmenopausal bone loss, circulating levels of osteocalcin and BMD in a twin study
and a population-based study. A positive association has also been found between a
haplotype defined by these three polymorphisms and osteoporotic fracture in one
study (Uitterlinden A et al, 2001). But other studies have shown conflicting results of
VDR alleles in relation to BMD or fracture (Ferrari SL & Rizzoli R, 2005). A
retrospective meta-analysis of Bsm\ polymorphism confirmed the association of spine
BMD with relatively modest effects, but no association with femoral neck BMD
(Thakkinstian A et al, 2004). Another meta-analysis of thirteen studies including 1632
fractures and 5203 controls showed no evidence of a relationship between the VDR
Bsml or Taql polymorphism and fracture risk with any genetic model and significant
between-study heterogeneity (Fang Y et al, 2006). It still remains unclear whether
these are functional variants or not, although one study suggested that these
polymorphisms may act as markers for RNA stability because they are in LD with a
polymorphic polyA tract in the 3' UTR of VDR mRNA (Morrison NA et al, 1994).
Gross C et al (1996) described a polymorphism in exon 2 recognized by the Fokl
restriction enzyme, which creates an alternative translational start site, resulting in the
production of two isoforms of the VDR proteins differing in length by three amino
acids. The Fokl polymorphism is not in LD with the three polymorphisms in the 3'
UTR. The association of the Fokl polymorphism with BMD has been found in some
populations (Arai FI et al, 1997; Gennari L et al, 1999; Bandres E et al, 2005 &
Falchetti A et al, 2007), but in not others (Eccleshall TR et al, 1998; Langdahl BL et
al, 2000). Functional studies have also yielded inconclusive results (Arai H et al, 1997;
Jurutka PW et al, 2000; Colin EM et al, 2000 & Gross C et al, 1998).
Recently, another polymorphism has been identified in the promoter of the VDR gene,
which is located in a binding site for the transcription factor Cdx-2 (Arai H et al,
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2001). Functional differences showed that the "A" allelle had increased binding of the
Cdx-2 protein and increased transcription activity of the VDR promoter compared
with the "G" allele in the human colonic carcinoma cell line Caco-2. This
polymorphism has been associated with BMD in a Japanese population (Arai H et al,
2001) and with fracture in other populations (Fang Y et al, 2003 & Casado-Diaz A et
al, 2007). A large-scale haplotype study involving 6418 subjects of the Rotterdam
Study has shown that certain haplotypes defined by polymorphisms in the promoter
and 3' UTR were associated with an increased risk of fracture (Fang Y et al, 2005).
This result was supported by functional studies that indicated the risk haplotypes
resulting in a lower VDR mRNA level due to decreased transcription (associated with
promoter haplotypes) and increased degradation (associated with 3' UTR haplotypes).
However, the GENOMOS study involving 26,242 subjects, has shown no association
of the Fokl or any polymorphism in the 3' UTR with BMD, but the Cdx2
polymorphism was associated with risk for vertebral fractures (Uitterlinden A et al,
2006). Therefore, the complex mechanism by which these polymorphisms
predisposed to fracture or BMD remains unclear.
1.4.3.3.Estrogen Receptor Alpha Gene (ESR1)
Estrogen deficiency following the menopause is a major risk factor for osteoporosis
and it exerts its effect on bone through interaction with the estrogen receptors.
Estrogen receptor alpha, encoded by the ESR1 gene, is a strong functional candidate
in osteoporosis. A number of studies have looked for evidence of an association
between ESRl alleles and BMD, mostly focussing on three polymorphisms: a TA
repeat in the promoter and two polymorphisms in the first intron which are recognized
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by Xbal and Pvull restriction enzymes respectively. An association between the TA
repeat in the ESR1 promoter and BMD has been found in both Japanese and US
populations. Associations of the Xbal and Pvull polymorphisms with BMD have also
been observed in postmenopausal and younger pre-menopausal Asian women. But
inconsistent results have been reported possibly because of small sample size and
population heterogeneity (reviewed by Williams & Spector, 2006). A meta-analysis of
published studies including more than five thousand women from 22 eligible studies
concluded that homozygotes for the Xbal XX genotype have significantly higher
BMD and a reduced risk of fractures compared with other genotypes (Ioannidis JP et
al, 2002). More recently, a prospective meta-analysis of data from over 18,000
subjects of eight European centres in the GENOMOS study, confirmed the association
of the Xbal XX genotype with reduced risk of fractures. The effects on fracture
seemed to be independent of BMD in this study, however, and no association was
observed with BMD (Ioannidis JP et al, 2004). The mechanism responsible for the
increased fracture risk remains unclear. The haplotype defined by the polymorphisms
Pvull and Xbal of ESRJ alleles have been associated with other bone-related
phenotypes including ultrasound properties of bone and bone loss (Albagha O et al,
2005). This suggested that the ESR1 gene might have an effect on bone quality. Other
evidence from in vitro functional studies showed that the Xbal & Pvull
polymorphisms may regulate reporter gene transcription (Herrington DM et al, 2002;
Maruyama H et al, 2000). Interestingly, the Pvull polymorphism is located in
consensus recognition sites for the AP4 and Myb transcription factors, and both the
Xbal and Pvull polymorphisms are located in a region that is 70-80% conserved in the
human, mouse and rat genomes. Hov/ever, this does not exclude the possibility that
these polymorphisms are in LD with the causal ones elsewhere in the ESR1 gene.
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1.4.3.4 Lipoprotein Receptor Related Protein 5 (LRP5)
The LRP5 and LRP6 proteins function as co-receptors for canonical Wnt signalling.
Wnt signalling plays an important role in the development and maintenance of many
organs and tissues. In particular, the canonical or Wnt/p-catenin signaling through
LRP5 has been identified as a key pathway in the regulation of BMD and bone
strength (Johnson ML et al, 2004). Early studies showed that two rare mendelian bone
disorders, osteoporosis-pseudoglioma syndrome (OPPS, Gong Y et al, 1996) and high
bone mass syndrome (HBM, Johnson ML et al, 1997) mapped to the same region of
chromosome llql2-13. Subsequent work using positional cloning identified two
types of mutations in the LRP5 gene as the cause for these two disorders (Gong Y et
al, 2001 & Little RD et al, 2002). The OPPS syndrome is characterized by severe,
early onset osteoporosis and congenital blindness due to vitreous opacity and is
caused by loss-of-function mutations in LRP5 due to different homozygous missense,
nonsense, and frameshift mutations throughout the gene (Gong Y et al, 2001).
Conversely, gain-of-function mutations in the LRP5 gene lead to HBM, which is an
asymptomatic autosomal dominant disorder characterized by abnormally high BMD.
This was reported in association with a heterozygous missense mutation causing a
substitution of valine for glycine at codon 171 (G171V) of LRP5 within the first p-
propeller domain of the molecule (Little RD et al, 2002). Since then, several other
missense mutations have been identified as a cause ofHBM, and all of these cluster in
or around the first P-propeller domain of the LRP5 gene (Van Wesenbeeck L et al,
2003).
In addition to studies in humans, transgenic mice expressing truncated or non¬
functional LRP5 protein have deficits in bone formation and develop the clinical
features observed in OPPS patients (Kato M et al, 2002). Conversely, transgenic mice
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that over-express wide type LRP5 or a gain-of-function mutation (G171V) have
increased bone mass and strength (Babij P et al, 2003). These mice showed increased
mineral apposition rate, a reduced rate of osteoblast apoptosis but unaffected bone
resorption. Several functional studies have suggested that HBM-associated mutations
(G171V, G171R, A214T, A214V, A242T, T253I, and D111Y) had lower Dickkopf-1
(Dkkl) binding affinity, and impaird Dkkl-mediated inhibition of Wnt-stimulated
LRP5 signalling (Boyden LM et al, 2002 & Ai M et al, 2005). Taken together, these
data indicate that the LRP5 has an important role in determining bone mass, strength
and function.
Moreover, a QTL for BMD in the general population was also mapped at 1 lql2-13,
the LRP5 locus (Koller DL et al, 1998; Cam G et al, & Livshits G et al, 2002).
Several association studies and family-based study have been performed and found
various common polymorphisms to be associated with BMD and osteoporotic
fractures. Interestingly, many studies have reported strong associations with BMD in
men (Ferrari SL et al, 2004a; Koh et al, 2004; Urano et al, 2004; Van Meurs et al,
2006). This effect might be explained by gender differences in mechanical loading.
Recently the V667M and A1330V polymorphisms were specifically associated with
LS peak bone mass in the physically active subgroup of young, Danish men from the
Odense Androgen Study, which suggests a role for LRP5 as a mediator of load-
induced bone formation (Brixen K et al, 2006). A subsequent study found that genetic
variations in exons 10 and 18 of the LRP5 gene modulate Wnt signaling and the
relationship between physical activity and BMD in men, which suggests that Wnt-
LRP5 may play a role in the adaptation of bone to mechanical load in humans, and
may explain some gender-related differences in bone mass (Kiel DP et al, 2007).
Chapter 1: Introduction
The mechanism by which these polymorphisms affect LRP5 signalling has not been
investigated, but an interaction between the LRP5 A1330V polymorphism and a
coding polymorphism of the LRP6 (1062V) has been observed with additive effect on
fracture susceptibility in the Rotterdam Study (Van Meurs et al, 2006). In conclusion,
these data suggested that not only do rare mutations in the LRP5 gene affect BMD in
rare diseases; the subtle common polymorphisms also contribute to the genetic
regulation of BMD in the normal population. This also makes other components of
this pathway such as Wnts, Dkks, Frizzled, Kremen, and Sfrps, candidate genes for
osteoporosis in further study,
1.4.3.5 Transforming Growth Factor Beta-1 (TGF-P1)
TGF-pi is a multifunctional polypeptide produced by immune cells but it is also
abundant in bone matrix. It has been suggested that TGF-pi modulates proliferation
and differentiated functions of osteoblasts and also plays a role in coupling bone
resorption to bone formation (Noda M & Camilliere JJ, 1989; Bonewald LF & Mundy
GR, 1990). Mutations in the TGFBI gene cause Camurati-Engelmann disease (CED),
a condition associated with increased bone turnover and osteosclerosis affecting the
diaphysis of the long bones that is inherited in an autosomal dominant manner
(Kinoshita A et al, 2000; Janssens K et al, 2000).
Most causal mutations are located within the coding region of the latency-associated
peptide (LAP). TGF-pi is normally secreted as a complex composed of three proteins,
which are the bioactive peptide TGF-pi, latency-associated peptide-pi (LAP-pi), and
latent TGF-pi binding protein-1. TGF-pi forms a complex with LAP-pi
noncovalently, which is called the small latent complex, and in this configuration
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TGF-(31 is unable to bind to its receptors (Annes JP et al, 2003). Functional studies
have shown that the CED-causing mutations impair binding of the inhibitory LAP to
mature TGF-fil, resulting in activation of SMAD signaling (Janssens K et al, 2003).
Polymorphisms of the TGFBI gene have been studied extensively in relation to
osteoporosis, including polymorphisms in promoter; intron 4 & 5 and exon 1 & 5.
These polymorphisms of TGFBI gene have been associated with BMD, osteoporotic
fractures and biochemical markers of bone turnover in some populations (Langdahl
BL et al, 1997; Yamada Y et al, 1998; Yamada Y et al, 1999; Hinke V et al, 2001;
Keen RW et al, 2001; Langdahl BL et al, 2003;Dick IM et al, 2003), but not in others
(Ziv E et al, 2003; McGuigan FE et al, 2007). These conflicting results may be
explained by the differences in the ethnic makeup of the populations studied and
small sample size.
1.4.3.6 Bone Morphogenic Protein-2 (BMP2)
Bone morphogenetic protein-2 (BMP-2) is a growth factor located on chromosome
20pl2 that belongs to the TGF-p superfamily. BMP-2 plays a critical role in early
embryogenesis, skeletal development, and osteoblast differentiation (Thies RS et al,
1992; Kanzler B et al, 2000; Spinella-Jaegle S et al, 2001). Recent studies have also
linked the BMP2 gene to osteoporosis. Turgeman G et al (2002) reported that
systemic administration of recombinant human BMP2 abrogated bone loss in two
mouse models of osteoporosis. Polymorphisms of the BMP2 gene have also been
associated with regulation of BMD and susceptibility to osteoporotic fractures.
Styrkarsdottir II et al (2003) identified a locus for regulation ofBMD on chromosome
20pl2 by a linkage study in an Icelandic population, and subsequently identified a
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missense polymorphism (Ser37Ala) located in exon 2 of the BMP2 gene associated
with osteoporotic fractures by positional cloning. This polymorphism (Ser37Ala) was
overrepresented in Icelandic and Danish patients with osteoporosis (Styrkarsdottir U
et al 2003). The association of the Ser37Ala polymorphism with lumbar spine BMD
was also found by Reneland RH et al in an international sample of 805 women from
Australia, New Zealand, United Kingdom, and Belgium (2005). But associations of
the Ser37Ala or the Argl89Ser (located in exon3) polymorphism with osteoporosis
were not observed in the Rotterdam Study (Medici M et al, 2006) or in healthy
American whites (Ichikawa S et al, 2006). The mechanisms by which these
polymorphisms affect BMP signalling and bone mass have not yet been investigated.
A functional study suggested that one polymorphism (rsl5705) disrupted a putative
posttranscriptional regulatory motif within the highly conserved 3'-untranslated
region of BMP2 gene, altered BMP2 RNA decay in vitro and thus affect BMP2
protein expression level (Fritz DT et al, 2006).
1.4.3.7 Interleukin-6 (IL-6)
Interleukin-6 (IL-6) is a pleiotropic cytokine produced by osteoblasts, monocytes and
T cells in bone. IL-6 plays an important role in post-menopausal bone loss by
promotion of osteoclast differentiation and activation (Manolagas SC, 1998).
Polymorphisms in the IL-6 gene promoter region have been associated with IL-6 gene
expression levels (Ferrari SL et al, 2003; Fishman D et al, 1998; Terry CF et al, 2000),
serum levels of IL-6 (Brull DJ et al, 2001; Fishman D et al, 1998) and C-reactive
protein (CRP) (Ferrari SL et al, 2003), a marker of systemic IL-6 activity. Moreover,
the IL-6 polymorphisms have also been associated with low BMD, reduced ultrasound
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properties of bone and increased risk of fractures (Feng D et al, 2003; Ferrari SL et al,
2003; Nordstrom A et al, 2004) in elderly women. In addition, the -174GG genotype
was overrepresented in younger women and men with reduced peak BMD (Garnero P
et al, 2002; Lorentzon M et al, 2000), and estrogen deficient women (Ferrari SL, et al,
2004b) Significant interactions were also found between the IL-6 -174 genotypes and
years since menopause, estrogen status, dietary calcium and vitamin D intake in
women in the Offspring Cohort of the Framingham Heart Study, that comprises 1574
unrelated men and women (mean age 60 years) (Ferrari SL, et al, 2004b).
1.4.3.8 Methylenetetrahydrofolate Reductase (MTHFR)
MTHFR is an enzyme which catalyses the reduction of 5, 10-
methylenetetrahydrofolate to 5-methylenetetrahydrofolate which is important in
homocysteine metabolism. Mutations affecting this enzyme are one of the causes of
homocysteinuria, a rare autosomal recessive disease characterized by excessive
homocysteine in plasma and urine. Some studies have also shown a relationship
between BMD or fracture incidence and homocysteine (Gjesdal CG et al, 2006;
McLean RR et al, 2004). This makes MTHFR gene a candidate gene for osteoporosis.
A common nonsynonymous C/T polymorphism (C677T) of the MTHFR gene results
in an alanine-to-valine substitution, which causes a mild decrease in enzyme activity.
The relationship between the C677T genotype and osteoporosis has been investigated
in several populations, but the results are conflicting. For example, the association of
C677T genotype with BMD was observed in postmenopausal Japanese women
(Miyao M et al, 2000), postmenopausal women in Danish Osteoporosis Prevention
Study (Abrahamsen B et al, 2003), but not in another Danish population (Jorgenssn
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HL et al, 2002), Iranian women (Golbahar J et al, 2004), or postmenopausal British
women (Baines M et al, 2007). A subsequent meta-analysis of published studies
concerning the C667T genotype and BMD between the 2000-2006, found that
individuals with the TT genotype showed a small but significantly reduced BMD
compared to those with the TC/CC genotypes in women (Riancho JA et al, 2006).
Only a few studies on the relationship between MTHFR genotypes and fractures have
been published, and the results were mixed (Bathum L et al, 2004; Jorgensen HL et al,
2002; Villadsen MM et al, 2005).
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1.4.4 Genetic Analysis ofMice
1.4.4.1 Genetic Linkage Studies in Mice
Genetic studies in mice including quantitative trait loci (QTL) mapping, transgenesis
and gene inactivation ("knock out") have provided powerful tools for dissecting the
genetics of osteoporosis and other diseases. Genetic mouse models have several
advantages: mice are cheap and easy to manipulate; environmental factors can be
controlled; large number of progeny may be generated and mouse genetic resource are
quite extensive.
Genetic linkage studies in mice have succeeded in identifying several QTLs
regulating osteoporosis-related traits. To perform QTL mapping, typically two
different inbred strains of mice with low and high BMD are crossed to produce a first
generation (Fl). Then the F1 are inbred to generate a second generation (F2). The F2
mice have varying levels of BMD because of segregation of the alleles that regulate
BMD in the Fl x Fl cross. All of the F2 progeny undergo phenotype assessment and
then DNA samples are obtained for the genome-wide linkage analysis. The putative
QTL region identified in linkage analysis is then narrowed by using a variety of
breeding schemes, such as Interval Specific Congenic Recombinant (ISCR) strains
which allows fine mapping of a QTL into a lcM interval. This design is based on
systematic marker-directed construction of a series of congenic strains (for example,
Frankel et al. 1995; Morel et al. 1996; Yui et al. 1996), each is recombinant at a
specific 1-cM sub-interval out of a series of small tandem intervals covering a
chromosomal region, to which a QTL was previously mapped (Darvasi A, 1997). It
has been shown that a specific and previously detected QTL of moderate or even
small effect can be accurately mapped into a 1 -cM interval in a program involving a
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total of no more than 1000 individuals (Bennett B et al, 2002; Ehringer MA et al,
2002; Ruf C et al, 2004). This reduced interval size will facilitate identification of
candidate genes, through bioinformatics, gene expression, and DNA sequencing
strategies.
Functional studies are then required to demonstrate a candidate gene underlying the
QTL of interest, such as gene expression analysis (RT-PCR, microarray), RNA
interference and transgenic mice (knockouts, knockins). For example, recently the
candidate gene Aloxl5 was identified as a negative regulator of peak BMD by
microarray analysis in inbred mouse strains. The mouse chromosome 11 region which
harbours the Aloxl5 gene, was strongly linked to peak BMD in a genome-wide
linkage study (Klein RF et al, 1998). To identify genes that might regulate BMD in
this region, Klein RF et al (2004) generated a DBA/2 (D2) background congenic
mouse with an 82-megabase (Mb) region of chromosome 11 replaced by the
corresponding region of the C57BL/6 (B6) genome. The congenic mice with the B6
chromosome 11 region had increased peak BMD and improved measures of femoral
shaft strength relative to heterozygous or D2 littermates. After narrowing down the
BMD QTL to a 31-Mb region on chromosome 11 by linkage analysis, the gene
expression in B6 and D2 mice was analyzed by microarray analysis. The Aloxl5 gene
was identified as the only differentially expressed gene within this region, which was
confirmed by RT-PCR analysis. The Aloxl5 gene encodes 12/15-lipoxygenase
(12/15-LO), an enzyme mediating endogenous ligands for the peroxisome proliferator
activated receptor-y (PPARy) which is involved in a pathway that stimulates
adipogenesis and inhibits osteoblastogenesis (Huang JT et al, 1999; Kuhn H et al,
2002; Lecka-Czernik B et al, 2002; Khan E & Abu-Amer Y 2003). Phenotyping of
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the Aloxl5 knockout mice showed that 12/15-LO-deficient mice had significantly
higher whole body BMD and increased biomechanical indices of femoral shaft
strength than that of mice homozygous for the 12/15-LO D2 allele. Moreover, an in
vivo study showed that pharmacologic inhibitors of this enzyme improved bone
density and strength in two rodent models of osteoporosis (Klein RF et al, 2004). A
recent study has reported that polymorphic variation in a human homolog of this gene
(Aloxl2) also regulates BMD in man (Ichikawa S et al, 2006). This association still
needs to be replicated in other population and the molecular mechanism needs to be
investigated by functional studies.
Many QTLs regulating BMD were reported for genome-wide linkage studies in mice,
but so far only one gene (Aloxl5) has been identified by positional cloning in inbred
strains in mice to date. As the linkage studies in human, the typical size of a QTL
identified by linkage analysis is too large to detect the genes or gene variants with
modest effects on osteoporosis-related traits. In addition, the genetic variants are
essentially in LD with each other making identification of the causal variant difficult.
Moreover, the most obvious drawback of this approach is that the QTLs regulating




1.4.4.2 Transgenic Mouse Models
Recently, the development of transgenic and gene-targeting technology combined
with the sequencing of the mouse genome has dramatically increased our ability to
create mouse models in which the functional significance of genes, gene variants, and
quantitative trait loci (QTL) can be determined. A transgenic mouse is an organism
that has had foreign DNA (transgene) introduced into one or more of its cells
artificially, where the transgene is stably maintained, transmitted and expressed. The
foreign DNA introduced can be a gene from humans or another species which is
inserted into the mouse genome (transgenesis mouse model), or an endogenous gene
which is disrupted (knockout mouse model) or mutated (knockin mouse model). This
can be achieved in a number of ways: microinjection of DNA into the pronucleus,
homologous recombination in embryonic stem cells, retroviral transfer and nuclear
transfer.
Pronuclear injection of fertilized eggs is the most common and convenient way to
make transgenic mice. Several hundreds copies of the transgene are injected directly
into the male pronucleus of the recently fertilized host egg. These oocytes are
subsequently transferred into the uterus of pseudo-pregnant recipient mice. The
offspring is screened to confirm a copy of the transgene in every cell. These
successful offspring are called founders. Since the integration of the transgene into the
host genome is random, the transgene can integrate anywhere in the genome and
multiple copies often integrate at a single locus in a head-to-tail fashion. In addition to
insertional mutations, deletions and complex rearrangements of the host genome can
occur. Therefore, only a small proportion of the mice born are transgenic and only a
proportion of those express the gene well. The success rate of producing transgenic
mice by this method is very low. However the microinjection is the predominant
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transgenesis method. It has been often used to characterize the ability of a promoter to
drive a direct tissue-specific gene expression. In this case, a reporter gene is placed
under the control of the target promoter and the reporter gene product's activity is
quantitatively measured. Commonly used reporter genes include the gene which
encodes green fluorescent protein, luciferase gene and lac Z gene which encodes the
protein beta-galactosidase. Another major use for transgenic mice produced by
pronuclear injection of DNA is to examine the effects of over-expressing and
misexpressing endogenous or foreign genes at specific times and locations in the
animal.
Less random than other methods, embryonic stem cell transfer is based on
homologous recombination. Embryonic stem cells (ESCs) are stem cells derived from
the inner cell mass of a blastocyst, which is an early stage embryo. ESCs are
pluripotent, meaning they are able to develop into almost any type of tissue when
given sufficient and necessary stimulation for a specific cell type. When given no
stimuli for differentiation, ESCs will continue to divide in vitro and each daughter cell
will remain pluripotent. Embryonic stem cell transfer involves isolation of stem cells
from a blastocyst, transfection of the transgene (by electroporation), selection of the
stem cells in which the transgene has undergone homologous recombination at the
desired locus and injection of the selected stem cells containing the desired DNA into
an embryo of the blastocyst-stage. The resulting chimera will undergo further
selective breeding for homozygous expression of the desired gene. This is also called
gene-targeting.
However, homologous recombination is an extremely rare event. The most common
strategy for selecting the rare cells with the homologous recombination is the use of
genes conferring drug resistance and sensitivity. Typically, the positively selectable
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gene, neo, which confers resistance to an antibiotic called G418 driven by a
constitutive promoter (PGK) is inserted into the targeting construct so that neo is
flanked by large stretches of DNA (2-7 kb) that exactly matches the genomic
sequences surrounding the desired insertion point. A negative selection gene, such as
thymidine kinase (TK) gene, is often placed outside of the homologous region of the
targeting construct to select against ES cells that incorporate DNA by non¬
homologous recombination. Cells that express the TK gene are killed by the antibiotic
Gancyclovir. Therefore, the stem cells that incorporate DNA by homologous
recombination will survive in both G418 and Gancyclovir because only the
homologous region of the targeting construct including neo is inserted into the
genome while the flanking TK gene is outside of the homologous region and so it is
not inserted. On the other hand, if the targeting construct is inserted randomly, both
neo and TK will be inserted into the genome. That means the cells will resist the
G418 but will be killed by Gancyclovir. After the selection, the neo inside the genome
can be precisely excised using the Cre/loxP system.
The Cre/loxP system is a tool for precise excision of DNA. Cre is a 38kDa
recombinase originally from the PI bacteriophage, which mediates intramolecular and
intermolecular site- specific recombination between loxP (locus of X-over PI) sites
(Sauer B, 1993). The LoxP sequence is derived from the PI bacteriophage, and
comprises two 13bp inverted repeats separated by an 8bp asymmetric spacer region
(Kuhn R & Torres RM, 2002). When cells that have loxP sites in their genome also
express Cre, the enzyme Cre catalyzes the site- specific recombination in the 8bp
asymmetric spacer region by binding loxP sites. That means the DNA sequence
between two loxP sites is excised by the Cre and then ligated back together leaving
one loxP site behind, when two loxP sites are in direct orientation. Otherwise, if two
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loxP sites are in opposite orientation to each other, the DNA sequence between them
is inverted.
The Cre/loxP system has the advantage of working in almost any type of cell.
Therefore this precise removal of DNA by Cre/loxP system can be used to regulate
the time specific / tissue specific expression of a transgene and the level of the
expression. For example, to make tissue-specific conditional knockouts, the mouse
strain having a target gene flanked by loxP sites in a direct orientation is mated with a
mouse strain with Cre targeted to a specific tissue or cell type. Since the
recombination only occurs in those cells expressing Cre recombinase, the target gene
is only knocked out in those cells. The target gene can be a reporter transgene (Orban
PC et al, 1992), or a functional endogenous gene (Kuhn R et al, 1995). The Cre/loxP
system is also used to 'switch on' a transgene expression by cutting out an intervening
stop sequence between the promoter and the coding region of the transgene (Lakso M
et al, 1992). A more powerful approach to controlling gene expression has been
developed: the expression of Cre is controlled by the tetracycline-regulated
transcriptional system (Utomo ARH et al, 1999). In this case, the recombination only
takes place when the tetracycline is administered to activate the Cre expression, which
allows the transgene to be turned on or off at any time.
Therefore, compared to the traditional "gain-of-function" mutation created by
microinjection of the gene into the one-celled zygote, gene-targeting based on
homologous recombination in stem cells has been increasingly used to precisely
modify the gene of interest. These manipulations include site-specific deletions,
insertions, gene duplications, gene rearrangements and point mutations. In addition,
transgenic technology also can be used for gene identification.
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Many human genetic diseases can be modeled by introducing the same mutation into
a mouse or other animal, especially in the major gene diseases. For example, a
transgenic mouse model of osteogenesis imperfecta (01) containing an internally
deleted human COL1A1 gene (encoded the alphal (I) chain of type I procollagen)
developed a lethal phenotype with extensive fractures of ribs and long bones similar
to the fractures seen in lethal variants of OI due to the biosynthesis of shortened pro
alphal (I) chains and procollagen suicide (Khillan JK et al, 1991). Since then, this
line of transgenic mice has been widely used to study the mechanism of 01 in vivo
such as the bone fragility at different sites and ages and mineral changes by means of
ultrastructural, microanalytical, and spectroscopic studies (Cassella JP et al, 1994;
Pereira RF et al, 1995), which has dramatically increased our understanding of the
molecular mechanism of 01.
However, currently there is no such transgenic mouse model available for
osteoporosis. Considering the polygenic background of osteoporosis, it is unlikely to
establish a perfect mouse model for osteoporosis by introducing any of the human
candidate gene variants with modest effect into the mouse genome. But genetically
modified mice containing a potentially causal polymorphism or variant of a human
candidate gene would be very helpful to study the molecular mechanism underlying
associations and to test drugs that target to a specific molecular pathway. Although
similar genetic manipulations can be performed in tissue culture, the interaction of
transgenes with the complex components of an intact organism provides a much more
reliable and complete picture of the candidate gene's function.
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1.5 Type I collagen
Type I collagen is the major protein of bone accounting for 90% of the organic
content bone (von der Mark 1999). The properties of type I collagen affect the
mechanical properties of bone and provide a framework for mineralization. Type I
collagen is synthesized in large amount by fibroblasts, osteoblasts and odontoblasts. It
is a triple-helical, supercoiled molecules consisting of two identical a 1(1) polypeptide
chains and a structurally similar, but genetically different a2(I) polypeptide chain.
Collagen a chains are characterized by a unique Gly-X-Y highly repetitive amino acid
sequence (where X is frequently proline and Y is frequently hydroxyl-proline). The
repetitive sequence allows three polypeptide a chains to fold into a right-handed triple
helix of 1.5 nm diameter.
The biosynthesis of type I collagen is a complex process (Figure 1.5). The type I
collagen molecule is assembled initially as a soluble precursor, type I procollagen.
Individual a 1(1) and a2(I) polypeptide chains (1464 and 1366 amino acids
respectively) are synthesized on membrane-bound ribosomes. They then enter the
lumen of the rough Endoplasmic Reticulum (ER) where selected proline and lysine
residues are hydroxylated to form hydroxyproline and hydroxylysine respectively.
Some of the hydroxylysine residues undergo further glycosylation. Two procollagen
a 1(1) polypeptide chains and one a2(I) polypeptide chain are assembled together to
form triple helical molecules, type I procollagen, by hydrogen-bounds between the
chains. This structure is stabilized by intra-chain disulphide bounds between the C-
propeptides. Each procollagen molecule has three structurally distinct domains; an N-,

























Collagen fibril Collagen fiber
Type I collagen is a triple helical protein composed of three peptide chains derived
from two distinct genes (COL1A1 & COL1A2). Collagen precursor chains (al & a 2)
are assembled in the ER lumen to form triple-helical procollagen molecules. After
extensive posttranslational modification, procollagen is secreted from cell and
converted to collagen in a peptide-cleaving reaction catalyzed by procollagen
peptidase. Subsequently, the triple helical collagen molecules self assemble into
collagen fibrils and these are crosslinked to produce mature collagen fibers.
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These procollagens are then transported into the Golgi apparatus of the cell and
secreted into the extracellular matrix in the form of soluble precursors. During the
secretion, the N- and C- propeptides are removed by procollagen N and C proteinaes,
which converts procollagen into collagen. Collagen molecules then self-assemble to
form collagen fibrils. Fibrils are greatly strengthed by the formation of covalent intra-
and inter-molecular cross-links between lysine residues of the collagen molecules.
Collagen fibrils finally undergo intermolecular and interfibrillar crosslinks to produce
mature collagen (collagen fibres), which are several micrometers in diameter.
Measurement of these bone-derived collagen cross-links in urine has proved to be a
useful measure of bone resorption. The propeptides of collagen (P1NP & PICP)
which are cleaved off during collagen processing, are also used clinically as
measurement of bone formation. Structural or quantitative defects in type I collagen
cause the disease, osteogenesis imperfecta (01), which is characterized by increased
bone fragility and premature multiple fractures (Row DW, 1991).
In addition, changes in post-translational modification of collagen are also associated
with bone diseases. Cartilage-associated protein (CRTAP) forms a complex with
cyclophilin B and prolyl 3-hydroxylase 1, which is encoded by LEPRE1, and
hydroxylates one residue in type I collagen, alphal(I)Pro986. It has been reported that
null mutations of CRTAP cause recessive osteogenesis imperfecta including type II &
VII (Morello R et al, 2006). Moreover, null LEPRE1 alleles cause a recessive
metabolic bone disorder resembling lethal/severe osteogenesis imperfecta, where the
LEPRE1 mutations led to premature termination codons and minimal mRNA and
protein. The affected collagen had minimal 3-hydroxylation of alphal(I)Pro986 but
excess lysyl hydroxylation and glycosylation along the collagen helix. The collagen
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secretion was moderately delayed, but total collagen secretion was increased (Cabral
WA et al, 2007).
The increased enzymatic collagen crosslinks may be associated with increased
ultimate stress and stiffness (Viguet-Carrin S et al, 2006). Therefore, the collagen
properties are an important determinant of bone strength and collagen abnormalities
can cause different clinical disorders.
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1.6 Type I Collagen Genes
The COL1A1 and COL1A2 genes code for the procollagen al(I) and a2(I) polypeptide
chains respectively. The COL1A1 and COL1A2 genes are located on chromosomes
17q21-q22 and 7q21.3-q22.1, respectively (Retief E et al, 1985). Human COL1A1 is
18 kb in size and consists of 51 exons (Chu ML et al, 1984; Ramirez F et al, 1985),
and COL1A2 is 38 kb in size and consists of 52 exons (Ramirez F et al, 1985; de Wet
W et al, 1987). Both genes are characterized by numerous short exons interrupted by
longer introns. The central triple helix regions are encoded by 44 exons, which are all
multiples of 9 bp in length corresponding to the repetitive Gly-X-Y triple amino acid
sequences. Two exons at 5' end code for the N-terminal domain and four exons at the
3' end code for the C-terminal domain and 3' untranslated regions. Although the
COL1A1 and COL1A2 genes are in different length (18kb and 40kb respectively), the
transcribed mRNA molecules have a similar size. Sequence analysis of COL1A1 and
COL1A2 showed significant homology among species, indicating the collagen genes
are evolutionary conserved (Von der Mark, 1999).
Although these two genes are on different chromosomes, they are co-ordinately
regulated so that the ratio of the steady-state levels of mRNA for COL1A1 and
COL1A2 is 2:1. This ratio correlates with the fact that two al(I) and one a2(I)
poplypeptides are in the triple helix structure of collagen (Slack JK et al, 1993). It is
still unclear how the transcription of collagen genes is co-ordinate in this way. The
transcriptional regulation of the two genes is complex since collagen protein is
synthesized in a tissue-specific manner and at widely differing levels during normal
embryonic and postnatal development. Furthermore, the synthesis of type I collagen
responds both positively and negatively to stimuli generated by tissue injury and
repair, cytokines, hormones and is up-regulated in a variety of fibrotic disorders.
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The expression of both COL1A1 and COL1A2 are regulated by the interactions of
trans-acting enhancers and repressors with multiple cX-acting elements. A number of
regulatory elements required for basal and inducible expression of COL1A1 have been
identified in the promoter and first intron of both genes with the positive and negative
regulatory factors, as described below.
1.6.1 COL1A1 Promoter
The regulatory regions within the promoter of the COL1A1 gene contain some ex¬
acting elements which are responsible for the basal, tissue-specific and cytokine-
regulated gene expression by interacting with different trans-acting factors. Several
cytokine-responsive elements have been identified, such as a TGF-P response element,
a TNF-a responsive element and an IFN-y responsive element (Rossert J et al, 2000).
Reporter assays have identified several cX-acting elements in the promoter of
COL1A1 gene which regulate the expression of reporter genes such as luciferase and
lacZ genes in vitro or in vivo. For example, three elements located upstream of the
proximal promoter (-800bp, -1700bp and >-2300bp) drive the expressions of reporter
genes in skin fibroblasts, osteoblasts/ odontoblasts and tendon/ facial fibroblasts,
respectively (Rossert J et al, 2000). These results are consistent with the observations
that the sequences up to -2.3kb upstream of the transcriptional start site are important
for COL1A1 transcription in bone, whereas sequences between -3.5kb and -1.7kb are
important for transcription in tendon (Bogdanovic Z et al, 1994). Subsequent work
has defined an element containing a TATA motif at -1683 to -1670bp that enhances
Collal transcription in mouse calvarial bone (Dodig M et al, 1996, Figure 1.6). Most
of the transcription factors that bind to these elements are unknown, but some in vitro
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experiments suggested that they induce tissue-specific expression by modifying the
chromatin structure (Rossert J et al, 2000).
This proximal promoter of COL1A1 is highly conserved between species. Several
studies have shown that DNA sequences between -222bp and -80bp of proximal
promoter of mouse Collal have very strong transcriptional activity which is reduced
by the addition ofmore upstream sequences (Karsenty G & de Crombrugghe B, 1990).
There are several cis-acting elements for transcription factors with positive and
negative effects on transcription situated within this crucial region (Figure 1.6). The
promoter TATA box is situated in this crucial region along with other four cis-acting
elements, and binds the transcription factor TFIID to initiate the transcription. The
other four cA-acting elements in the proximal promoter are involved in the binding of
two inhibitory factors 1 and 2 (IF1 and IF2), and one enhancer (CCAAT bind factor,
CBF, Saitta B et al, 2000). IF1 binds to two upstream elements located at -190 to -
170bp and -170 to -130bp ofmouse Collal promoter. This binding is only present in
collagen-producing cells. IF2 binds to two GC-rich 12bp repeat sequences located in
between -133 and -71bp and competes with the enhancer CBF. CBF inhibits IF2
binding by a stronger interaction with CCAAT motif (Karsenty G et al, 1991).
Mutations in binding sites of IF1 or IF2 that caused inhibition of the binding of IF1 or
IF2 increased the Collal promoter activity (Karsenty Q de Crombrugghe B, 1990 &
1991). Recently, CBF was reported to interact with CCAAT box located at -100 to -
96bp of the human COL1A1 promoter and the binding activity is 3-5 fold higher in
SSc fibroblasts (Ghosh AK, 2002).
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Figure 1.6 Schematic presentations of the cis elements in the mouse and human
COL1A1 proximal promoter
Mouse col la! proximal promoter
-3469/-3450 -1684/-1670 -1574/-1555 -1347/-372
Site A TATA Site B OSE2
Human COLIAI proximal promoter
II I I =
-1670/-1663 -1347/-372
PCOL1 OSE2
Cis-elements in the proximal promoter of mouse and human COLIAI gene are
showing in colored boxes.
In the human COLIAI gene, reporter assays have shown that the short segment of the
promoter between -220 and +40bp drives luciferase gene expression at high levels,
(Garcia-Giralt N et al, 2005; Slack JL et ah 1993). Inhibitory elements have also been
mapped in the human COLIAI promoter between positions -2300 and -205, and the
elements were subsequently mapped to a narrow region between -1284 and -254.
However the precise elements within this region that mediate inhibition of
transcription have not been fully identified yet.
Recently, a polyT region between -1670 and -1663 (PCOL1 site) was identified in the
human COLIAI promoter homologous to the rat Collal promoter site B (-1574 to -
1555) which binds nuclear matrix promoter 4 (nmp4) (Garcia-Giralt N et ah 2002). A
subsequent study has shown that Nmp4. the human homologue of the rat nmp4, is
present in nuclear extracts of MG-63 human osteosarcoma cells and is able to bind to
the PCOL1 site in the human COLIAI promoter (Garcia-Giralt N et ah 2005). Nmp4
is a Cys2His2 zinc finger protein. The zinc finger motif is one of the most common














not only for protein-DNA interaction but also for protein-RNA and protein-protein
interactions (Mackay JP & CrossleyM, 1998; Shastry BS, 1996). Despite the vast
DNA recognition potential of Cys2His2 zinc finger proteins, the Nmp4 protein is one
of the few transcription factors known to be associated with the minor groove of
homopolymeric (dA-dT) sites (Torrungruang KT et al. 2002). The Nmp4 protein
comprises four isoforms 11H, 13H, 21H and 28H, and binds the site A (-3469 to -
3450) and B (-1574 to -1555) in rat Collal promoter (Thunyakitpisal P et al, 2001).
This binding regulates gene expression by bending or looping DNA to alter
interactions between other trans-acting proteins. The Nmp4 binding sites in the rat
Collal promoter are within or proximal to the distinct cA-regulatory regions that
mediate basal transcription in osteoblasts within bone and in cell culture
(Torrungruang KT et al. 2002). Yet there is no clear evidence of cA-acting elements
present near the Nmp4 site in human COL1A1 promoter.
There is a potential Osterix binding site situated upstream of Nmp4 binding site in
human COL1A1 promoter (personal communication, Benoit de Crombrugghe), but
there is no evidence yet about whether Osterix interacts with Nmp4. Osterix is one of
the two essential transcription factors for osteoblast differentiation and regulates the
expression of many important osteoblast genes including type I collagen genes
(Nakashima K et al, 2002). Osterix is encoded by the Sp7 gene and belongs to zinc-
finger family (Sp) of proteins having 78% identity with Spl in the three zinc-finger
DNA-binding domain, but there is little homology elsewhere.
Furthermore, Nmp4 inhibits the activation of osteoblast genes in response to
parathyroid hormone (PTH), prostaglandin E2 and BMP2. For PTH, the possible
mechanism is that PTH enhances the DNA-binding activity of nmp4 to the rat Collal
promoter (Alvarez M et al. 1998). This is in agreement with studies showing that PTH
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inhibits osteoblast growth and collagen synthesis in intro (Bogdanovic Z et al, 2000;
Kream BE et al, 1993). Recently, Nmp4 was found to be involved in the modulation
of BMP2-induced osteoblast differentiation and was suggested to act as an inhibitor of
BMP/Smad signalling. In osteoblastic MC3T3E1 cells, the over-expression of Nmp4
suppressed BMP2-induced expression of osteoblastic differentiation markers
including type I collagen (Shen JZ et al, 2002). Therefore, the interaction between the
Nmp4 and its binding site in human COL1A1 promoter may alter promoter activity
and contribute to gene transcription and expression.
Several other factors have been demonstrated to regulate COL1A1 transcription. The
Spl is ubiquitously expressed and regulates gene expression in all cell types. Spl
protein belongs to the Sp family of transcription factors which have a highly
conserved DNA-binding domain consisting of three zinc fingers close to the C-
terminus and glutamine-rich amino acid domains at the N-terminal regions (Kadonaga
JT et al, 1987). The zinc fingers preferably bind to the GC box, 5'-
(G/T)GGGCGG(G/A)(G/A)(C/T)-3' and the glutamine rich regions are strong
activation domains through which Spl forms protein-protein interactions with other
trans-acting factors.
There is evidence that Spl and NF-1 interact with each other to regulate COL1A1
gene transcription. NF-1 and Spl binding sites overlap in the mouse Collal proximal
promoter (-138 to -77bp, Figure 1.6). In NIH/3T3 cells over-expression of NF-1
increased expression of a Collal-reporter gene and mutations in the NF-1 site led to
reduced expression of the reporter gene, whereas over-expressing Spl inhibited both
basal and NF-1 stimulated expression of the reporter gene (Nehls MC et al, 1991). In
co-transfection studies using Drosophila Schneider L2 cells, both NF-1 and Spl
stimulated gene expression and Spl was found to be a stronger transactivator than
63
Chapter 1: Introduction
NF-1. Co-expression of NF-1 with Spl resulted in inhibition of Spl activation by
NF1 (Nehls MC et al, 1992). In the human COL1A1 promoter, a short region in the
proximal promoter (-129/-107 bp and -104/-78 bp) containing two tandem NF-l/Spl
elements up-regulated transcriptional activity in SSc fibroblasts, and indeed, SSc
fibroblasts contained 3.4-fold greater DNA binding activity recognizing these
elements than normal cells (Hitraya EG et al, 1998).
There is also evidence that Spl and Sp3 interact in human COL1A1 promoter. The
Spl and Sp3 proteins bind GC- rich sequences and these interactions can be
cooperative or Sp3 can decrease Spl-dependent transactivation. Chen SJ et al (1998)
reported the interactions of Spl, Sp3 and CTF/NF-1 proteins present in human skin
and lung fibroblasts nuclear extracts in the region between -129 to -107bp of human
COL1A1 promoter (Figure 1.6). It was concluded that although over-expressing Spl
or Sp3 transactivated the COL1A1 promoter, excess Sp3 can block the Spl-stimulated
COL1A1 promoter activity (Chen SJ et al, 1998).
Spl also directly interacts with TATA-binding protein factors (TAFs) and other
nuclear cofactors which comprise the basal transcription factors. In the human
COL1A1 promoter, Spl has been demonstrated to play an important role in
enchancing gene expression with a Spl site upstream of TATA box (-87 to -82bp,
Figure 1.6), is obligatory for transciprional activation (Li L et al, 1995; Poppleton HM
& Raghow R, 1997).
Runx2 (also called Cbfal) is a runt-related osteoblast-specific transcription factor,
which actives the expression of type I collagen genes in osteoblasts by binding to the
OSE2 binding sites. There are two OSE2 sites (Figure 1.6) in the mouse Collal
promoter (-1347 and -372bp) and one in the first exon (+12bp) ofmouse colla2 gene,
which are conserved in the mouse, rat and human (Kern B et al, 2001).
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1.6.2 The First Intron of the COL1A1 Gene
The COL1A1 first intron is also important in regulating gene expression. The first
evidence was obtained from the lethal phenotype of homozygous Mov 13 mice which
contain the Moloney murine leukaemia retrovirus (MMLV) within the first intron of
Collal (Schnieke A et al, 1983). Subsequent work showed that the retroviral
insertion resulted in transcriptional inactivation of the gene in mouse embryo cell
lines (Hartung S et al, 1986) but a normal amount of type I collagen present in dentin,
which suggested that the first intron may have a tissue-specific effect on
transcriptional regulation (Kratochwil K et al, 1989). In addition, it was shown that
the first intron along with the integrated retrovirus was spliced out in osteoblasts and
odontoblasts, which indicated that incorrect splicing could not account for the
lethality of the mutation in homozygous mice and the different cw-acting elements
affected gene regulation in tissue-specific manner.
Recently, mice with a large deletion in first intron of Collal gene and normal splicing
have been generated to identify the function for the first intron in expression of a 1 (I)
collagen. Hormuzdi et al created a large deletion in first intron of Collal gene in
mice using a gene-targeting approach and demonstrated an age-dependent reduction
in expression of the mutated allele in lung and skeletal muscle (Hormuzdi SG et al,
1998). Later this group found that the expression of mutated allele increased
substantially to a level near that of the wide-type allele when responding to
physiological signals, which implies that reduced expression of the mutated allele is
conditional and can be reversed by the function of elements elsewhere in the gene
(Hormuzdi SG et al, 1999). More recently, Rahkonen O et al (2004) reported that
mice homozygous for this deletion are predisposed to dissection and rupture of the
aorta during their adult life, because the integrity of the aortic wall depends on an
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adequate content of type I collagen and the first intron functioned in continued
synthesis of collagen. Another study has shown that the mechanism of this dissection
is decreased type I collagen synthesis and content in the aortic wall (Marjamaa J et al,
2006).
Assays of collagen transcription in vitro also supported the above results in showing
that deletion of the first intron results in a 2-3 fold reduction in COL1A1 transcription
(Bonstein P & McKay J, 1988). Several elements within the first intron have been
implicated in transcriptional regulation. For example, there is evidence that the first
intron of COL1A1 contains negative regulatory elements which exert an inhibitory
effect on transcription in reporter assays but only in the presence of upstream
promoter sequences between -625 and -293 (Bornstein P et al. 1996). The region
between +380 and +1440bp in first intron of COL1A1 is involved in regulatory
transcription of the collagen gene in scleroderma skin fibroblasts (Hitraya EG &
Jimenez SA, 1996). Taken together, these findings suggested that the first intron of
COL1A1 gene can exert bidirectional effects on transcription which may be due to the
interactions between different transcription factors bound to the promoter and first
intron.
A series of transcription factors have been identified that regulates the COL1A1
expression by interacting with the first intron, promoter and upstream regulatory
elements of the gene. The protein API belongs to a family of transcription factors
comprised of c-Fos and c-Jun proteins. These modulate the target gene expression as
homo- or heterodimers. An API binding site was found located in a 29bp sequence
between +292 to +670 bp of first intron of the human CGL1A1 gene and was found to
be involved in transcriptional regulation of COL1A1 expression (Liska DJ et al, 1990).
Slack JL et al (1992) reported that transformation of rodent fibroblasts by oncogenic
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Ras resulted in transcriptional inhibition of Collal gene and later they found that
Ras-mediated inhibition of COL1A1 transcription in fibroblasts was achieved through
an API binding site in first intron (Slack JL et al, 1995). As c-jun and c-fos are also
activated by phorbol 12-myristate 13-acetate (PMA), the inhibition of COL1A1
transcription by PMA may be through an API response element. Estradiol has also
been shown to suppress the Type I collagen synthesis in murine mesangial cells via
stimulation ofAPI activity (Silbiger S et al, 1999).
There are several Spl binding sites in the first intron. Two tandem Spl binding sites
are located in a 274bp region of first intron and a DNA-protein complex formed with
this element inhibits the COL1A1 promoter activity (reviewed by Ghosh AK, 2002).
Transmission electron microscopic analysis of DNA-protein complexes showed that
protein-protein interactions between Spl and other transcription factors bring the
promoter and intron into physical contact with each other, with the resulting looping
out of the intervening DNA. It is possible that this interaction creates an optimum
environment for the binding of the transcriptional machinery (Vergeer WP et al,
2000). Further work will be needed to identify the transcription factors which interact
with Spl and co-regulate COL1A1 transcription and expression.
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1.7 The Aims of the Study
The general aim of this study was to utilize some of the approaches described earlier
to examine the roles of three polymorphisms in the 5' flank of the COL1A1 gene in
the pathogenesis of osteoporosis.
The specific aims of this study were:
1. To investigate the role of three polymorphisms and haplotypes defined by three
polymorphisms in osteoporosis by means of association analysis in a cohort of
Scottish premanopausal women, Scottish female patients with osteoporotic
fractures and age-matched female controls..
2. To ascertain whether the promoter and intronl polymorphisms have functional
roles by studying DNA-protein binding and gene transcription.
3. To investigate the association between the three polymorphisms and haplotypes
and the mechanical properties of bone ex vivo.
4. To further define the functional roles of three polymorphisms and haplotypes in
bone in vivo by generating an animal model of osteoporosis mediated by the
polymorphisms.
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2.1 Materials
2.1.1 Suppliers
Sigma-Aldrich Limited, Poole, Dorset, UK
Sigma-Genosys, Ltd, London Road, Pampisford, Cambridge, UK
Invitrogen Ltd, Paisley, UK
Promega, Ltd, Southampton, UK
Qiagen Ltd, West Sussex, UK
GRI, Essex, UK
New England Biolab (UK) Ltd, Hitchin, Hertfordshire, UK
Stratagene, Amsterdam, Netherlands
Cambrex Bio Science Rockland Inc, Rockland, USA
Roche Diagnostics Ltd, Lewes, East Sussex, UK
Hybaid, Teddington, UK
ABgene, Surrey, UK
Anachem Ltd, Bedfordshire, UK
Sarstedt, Leicester, UK
Corning Ltd, Buckinghamshire, UK
Cheshire Scientific Ltd, South Wirral, UK
Fisher Scientific Ltd, Leicestershire, UK
Sciquip Ltd, Shropshire, UK
Applied Biosystems, CA, USA
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USB Corporation, Cleveland Ohio, USA
Amersham Pharmacia Biotech UK Ltd, Buckinghamshire, UK
2.1.2 General Plasticware
Micro tubes 0.5ml, 1.5ml and 2ml Sarstedt
Tissue culture plasticware Corning
0.2ml Flat and domed cap tube Abgene
Thermo-Fast 96, shirted plate Abgene




Horizontal electroporesis tank Hybaid
MJ Research Thermocycler GRI
Balance Fisherbrand PS-200 Fisher
Microcentrifuge eppendorf 5415D Fisher
IKA Minishaker MS 2 Fisher
Syngene Bio imaging system Fisher
Sigma Laboratory centrifuge 4-15, 4K15 Sciquip
Micro Pipette (2pl, 10 pi, 100 pi, 200 pi, 1000 pi) Anachem
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2.1.6 Molecular Biology Products
Hinc II DNA ladder
1 kb DNA ladder (for quantification)
1 kb DNA ladder
Bovine serum albumin
dNTPs
Qiagen plasmid mini kit
Qiagen Endofree plasmid Maxi kit
Qiagen PCR purification kit
QIAquick gel extraction kit
QIAEXII gel extraction kit
PRISM Bigdye™ Terminator cycle sequencing kit
QuickChange™ Site-Directed Mutagenesis Kit
Restriction endomucleases and buffer
Taq PCR core kit
Seakem®GTG® Agarose
Ethidium Bromide
Orange G loading dye
PCR primers and oligos

























T4 DNA Ligase and buffer
XL-1 blue supercompetent cells
ExoSAP IT™
DYEnamic™ ET dye terminator sequencing kit
pGL -3 luciferase vectors (control & basic)
pRL -TK vector
T4 DNA Polymerase, buffer and EDTA







Bicinchoninic Acid Protein Assay
LightShift Chemiluminescent EMSA Kit
6% (w/v) native polyacrylamide gel
Anti-spl
hrSPl, USF, anti-USF
Platinum® Pfx DNA Polymerase
pBlueScript SK (-) vector
QuickChange™ Site- Direct Mutagenesis Kit
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Agarose powder Bio-Rad
Effectene Transfection Reagent Qiagen
2.1.7 Computer Softwares
All the sequence files were read by program "Chromas Pro 1.33" (Technelysium Pty
Ltd). The haplotypes were constructed by program "PHASE" (Stephens M et al, 2001;
Stephens M & Donnelly P, 2003). The probability threshold at which haplotype
phases are called as "correct" is 90% for all the association analyses in this thesis.
The statistical analysis was performed with program "Minitab version 12" (Minitab
Inc. USA). The quantification of the gel shift results were performed with program
"Genetools" (Syngene Bio Imaging, UK).
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2.2 Stock Solutions and Media
2.2.1 General Buffers
1 x TBE:
89 mM Tris base
89 mM Boric acid
2 mM Disodium EDTA





Adjusted to pH 7.0 with 5M NaOH. Volume to 1L with deionized water. Autoclaved
and stored at room temperature.
LB agarplates:
To 1L of LB medium (prior to autoclaving) 15g of bacto-agar were added. Mixed and
then autoclaved. When antibiotic selection was required carbenicillin was added to a
final concentration of 50ug/ml. Approximately 30ml LB agar was poured into each
9cm Petri dish. Plates were allowed to set at room temperature and stored at 4°C.
NZT broth:
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Deionized water added to a final volume of 100ml. Autoclaved and stored at 4°C. The
following reagents were filter sterilized and added immediately prior to use:
2.5ml MgCl2 (1M)
2.5ml MgS04 (1M)
4.0ML 20% (w/v) glucose
2.2.3 Other solutions
1OXAnnealing buffer:




Acetone/DMF (ES cell DNA extraction buffer):
140ml 70% acetone
10ml 5% Dimethyl Formamide
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2.3 Study Populations
2.3.1 APOSS Population
The subjects were taken from the Aberdeen Prospective Osteoporosis Screening
Study (APOSS) population. Participants in the study were randomly selected from the
community health index, which is a database of all patients registered with general
practitioners in Scotland, focussing on those living within a 25 mile radius of
Aberdeen. This was a population-based screening study for osteoporotic fracture risk,
involving 5119 women aged 45-54 years who were initially assessed over a 4 year
period between 1990 and 1994. At this assessment, participants were weighed on a set
of balanced scales calibrated to 0.05 kg (SECA, Hamburg, Germany) and height was
measured with a stadiometer (Holtain, Ltd., Crymych, UK). Participants also
completed a risk factor questionnaire including questions on menopausal status,
physical activity, smoking and use of hormone replacement therapy (HRT). Details of
this population have been previously described (MacDonald HM et al, 2003). Women
were classified as premenopausal if they were menstruating regularly, as
perimenopausal if their menstruation was irregular and/or up to 6 months had elapsed
since their last period; and as postmenopausal if their menstruation had ceased for 6
months or more. On the basis of this information we categorized subjects into five
groups as follows: 1= premenopausal, no HRT; 2 = perimenopausal, no HRT; 3 =
postmenopausal, no HRT; 4 = postmenopausal, previous HRT user; 5 =
postmenopausal, current HRT user. Following this assessment, the BMD results were
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disclosed to participants and their general practitioners and subjects with BMD values
in the lowest quartile of the population were advised to consider taking HRT therapy
(Torgerson DJ et al, 1997).It has been previously found that the uptake of HRT in this
group (approximately 30%) is 6% greater than in women who had not undergone
BMD screening (Torgerson DJ et al, 1997).
All participants were invited to undergo further assessment between 1997 and 1999
and a total of 3883 women of the original 5119 attended at this time (75.8%). The
participants in the present study comprised 3270 women who consented to give blood
samples for DNA extraction and were successfully genotyped for at least one of the
polymorphisms studied.
The APOSS data collection and DNA extraction were finished within the Department
ofMedicine & Therapeutics, the University of Aberdeen prior to this project.
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2.3.2 Fracture and Control Populations
This study included analysis of two case and two control groups, all exclusively from
North East Scotland. The hip fracture group comprised 303 consecutive female
patients who were admitted over a 2-year period to Aberdeen Royal Infirmary (ARI)
with osteoporotic hip fracture resulting from low-energy trauma (typically a fall from
a standing height or less). Patients were excluded who had sustained a hip fracture as
a result of significant trauma (e.g. motor vehicle accidents, or falls from a ladder), and
who were suspected to have sustained a pathological fracture (e.g. Paget's disease or
malignancy). The control group for hip fracture was recruited from patients admitted
the same hospital who had fallen but not sustained a hip fracture. These patients had
mostly been admitted to the geriatric acute assessment ward at ARI.
The vertebral fracture group comprised 151 female vertebral fracture patients
diagnosed clinically and radiographically in the north east Scotland. The control
group comprised 143 age-matched healthy females selected from the same area who
had responded to an advertisement for volunteers to take part in a study of treatment
for osteoporosis. Underlying secondary causes of osteoporosis, such as corticosteroid
therapy and endocrine disorders, were excluded in both fracture populations by
medical history, physical examination, and laboratory investigations.
All the subjects involved in this study gave informed consent to being included and
the study was also approved by the local ethics committee.
The data collection was finished within the Department of Medicine & Therapeutics,
the University of Aberdeen prior to the start of this project.
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2.3.3 Subjects for the Biomechanical Tests
Biomechanical studies were performed on trabecular bone samples from femoral
heads obtained from 23 male and 71 female patients who were admitted to Aberdeen
Royal Infirmary and underwent hip replacement surgery as a result of osteoporotic hip
fracture. The age at fracture ranges from 58 to 101 years old with an average of 81.7
years. The study was approved by the local hospital ethical committee, and all
patients gave informed consent to tissue samples being taken.
The data collection was finished by Dr. Tracy Stewart, in the University of Aberdeen
prior to the start of this project.
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2.3.4 Bone Density Measurements
Bone mineral density (BMD) was measured at the femoral neck (FN-BMD) and
lumbar spine (L2-4) (LS-BMD) by dual energy x-ray absorptiometry using Norland
XR26 and XR36 densitometers. The majority of women were scanned using an XR26
machine, but 357 women (11.5%) were scanned using a XR36 machine. There was a
small difference (1.258%) in mean BMD value between the machines and a
correction factor was used to convert the XR36 values to XR26-equivalent values.
There were no significant differences in the proportion of women scanned on each
machine across different genotypes.
The BMD measurements were performed in the Aberdeen Royal Cornhill hospital
prior to the start of this project.
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2.4 Genotyping Methods
2.4.1 DNA Extration
DNA had been extracted from blood prior to the start of the project for all the patients
using the following protocol: whole blood was collected from subjects into sodium
EDTA Vacutainer® tubes (Becton Dickinson, Dublin, Ireland) and DNA extraction
was performed using a commercially prepared kit according the manufacturers
instructions (Nucleon II DNA extraction kit, Scotlab, Cambridge, UK). The purity of
the extracted DNA was determined from OD260/OD280 ratio and the concentration was
determined by reading the OD260 using a UV spectrophotometer (GeneQuant
RNA/DNA Calculator, Pharmacia Biotech, Cambridge, UK). DNA was then stored at
-20°C. The DNA extraction was performed within the Department of Medicine &
Therapeutics, the University ofAberdeen prior to the start of this project.
DNA was extracted from bone in the biomechanical tests by Dr. Tracy Stewart using
the method described by Steward TL & Mann V (2003). Fresh or freshly frozen bone
that contains marrow was disrupted into about 1 cm3 per piece using bone cutters and
transferred to a clean 5-mL bijoux container. lmL of DNA extraction buffer was
added into each bijoux and mixed well until a slurry was obtained. Then 500pi
aliquots of the slurry were transferred into an Eppendorf tube for each sample. One
volume of Tri-saturated phenol was added into each tube followed by one volume of
chloroform. Each sample was mixed well and centrifuged at 10,000g for 20 minutes
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to separate the phases. The upper layer was then transferred to a fresh tube and one
volume of ice-cold isopropanol and 0.1 volumes of 3M sodium acetate were added
into the tube. Each sample was mixed well and standed for 15 minutes on ice before
proceeding to the centrifuge step (10,000g for 20 minutes). The supernatant was
discarded carefully. The DNA pellet was washed with 1.75 mL of ice-cold ethanol
and centrifuged at 10,000g for 5 minutes. The wash was repeated once. Finally the
DNA pellet was dissolved in 10-50pl of water and quantitated by the same method
described above. DNA was then stored at -20°C.
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2.4.2 Polymerase Chain Reaction (PCR)
Genotyping for -1997G/T and -1663In/delT was carried out by DNA sequencing of
PCR-amplified fragments of genomic DNA whereas genotyping for the Spl
polymorphism was carried out predominantly by TaqMan analysis as previously
described (Uitterlinden AG et al, 1998). All PCR reactions were performed in 96 well
plates in a 25-pl volume containing the following reagents:
2.5pl 10x PCR buffer (Qiagen, UK)
2.0pl dNTP (lOmM each)
5.0pi Q-solution (Qiagen, UK)
2.5pl primer mix (lOpM each of forward and reverse primer)
0.625U Taq DNA polymerase (Qiagen, UK)
50ng genomic DNA
Xul ddlUO up to 25ul
The PCR reactions were carried out on a Gene Engine thermocycler (MJ Research Inc,
USA). For the -1997G/T and -1663In/delT polymorphisms, we generated a 513bp
fragment using the following primers: 5'-TCACTAACCCTCATACTACCAAGC-3'
and 5'-AAGATTCCATTGCCTCCCCC-3'. The thermal cycling protocol for both
fragments consisted of an initial incubation for 5 min at 94°C, followed by 31 cycles
of 60 sec at 94°C, 30 sec at 61 °C and 60 sec at 72°C followed by an extension step at
72°C for 5 min in the last cycle.
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2.4.2 Sequencing Reactions
The PCR products were treated with ExoSAP IT™ according to the manufacturers
instructions (USB Corporation, USA) and sequenced using the DYEnamic™ ET dye
terminator cycle sequencing kit according to manufacturers instructions (Amersham
Pharmacia Biotech UK Ltd, UK). The sequencing reactions were analyzed using a
MEGABACE™ automated DNA sequencer (Amersham Pharmacia Biotech UK Ltd,
UK). The 513bp fragment containing both -1997G/T and -1663In/delT
polymorphisms was sequenced using the forward or reverse PCR primer or an internal
reverse primer 5'-CCTTTAATTATAGCCCCTGCA-3'. A random sample of 5% of
subjects were genotyped twice for each polymorphism to minimize genotyping errors,
with the exception of the -1663In/delT polymorphism where all subjects who were
heterozygous or homozygous for the -1663InT allele were genotyped twice.
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2.5 Luciferase Reporter Assay
2.5.1 An Overview of the Technique
Luciferase reporter assay systems are currently one of the best non-toxic, rapid and
sensitive methods to measure gene expression. The assay is based on the detection of
luciferase activity driven by a promoter or enhancer cloned upstream of the luciferase
gene. Luciferase activity correlates with transcription regulated by DNA regulatory
elements cloned upstream of the reporter gene as well as responses to extracellular
and intracellular signals. In the quantification of gene expression using Firefly
luciferase (pGL3-control/ basic vector), a second Renilla luciferase vector (pRL-TK
vector) is commonly used as internal control in combination with the primary Firefly
luciferase vector to co-transfect mammalian cells. The Dual- Luciferase® Reporter
(DLR) Assay System integrates the assays of both firefly and Renilla luciferase from
the same sample by the sequential measurement of their cognate substrate luciferins,
respectively.
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2.5.2 Construction of COL1A1-Luciferase Reporter Vectors
2.5.2.1 Generating 5* COL1A1 DNA Fragment by Long-PCR
To create the reporter vector, a PCR was carried out to amplify 4kb of 5' human
COL1A1 sequence containing promoter, exonl, intronl and part of exon2 with the
following primers, Kpnl forward: TCACACGCCAGGTACCCAAA and KprA reverse:
TCACGTCATCGCACAACACCT. The PCR was performed in a 0.2 ml PCR tube in
a 25 pi volume containing 2.5 pi 10x PCR buffer (Qiagen Ltd, UK), 2.0 pi of dNTP
(lOmM each), 5.0 pi of Q-solution, 2.5 pi of primer mix (lOpM each of forward and
reverse primer), 0.5 Pi Taq DNA polymerase (Qiagen Ltd, UK) and approximately
80ng human genomic DNA. The thermocycle protocol for this PCR consisted of an
initial incubation for 5 min at 94°C, followed by 9 cycles of 15 sec at 94°C, 1 min at
56°C and 4 min at 68°C followed by 20 cycles of 94°C for 1 min, 56°C for 1 min and
68°C for 4 min with 10 sec increase per cycle. The PCR product was then digested
with Kpnl restriction enzyme and purified with Qiagen PCR purification Kit. 1 pi of
the purified Kpnl digested product was then loaded on 1% agarose gel along with lkb
DNA ladder (NEB, UK) for an approximate quantification.
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2.5.2.2 Modification of the pGL3-basic Vector
To keep the translational reading frame of the luciferase gene intact, the pGL-3 basic
vector (Promega, UK) was modified prior to the cloning of the 5' COL1A1 sequence.
As shown in Figure 2.1, the pGL-3 basic vector was first double-digested by Smal and
Ncol to release a 57bp fragment from the Multiple Cloning Sites (MCS) region. The
double-digestion was set up in a 0.2 ml PCR tube containing 3ug of pGL-3 basic
plasmid, 30 U of each enzyme (NEB, UK), 3 pi of 10X NEbuffer4 , 1.5 pi of 20X
BSA (NEB, UK) and deionized water up to 30 pi. The digest mix was incubated at
37°C for 3 hours and 65°C for 20 minutes. The digested products were then run on a
1% agarose gel and the 4.8kb band was extracted by Qiagen Gel Extraction Kit
followed by quantification on the gel.
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Figure 2.1 Diagram ofmodification of pGL3-basic vector.
Kpnl SmaI
v v v Ncol
GGTACCGAGC... GCTAGCCCGGGCT... CACCATGGAAGACGCCA
CfATGGCTCG... CGATCGGC^CCCGA... GTGGTAC^CTTCTGCGGT
Smal + Ncol digestion
KPnl
, »
1 GGTACCGAGC... GCTAGQ£C CATGGAAGACGCCA
CCATGGCTCG... CGATCGGG^ £TTCTGCGGT
Filling in 5'overhang of






As shown in Figure 2.1, to fill in the 5' overhang of the Ncol digest, the purified DNA
(lug) was incubated at 12°C with 3 units of T4 DNA polymerase (NEB, UK), 3 pi of
10X NEbuffer2, lOOpM dNTPs, 1.5 pi 20X BSA and deionized water up to 50 pi.
Stop reaction by adding 1 pi of 500mM EDTA into the 50 pi mix and heating to 75°C
for 20 minutes. Then 2 pi of the DNA from the reaction was used in a self-liagtion
with 1 unit T4 DNA ligase (Roche, UK), 1 pi of ligation buffer and 6 pi of deionized
water. The ligation mix was incubated at 16°C for 16 hours. 1 pi of the ligation mix
was added to 50 pi of Subcloning Efficiency1 M DF15 alpha competent cells
(Invitrogen, UK). The cells were incubated on ice for 30 minutes and followed by 20
seconds incubation at 37°C. 850 pi of pre- warm LB broth was added into the cells
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and incubated at 37°C for 1 hour with constant shaking at 225rpm. 200 jil of the
mixture was spread on a pre- warm LB agar plate and incubated overnight at 37°C.
Two clones was picked out from the agar plate with yellow tips on the next day and
incubated in 5ml LB broth with 80ug/ml carbenicillin at 37°C overnight with constant
shaking at 225rpm. The plasmid DNA was purified from bacteria by Qiagen MiniPrep
Kit according to the manual and quantified by BIO-TEK plate reader (Synergy HT,
UK).
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2.5.2.3 Generating CQLi^l-luciferase Reporter Vectors
To take up the 4kb Kpnl digested COL1A1 5' fragment, 3ug of the modified pGL3-
basic vector was digested with 30 units of Kpnl restriction enzyme (NEB, UK) with 3
pi 10X NEbuffer 1, 1.5 pi 20X BSA and deionized water up to 30 pi at 37°C for 2
hours. The digestion mix was purified with Qiagen PCR purification kit and then
dephosphorelated with Shrimp Alkaline Phosphatase (SAP, USB corporation, UK).
The SAP treatment was set up as follows:
3 pi Shrimp Alkaline Phosphatase (1 U/pl)
4 pi 10X Shrimp Alkaline Phosphatase reaction buffer
30 pll purified digested DNA (<3 ug)
3 pi ddH20
The reaction was incubated at 37°C for 30 minutes and stopped at 65°C for 15
minutes. The DNA from the SAP treatment was used directly as vector in the ligation
reaction. The following formula was used to calculate the amount of insert and vector
in the ligation reaction:
[{Amount of vector (ng) * length of insert (kb)}/length of vector (kb)]* A
The molecular ratio of vector DNA to insert ('A' in the formula) is 1:3 for sticky ends
when insert DNA and vector were approximately similar in length, otherwise ratio 1:1
or 1:2 was used.
In this study, the molar ratio of insert to vector was 3. Therefore, the reaction mix
contained lOOng of 4.8 kb vector, 250ng of 4kb insert, lpl of T4 DNA ligase (1U/ pi,
Roche, UK), lpl of 10X ligation buffer and water up to lOpl.
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The ligation mix was incubated at 16°C for 16 hours. 2 pi of the ligation mix was
added to 50 pi of Subcloning Efficiency™ DH5acompetent cells (Invitrogen, UK).
The transformation and the incubation of the agar plate were carried out as described
above. Four clones were picked out to incubate in 5ml LB broth at 37°C overnight
with constant shaking at 225rpm. After the same procedures for miniprep and
quantification, the plasmid DNA was selected by a Bsrgl digest. The expected bands
were 3546bp and 5248bp. The plasmid with correct digestion products was sequenced
with primers listed in Appendix 1.2. The sequence reactions with these primers
covered all the 4kb insertion and lOObp of luciferase gene.
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2.5.2.4 Creating Eight Haplotypes by Site-Directed Mutagenesis
The other seven possible haplotypes defined by the three 5' COL1A1 polymorphisms
were introduced into reporter vectors by Site-Directed Mutagenesis reaction (SDM).
The basic procedure utilizes a supercoiled double-stranded DNA vector with an insert
of interest and two synthetic oligonucleotide primers containing the desired mutation
(Figure 2.2). The primers, each complementary to opposite strands of the vector, are
extended during temperature cycling by DNA polymerase to generate mutated
plasmid containing staggered nicks. Following temperature cycling, the product is
treated with Dpnl digest which is used to digest methylated and hemimethylated
parental DNA template for selection of mutation-containing synthesized DNA. After
the Dpnl selection, the nicked vector DNA containing the desired mutations is then
transformed into competent cells.
QuikChange® II XL Site-Directed Mutagenesis kit (Strategen, UK) was used to create
other seven reporter vectors containing all possible haplotypes. All the primers were
designed complementary between 35-45bp with PAGE purification (listed in Table
2.1). The mutagenesis reaction was carried out in 0.2 pi PCR tubes. The reaction was
prepared as indicated below:
5pi 10X reaction buffer
10-50ng dsDNA template (plasmid DNA)
1.25pl primer F (lOOng/pl)
1.25pl primer R (lOOng/pl)
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1 (0.1 dNTP mix
3(0.1 QuikSolution Reagent
ddH20 was added in to a final volume of 50jol. l(ol of PfuUltra HF DNA polymerase
(2.5U/fdl) was added last into the reaction. The thermal cycling protocol consisted of
an initial incubation for 1 min at 95°C, followed by 18 cycles of 50 sec at 95°C, 50
sec at 60°C, and 9 min of 68°C followed by an extension step at 68°C for 7 min in the
last cycle.
After 1 hour incubation with 1 pi Dpnl restriction enzyme (10U/ pi), 2 pi ofmix were
transformed into XLIO-Gold ultracompetent cells according to the manufacturer
instructions (Stratagene, UK). All the nicked vectors containing desired mutations
were then purified from bacterial culture using Mini Prep Kit (Qiagen, UK) and
sequenced to confirm the base changes.
Table 2.1 SDM primers used to create haplotypes in reporter vectors













Polymorphisms are in Bold Italics. F: forward primer; R: reverse primer
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Gens in plosmid with




Denature the plasmid and anneal the
oligonucleotide primers („/) containing
the desired mutation (x)
Using the nonstrand-displacing
action of PfuTurbo DNA polymerase,
extend and incorporate the
mutagenic primers resulting
in nicked circular strands
Digest tie methylated, nanmutated
parental DNA template with Dpn I
Transform the circular, nicked dsDNA
into XL1 -Blue supercompetent cells
After transformation, the XL1 -Blue
supercompetent cells repair the
nicks in the mutated plasmid
Legend
— Parental DNA o osmid
Mutagenic primer
— Mutated DNA plasmid
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2.5.3 Quantification of Reporter Vectors by Fluorometry
DNA concentration was measured using Quant-iT™ PicoGreen® dsDNA Assay Kit
on a BIO-TEK Synergy HT multiwell plate reader. First, a standard curve was
constructed using double-stranded X DNA at known concentrations. DNA samples at
known concentrations were analyzed in duplicate and their average concentrations
calculated from the standard curve regression equation. Hoechst dye (100 pi at
20ug/ml) was added to each well of a black 96 well microtitre plate with clear bottom
along 100 pi of either DNA at known concentrations or DNA standards of known
concentrations. The plate was read after incubation at room temperature for 5 minutes.
The fluorometer measured the relative each sample at 360 nm excitation and 460 nm
emission wavelengths to create a concentration value. Each well was read twice and a
mean value calculated.
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2.5.4 Transfection of the Vectors into HQS TE85 Cells
All transiently transfection experiments were carried out using the human
osteosarcoma cell lines, HOS-TE85. HOS TE85 and another human osteosarcoma cell
line MG-63 are considered suitable models of osteoblastic phenotype, including the
synthesis of type I collagen (Clover J & Gowen M, 1994).
Cells were cultured in 75cm2 tissue culture flasks in alpha MEM medium (Invitrogen)
supplemented with 10% fetal calf serum (FCS, Invitrogen), 50 IU/ml penicillin
(Invitrogen) and 2 mM glutamine (Invitrogen). Medium was renewed every 3 days.
Cells were incubated at 37°C in a humidified atmosphere of 5% CO2.
Twenty- four hours prior to the transfection, cells were cultured in 24-well plates with
the density of 4 x 104. On the day of transfection, cells with less than 50% confluence
were transfected with pGL -3 control vector, pGL -3 basic vector and eight COL1A1-
luciferase reporter vectors with eight different haplotypes, respectively using Magnet
Assisted Transfection (IBA, Germany) according to the instructions. With this new
technique nucleic acids are first associated with magnetic particles. After addition of
transfection complexes to the cells, the culture plate is simply placed on top of a
magnetic plate. The magnetic force rapidly draws the full nucleic acid dose towards
the cells and delivers the nucleic acid leading to fast and efficient transfection.
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2.5.5 Measurement of the Luciferase Activity
Twenty- four hours after transfection, cells were checked to be no more than 95%
confluent. The growth medium was removed from the cultured cells and 2ml of
phosphate buffered saline (PBS) was added to wash the surface of the 24-well plate.
The plate was swirled briefly to remove detached cells and residual growth medium.
The rinse solution was completely removed before applying passive lysis buffer (PLB,
promega, UK). 80 pi of IX PLB was added into each well in the 24-well plate to
completely cover the cell monolayer. The plate was wrapped with foil paper and
stored at -80°C for at least 24 hours prior to performing the DLR™ Assay.
Luciferase Assay Reagent II (LAR II, Promega, UK) was prepared by resuspending
the provided lyophilized Luciferase Assay Substrate in 10ml of the supplied
Luciferase Assay Buffer II. Once the substrates and buffer had been mixed, LAR II
was aliquot and stored at -80°C. Frozen aliquot (80 pi / sample, 2.5ml) of LARII was
thawed at room temperature before use. Stop & Glo® reagent was prepared by adding
1 volume of 5OX Stop & Glo® Substrate (promega, UK) to 50 volumes of Stop &
Glo® buffer. For each measurement (80 pi / sample) 50 pi of 50X Stop & Glo®
Substrate was added to 2450 pi of Stop & Glo® buffer just before use. The frozen 24-
well plates were thawed at room temperature before use. 40 pi of cell lysate from each
sample was carefully transfered into a 96-well clear bottom Castor plate without
bubbles. 40 pi of LAR II and Stop & Glo® reagents were added sequentially into the
same sample and the each luciferase activity was read by BIO-TEK Synergy HT
multiwell plate reader.
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2.5.6 Detection of the COLlAl-luciferase Fused Protein Expression
To confirm expression of the COL1A1 -luciferase fusion protein in transfected HOS
TE85 cells, total RNA of the cells was extracted, and reverse transcribed into cDNA.
PCR reaction was then carried out on this cDNA with one forward primer in COL1A1
exonl and the reverse primer in luciferase cDNA. The PCR product was loaded on
gel to verify the length followed by DNA sequencing.
2.5.6.1 RNA Extraction
Twenty- four hours post- transfection, cells were collected for RNA extraction. The
growth medium was removed from cultured cells and 330 pi of IX cold PBS was
added to wash the cells. The rinse solution was completely removed before applying
330 pi of TRrizol reagent to each well. The lysised cells were scraped off the plate
and transferred to DEPC treated 1.5ml eppendorf. The lysate from the same
transfection were collected in one eppendorf and mixed by pipetting up and down.
The lysate was incubated for 5 minutes at the room temperature. 200 pi chloroform
was added into each sample and mixed by shaking vigorously be hands for 15 seconds.
The mixture was incubated for 3 minutes at room temperature and then centrifuged at
12000g for 15 minutes at 4°C. The aqueous phase (500-600 pi) was transferred
carefully to the fresh DEPC treated 1.5ml eppendorf. 500 pi of isopropyl alcohol was
added to each sample and mixed by inverting. The sample was incubated for 10
minutes at room temperature and then centrifuged at 12000g for 10 minutes at 4°C.
The supernatant was removed and the pellet was washed with 1ml 75% ethanol for
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each sample. The sample was mixed by vortexing and then centrifuged at 7500g for 5
minutes at 4°C. The supernatant was removed and the pellet was dry for 5 minutes on
the bench. 20 pi ofDEPC treated water was added to each sample and the RNA pellet
was dissolved by heating at 60°C for 10 minutes. RNA was stored at -80°C.
2.5.6.2 RNA Purification and Reverse Transcription
The samples were treated with DNAse I to remove contaminated plasmid DNA before
reverse transcription. The DNase I (Invitrogen, UK) clean reaction was set up as
follows:
1 pi DNase I (lU/pl)
lpl 1 OX buffer
1 ug RNA
ddH20 up to 10 pi
The reaction was incubated at room temperature for 15 minutes. 1 pi of EDTA
(Invitrogen) was added to terminate the reaction. The mixture was incubated at 65°C
for 10 minutes to inactive the DNase I.
The reaction products were then used for cDNA production by reverse transcription.
The following components were added to a nuclease-free microcentrifuge tube:
1 pi oligo (dT)2o (50um, Invitrogen, UK)
I pi dNTP mix (lOmM each, Invitrogen, UK)
II pi lug clean RNA (from the DNase I reaction directly)
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The mixture was heated to 65°C for 5 minutes and incubated on ice for at least 1
minute. The following components were added to the mixture:
4 pi 5X fist- strand buffer (Invitrogen, UK)
1 pi 0.1M DTT (Invitrogen, UK)
1 pi RNaseOut Recombinant RNase Inhibitor (40U/pl, Invitrogen, UK)
1 pi Superscript III RT (200U/pl, Invitrogen, UK)
For the control reaction 2 pi of water was added to the reaction in stead of RNaseOut
Recombinant RNase Inhibitor and Superscript III RT. The reactions were mixed by
pipetting up and down gently. The reaction was incubated at 50°C for 60 minutes and
inactivated at 70°C for 15 minutes.
2.5.6.3 PCR Amplification of C01LL47-luciferase Fused cDNA
PCR primers were designed by Roche Universal Probe Library to optimize the
amplification of COL1A1 -luciferase fusion cDNA. After the optimization the
following primers were used for amplification of a 242 bp fragment from COL1A1-
luciferase fused cDNA: Collal_6¥ 5' ATGTTCAGCTTTGTGGACCTC 3' (binding
from the start code of COL1A1 exonl) and CollalJSR 5'
AGTTGCTCTCCAGCGGTTC 3' (binding to the luciferase cDNA). The PCR
reaction was set up as following:
2.5 pi lOx PCR buffer (Qiagen, UK)
2 pi dNTP (lOmM each)
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5 pi Q-solution (Qiagen, UK)
2.5 pi primer mix (lOpM each of forward and reverse primer)
0.625 pi Taq DNA polymerase (Qiagen, UK)
5 pi cDNA
4.875 pi ddH20
The reaction was transferred to a PCR microplate and mixed by pipetting up and
down. The thermal cycling protocol consisted of an initial incubation for 10 min at
95°C, followed by 35 cycles of 15 sec at 95°C, 30 sec at 60°C and 15 sec at 72°C.
This 242 bp qPCR product was then loaded on agarose gel to verify the length
followed by DNA sequencing.
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2.6 Electrophoretic mobility shift assay (EMSA)
2.6.1 An Overview ofEMSA
Electrophoretic mobility shift assay (EMSA) is a rapid and simple technique used to
detect the interaction ofDNA binding proteins with their DNA recognition sequences.
This method has been used widely to discover new proteins such as transcription
factors or protein mixtures that are capable of binding to a specific DNA sequence. It
is based on the observation that protein-DNA complexes migrate through a non-
denaturing polyacrylamide or agarose gel more slowly than free DNA molecules.
EMSA is carried out first by incubating the purified protein or a protein mixture such
as a nuclear extract with a radioactive or fluorescence labeled DNA fragment
containing the putative protein binding site(s). The reaction products are then
analyzed on a nondenaturing polyacrylamide gel. The specificity of the DNA-binding
protein for the putative binding site is established by competition experiments using
DNA fragments or oligonucleotides containing a binding site for the protein of
interest or other unrelated DNA sequences.
To detect the putative binding sites of transcriptional factor(s) in or around the -
1997G/T and the -1663in/del T polymorphisms, several EMSAs were performed
according to the manual of LightShift Chemiluminescent EMSA Kit (Pierce, UK).
Sense oligonucleotides corresponding to "-1997G", "-1997T", "-1663delT" and "-
1663inT" were synthesized and 3' end-labelled with biotin (invitrogen). Antisense
oligonucleotides were synthesized (invitrogen) and annealed with sense biotin-
104
Chapter 2: Materials and Methods
labelled oligonucleotides. The labelled oligonucleotides were incubated with cell
nuclear extract (MG63 and HOS TE85), pure human recombinant Spl (Promega, UK)
or Usf (SantaCruz, USA). Varying concentrations of unlabelled competitor
oligonucleotides were added to assess relative binding affinity of transcription factor(s)
to the "G", "T", "delT" and "insT" alleles. To identify the DNA-bound transcription
factor(s), some antibodies (anti-Spl, anti-Usf, anti-Osterix and anti-Nmp4) were
added to the binding reaction. The reaction products were then electrophoresed on a
6% (w/v) native polyacrylamide gel (invitrogen). The DNA was then rapidly (30
minutes) transferred to a positive nylon membrane, UVcross- linked, probed with
streptavidin-HRP conjugate and incubated with the substrate. The biotin-labelled
DNA was then visualized with Gene GOME imager (Syngene Bio Imaging, UK).
Band intensity was analysed with Gene Tools software
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2.6.2 Nuclear Protein Extraction for EMSA
Nuclear extracts from MG63 and HOS TE85 cells were used for EMSA experiments.
Cells were cultured in 75 cm2 tissue culture flask. Once confluent, the cells were
detached from the flask and the nuclear protein extractions were prepared by using
nuclear extraction kit (Acti motif). The extracts were aliquoted and stored frozen at -
80° C until use.
The concentration of the nuclear extract was determined with BSA as a standard
protein by the bicinchoninic acid protein assay (Pierce, USA). To set up the standard
curve, 10 pi of each concentration BSA (up to 20ug/ pi) was added into 200 pi of
BCA (dye). Several dilutions of each nuclear protein (1 pi, 1.5 pi and 2 pi) were
measured as expected concentration was about 3-5ug/ pi. All the samples were carried
out duplicate.
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2.6.3 Design and Formation of EMSA Oligonucleotide Probe
The oligonucleotide probes used in EMSA experiments were designed to span the two
promoter polymorphisms and surrounding bases within the promoter. All the single
stranded oligonucleotides were synthesized and HPLC purified (Invitrogen). All the
forward single stranded oligonucleotides were biotin 5' end-labelled. Double stranded
oligonucleotides were made from forward and reverse single stranded
oligonucleotides (Table 2.2)
Table 2.2 Single stranded oligonucleotides used in EMSA probe formation
Oligonucleotide DNA sequence
-1663insT (8T) F Biotin-CGGCCAGCCGACGTGGCTCCCTCCCCTTCTGTTCCTTTTTTTTCCCCTTTGCC
-1663 insT (8T) R GGCAAAGGGGAAAAAAAAGGAACAGAAGGGGAGGGAGCCACGTCGGCTGGCCG
-1663delT (7T) R GGCAAAGGGGAAAAAAAGGAACAGAAGGGGAGGGAGCCACGTCGGCTGGCCG
-1997G F Biotin- CGCCTATTAGGGAGGGGGTCTCTTGGAACTGACCC
-1997G R GGGTCAGTTCCAAGAGACCCCCTCCCTAATAGGCG
-1997T F Biotin- CGCCTATTAGGGAGGGGTTCTCTTGGAACTGACCC
-1997T R GGGTCAGTTCCAAGAGAACCCCTCCCTAATAGGCG
sp 1T F Biotin- AGGGAATGTGGGCGGGATGAGGGCCT
sp 1T R AGGCCCTCATCCCGCCCACATTCCCT
Polymorphisms are in Bold, underlined. F: forward oligo; R: reverse oligo
To generate a double stranded oligonucleotide, the complementary reverse
oligonucleotide strand was annealed to the biotin-labelled forward oligonucleotide
strand in a microcentrifuge tube:
2pl 1 pM biotin-labelled forward oligonucleotide strand
3pi 1 pM reverse oligonucleotide strand
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5pi 1OX annealing buffer
40pl Deionized water
The reagents were mixed well and centrifuged briefly before being incubated at 90°C
for 1 minute. The reactions were allowed to cool slowly to room temperature on the
bench (approximately 1 hour), resulting in annealing of complementary
oligonucleotide strands. The double stranded biontin-labelled oligonucleotide probes
were stored frozen at -20°C.
Varying concentrations of unlabelled double stranded competitors of the same
sequence as the labelled oligonucleotides were made by incubating corresponding
amount of unlabelled forward and reverse oligonucleotides with annealing buffer and
deionized water at 90°C for 1minute in a microcentrifuge tube. The reactions were left
to cool to room temperature and stored frozen at -20°C.
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2.6.4 The EMSA Binding Reaction
The binding reaction was performed in a 0.5 ml microcentrifuge tube at room
temperature. The reaction components were added in the order listed below. To
overcome strong non-specific interactions, a short pre-incubation at room temperature
was done before adding the biotin- labelled probe. The binding reactions were
incubated at room temperature for 20minutes. 5 pi of 5X loading buffer was then
added to each sample, pipetting up and down several times.
1 pi (1 pg/pl) Poly (dl.dC) (only used in the binding reactions for -
1663in/delT)
2 pi 1 OX binding buffer
1 pi protein source (nuclear extracts or hrSpl or USF)
1 pi biotin- labelled oligonucleotide probe
Deionized water to final volume of 20 pi
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2.6.5 Competition Assays and Super-shift EMSA
Competition EMSAs were carried out to compare the binding affinities of the
polymorphisc variants for relevant nuclear proteins. Unlabelled double stranded
oligonucleotides of varying concentration were added to the binding reaction to
compete with biotin- labelled probes. The greater the binding affinity of the
competitor, the weaker the resultant gel shift band. In super-shift assays antibodies
(Spl, Usf, Osterix, Nmp4, Actin, NFATcl) were added to the binding reaction before
adding the biotin- labelled probe. Each antibody bound specifically to its protein
resulting in a retarded band on the gel shift.
2.6.6 Electroporesis of Binding Reactions
A pre-cast 4-6% native polyacrylamide gel (12 wells, Invitrogen) was pre-
electrophoresed in 0.5X TBE buffer at 100V for 60minutes. Each well was flushed by
the running buffer and then 20pi of each sample was loaded on the gel. The gel was
run at 100V until the bromophenol blue dye migrated approximately 3/4 down the
length of the gel.
To transfer the binding reactions to nylon membrane by electrophorese, the gel and
nylon membrane (soaked in 0.5X TBE for at least lOminutes) were formed a
sandwich with two wet sponges and blotting papers in a clean electrophoretic transfer
unit according the manufacturer's instructions (BioRad). Transfer was carried out in
cool 0.5X TEB at 380 mA for 60minutes.
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When the transfer was complete, the membrane was cross-linked for 15minutes with
the membrane face down on a transilluminator equipped with 312 nm bulbs.
2.6.7 Detecting Biotin- labelled DNA by Chemiluminescence
The cross-linked membrane was then incubated with 10 ml Blocking Buffer (Pierce)
for 15 minutes at room temperature with gentle shaking on an orbital shaker. After
that, the membrane was incubated with 10 ml Conjugate/ Blocking Buffer for 15
minutes, and then washed four times with 10 ml Washing Buffer according the
manufacturer's instructions (Pierce). After washing, the membrane was transferred to
a clean tray and incubated with 10 ml Substrate Equilibrium Buffer for 5 minutes with
gentle shaking. The membrane was then incubated with 600 pi Substrate Working
Solution in a clean tray for 5 minutes without shaking.
The membrane was then exposed to Gene GOME imager (Syngene Bio Imaging, UK)
in a sealed exposure cassette. Continual exposure from 1 to 4 minutes was used to
visualize the membrane. Band intensity was analysed with Gene Tools software
(Syngene Bio Imaging, UK). After the exposure, membrane was wrapped with
kitchen cling film and stored at 4°C.
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2.7 Biomechanical Testing
All bone samples were stored at 4°C in a calcium phosphate-buffered 0.15M saline
solution (containing 0.2 mM CaC12-2H20, 0.2 mM Na2HP04, 0.01 mM
Na4P2O7-10H2O, and 0.4g of sodium azide/1) because this has been shown to preserve
the structure and composition of the bone (Lees S 1988).
Cylindrical cores of bone were removed from the superior region of the femoral head
using a 9-mm-diameter hollow drill bit as described previously (Li B & Aspden RM,
1997). This site was chosen to represent the region being the most highly loaded in
vivo (Hodge WA et al, 1986). Articular cartilage and the subchondral bone plate were
removed from the bone cores, and both ends were trimmed parallel. The resulting
cores of trabecular bone, having a mean ± SD of height 9.3 ± 1.2 mm, were subjected
to an unconstrained compression test using an Instron 5564 materials testing machine
(Instron, High Wycombe, UK). The test was performed at a strain rate of 10% per
minute. The apparent density of washed and defatted bone samples was calculated by
dividing the total mass by the sample volume, calculated from calliper measurements
of diameter and length. The stiffness and yield were determined from the
characteristics of the stress-strain curve using standard techniques described
previously (Li B & Aspden RM, 1997).
Genotyping was carried out by PCR and DNA sequencing as described in section 2.4.
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2.8 Generation of gene targeting constructs for polymorphic
COL1A1 alleles
2.8.1 Generation of Targeting Construct by Long PCR
The targeting construct contained 3.9 kb of the mouse Collal promoter, 3.6 kb of
human COL1A1 5' sequence (2.3 kb promoter and exonl & 1.3 kb intronl) used to
replace the proximal mouse Collal promoter, 5.3 kbof mouse Collal (exons 2 to 22)
and a selection marker (2 kb of Loxp-Neo-Loxp cassette), as shown in Figure 2.3.
The pBluescript SKII (-) plasmid (pSK II) was used as the background vector in all
the cloning steps carried out in this expepriment.
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Figure 2.3 Schematic presentation of endogenous mouse Collal gene, targeting
vector and control vector.
Endogenous
mouse collal
3 4 5 6 ... 22 23
1 I I II III
Mouse promoter Human 5" sequence mouse exons 2-22





1 2 3 4 5
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6... 22
PSK II (-) vector








2 3 4 5
t
P3
6... 22 23 24 25
//llll
PSK II (-) vector
3' screening PCR
(4.7kb)
This targeting event will replace the proximal promoter of the mouse Collal gene
with the human COL1A1 promoter, exonl and intronl. Loxp-Neo-loxp cassette serves
as a positive selection marker. A control vector with two extended homologous ends
was generated to screen recombination events at both homologous ends using long-
PCR reactions. The black boxes represent mouse Collal exons. The gold box
represents human COL1A1 promoter and intronl. The purple box represents human
COL1A1 exonl. PI, P2 & P3 represent three polymorphisms: -1997G/T, -
1663ins/delT & splG/T, respectively. Notl and Nsil site were used to linearize the
targeting for the targeting experiments.
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The human exonl was mocked to generate an exon with the same amino acid
sequence as mouse and keep the RNA splicing by inserting some mouse sequence
into the 5' and the 3' end of intronl (Figure 2.4). The full sequence of targeting vector
is presented in appendix 1.










The targeting vector comprised the human promoter sequence (in black), and part of
the human exonl (tailored to the same length as mouse exonl). The RNA splicing
sites (in orange boxes) ofmouse Collal gene were introduced to the 5' and 3' of the
human intronl by PCR primers.
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Only the DNA fragment of Collal exons (2-22) was generated by Hincll and Hindlll
double restriction digestion of PCOL-Xho-Wt lOx plasmid (from Mann V). All the
other four DNA fragments were amplified by long PGR amplification. All the PCR
primers are listed in Table 2. 3 and the PCR conditions are listed in Table 2.4.
Table 2.3 PCR primers used in subcloning































F, forward primer; R, reverse primer; underlined, mismatched bases used to introduce
a restriction site; Bold Italics, introduced restriction site.
Sequence homologous to the end ofmouse Collal exonl is shown in blue.
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All the PCR were performed in 0.2 ml PCR tube in a 50 pi volume containing the
following reagents:
5 pi 10X Pfx amplification buffer (Invitrogen, UK)
5 pi dNTP mixture (lOmM each)
5 pi 10 X PCRx Enhancer solution (Invitrogen, UK)
1 pi 50 mM MgS04
2.5 pi primer mix (10 mM each)
0.8 pi Platinum® Pfx DNA polymerase (Invitrogen, UK)
100 ng of template DNA with deionized water to final volume of 50pl
The PCR reactions were carried out on a Gene Engine thermocycler (MJ Research Inc,
USA). The PCR products were visualized on agarose gels directly.
Table 2.4 PCR conditions for subclonings
Name of
fragment
Template Thermal cycling protocol Product
size (bp)
Mouse P: mouse 6kb Initial incubation: 94°C for 3min 3900
COL1A1 (from Bonstein) 10 cycles: 94°C for 15sec, 62°C for 30sec + 68°C for 3min
promoter 20 cycles: 94°C for 15sec, 62°C for 30sec
68°C for 3min (lOsec increased per cycle )




(from Hobson E) 20 cycles: 94°C for 15sec, 60°C for 30sec + 68°C for 4.5min
Human P: 2300G (from Initial incubation: 94°C for 3min 1300
COL1A1
intronl
Hobson E) 9 cycles: 94°C for 15sec + 68°C for 2min
15 cycles: 94°C for 20sec + 68°C for 2min
+ lOsec increased per cycle
Final extension: 68°C for 3min
Loxp- P: Loxp vector Initial incubation: 94°C for 3min 2000
neo-loxp
cassette
(From Albagha O) 20 cycles: 94°C for 15sec, 60°C for 30sec + 68°C for 4.5min
P: plasmid vector.
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2.8.2 Subcloning and Site Direct Mutagenesis (SDM)
To subclone each targeting fragment (mouse Collal promoter, human COL1A1
promoter & exonl, human COL1A1 intronl and mouse Collal exons 2-22) into
pBlueScript® II SK (-) Phagemid vector (PSK (-), Stratagene, UK), restriction digest
was required to make sticky or blunt ends on both the inserts (PCR products) and PSK
(-) vector. The optimum incubation conditions for each restriction enzyme used in
subcloning are listed in Table 2.5.
Table 2.5 Enzymes and incubating conditions for subcloning.
Name of Restriction enzyme Restriction Optimum condition
subclone sequence
(5'-3')
Mouse Eagl C | GGCCG NEBuffer3, 37°C for 3
COL1A1 GCCGG | C hours
promoter Spel A|CTAGT NEBuffer2, 37°C for 3
TGATC I A hours
Houman Spel A | CTAGT NEBuffer2, 37°C for 3
COL1A1 TGATC I A hours
promoter & EcoRl G I AATTC NEbuffer EcoRl,exonl
CTTAA | G 37°C for 2 hours
Human EcoRI G I AATTC NEbuffer EcoRl,
COL1A1 CTTAA | G 37°C for 2 hours
intron 1
EcoRV GAT | ATC NEBuffer3, 37°C for 3
CTA | TAG hours
Mouse Hindlil A | AGCTT NEBuffer2, 37°C for 3
COL1A1 exons TTCGA I A hours
(2-22)* HincH GTY | RAC NEBuffer3, 37°C for 3
CAR I YTG hours
Loxp-Neo- Ajm C | TTAAG NEBuffer2, 37°C for 3
Loxp cassette GAATTIC hours
Mfel C I AATTG NEBuffer4, 37°C for 3
GTTAA I C hours
The cutting position inside a restriction site is indicated by symbol '
*: made by Mann V.
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All the digest reactions were performed in 50 pi reaction with the following reagents:
5 pi 10 X buffer (specific for the restriction enzyme, NEB, UK)
2.5 pi 20 X BSA (NEB, UK)
30 units restriction enzyme
30 pi PCR product (or up to 3 ug plasmid)
deionized water to final volume of 50 pi
After enzyme digestion all the products were visualized by 1% agarose gel
electrophoresis. Products of the correct size were extracted from agarose gel by a Gel
extraction kit (QIAGEN, UK) according to the manual. One pi of the purified DNA
was then loaded on 1% agarose gel along with 1 pi of lkb DNA ladder (NEB, UK)
for approximate quantification.
T4 DNA ligase (Roche, UK) was used to insert the DNA fragment into the PSK (-)
plasmid vector in each subcloning. The amount of insert and vector in the ligation
reaction were calculated by the same formula mentioned in section 2.5.2.3.
Therefore the ligation reaction mix was set up as follows:
1 -2 pi T4 DNA ligase (1 U/pl)
1 pi 10 X ligation buffer
80-100 ng vector DNA
Inserted DNA with deionized water to final volume of 10 pi
A control ligation was set up parallel each time with the same amount of vector,
liagase, ligation buffer and deionized water to final volume of 10 pi. The ligation
119
Chapter 2: Materials and Methods
reaction was performed in 0.2 ml PCR tube and incubated at 16°C for 16 hours on a
Gene Engine thermocycler (MJ Research Inc, USA).
After 16 hours incubation, 1 to 5 pi of the ligation mix was transformed into 50 pi of
XL 1-Blue supercompetent Cells (Stratagene, UK) according to the manual. 200 to
250 pi of each transformation were spread on pre-warmed carbenicillin selective agar
plates. Plates were incubated overnight at 37°C. The transformation reaction was
stored at 4°C. Additional cells may be plated out the next day, if necessary.
Average 4 to 10 colonies were chosen from each transformed plate to incubate in 5 ml
LB broth at 37°C overnight with constant shaking at 225rpm. Qiagen miniprep kit
was used to purify plasmid DNA from the bacterial culture. The concentration of each
plasmid DNA was determined by the absorbance ratio at 260/280 using a Bio-TEK
plate reader (Synergy HT, UK). A 20 pi restriction digest was set up to check if the
DNA was inserted into the correct position on the vector. The restriction enzymes and
their digested products were listed in Table 2.6. The digest products were then loaded
on agarose gel to check the sizes. The plasmids with correct digestion products are
then sequenced with primer M13F and M13R which flank the multiple cloning sites
(MCS) region of PSK II (-). All the primers used in sequencing reaction were listed in
Appendix 1. For long term storage of plasmid glycerol stocks were made using 700 pi
of transformed bacterial culture mixed with 200 pi 40% (v/v) sterile glycerol. This
mix was stored at -80°C.
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Table 2.6 Restriction enzymes used to check each ligation, and their products















The desired base changes on the three polymorphic sites of 5' COL1A1, and the
restriction sites Hindlll and EcoRl were introduced into subclones by the
QuickChange™ Site- Directed Mutagenesis Kit (Strategene, UK). Primers used to
make base change on three polymorphic sites are listed in Table 2.1 (page 97).
Primers used to introduce Hindlll and EcoRl are listed in Table 2.7. All the primers
were designed complementary between 35-45bp with PAGE purification. The
mutagenesis reaction was carried out in 0.2ml PCR tubes. The reaction was prepared
as indicated below:
5 pi 1 OX reaction buffer
10-50ng dsDNA template (plasmid DNA)
1.25 pi primer F (100 ng/pl)
1.25 pi primer R (100 ng/pl)
lpl dNTP mix
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ddH20 was added in to a final volume of 50 jal. One jal of PfuTurbo DNA polymerase
(2.5 U/pl) was added last into the reaction. The precise cycling parameters were
dependent upon the type ofmutation required and the plasmid length.
All the nicked vectors containing desired mutations were purified from bacterial
cultures using Mini Prep Kit (Qiagen, UK) and then sequenced to confirm the base
changes. The primers used in sequencing reaction are listed in Appendix 1.
Table 2.7 Primers used in site-directed mutagenesis





F, forward primer; R, reverse primer; Bold Italics, restriction site introduced by SDM
primer. Mutation introduced by SDM primer was indicated underlined.
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2.8.3 Transfection ofEmbryonic Stem (ES) Cells
To introduce the targeting vectors into mouse ES cells by electroporation, the
targeting vectors were first purified from a bacterial mega-culture (100ml) using
Endofree Maxi Prep Kit (Qiagen, UK). The concentrations and the purity of each
targeting vector were determined by Bio-TEK plate reader using the same method as
described before.
The targeting vectors were then linearized by Notl restriction digest in the first
targeting reaction because the Notl restriction enzyme only had one recognition site
on the upstream of mouse Collal promoter. The Notl digest reaction was set up as
follows:
200 pi targeting plasmid (300 ug, ratio of 260/280-1.80)
30 pi Notl (10 U/ pi, NEB, UK)
30 pi 10 X Buffer
3 pi 100XBAS
37 pi ddH20
The above reagents were mixed well in a 0.5ml microcentrifuge tube and then
aliquoted at 50 pi into 0.2 ml PCR tubes. The 0.2 ml PCR tubes were incubated at
37°C for 5 hours on Gene Engine thermocycler. To check if the Notl digestion was
complete, 1 pi of the digest product from each tube was loaded on a 0.7% agarose gel
along with lkb DNA ladder. The digested products were purified using phenol
chloroform extraction method. The completely digested products were sent to Julia
Doran's lab (MRC Human Genetic Unit) to perform the first targeting experiment.
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After the electroporation, the cells were incubated at 37°C overnight before adding
G418 (175 pg/ml) for selection of recombinant colonies..
For the second targeting, the same amount of ES cells with lOOug DNA saved from
the first targeting was electroporated following the same procedure. The G418
selection of the recombinant ES cells was carried out as the first time. The targeting
procedure for both constructs was conducted in parallel.
For the third targeting, the constructs were prepared as described above using Qiagen
Endofree Maxi Prep Kit and linearized by Notl and Nsil restriction digest (Figure 2.3).
The linear DNA was extracted by Elutrap Electro-seperation system (Schleicher &
Schuell). lOOug of purified DNA was used in the third targeting by the same
procedure as the first and the second targeting.
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2.8.4 Detecting the Recombination Events by Long PCR
Two long PCR reactions were designed to screen the recombination events at 5' and
3'. ES cells survived a selective G418 medium after electroporation were lysed and
the DNA was extracted. The concentration and purity of the extracted DNA were
analyzed by Bio-TEK plate reader. One pi of DNA from each ES cell and 1 pi of
18.4kb control construct were used in PCR screening.
The PCR conditions for both 5' and 3' screening were optimized using 18.4kb control
construct andJ or mouse 129/ola genomic DNA as template prior to the targeting. The
formula (from GenOway) to calculate 1 equivalent copy of 18.4kb control vector to
150ng 129/ola genomic DNA is:
{18400 bp x 150 ng}/ 6 x 109 bp = 4.6 x 10"4 ng
The control vector was then diluted to 0.1 equivalent copy, 1 equivalent copy and 10
equivalent copies used as template to optimize both PCR screening conditions. 150ng
of mouse 129/ola genomic DNA was used as control solo or mixed with control
vector in PCR optimization. Both 5' and 3' screening PCR were carried out in 0.2ml
PCR tube in a 25 pi volume containing the following reagents:
2.5 pi 10X PCR buffer (Qiagen)
2 pi dNTP mixture (lOmM each)
5 pi 5X Q solution (Qiagen)
2.5 pi primer mixture (lOnM each)
1 pi DNA (extracted from each ES cells or control construct)
0.8 pi Taq DNA Polymerase (12.5 U/ pi, Qiagen)
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distilled H20 to final volume of 25 pi
The primers for 5' screening PCR (6.3kb) are: ACTTGGGAGCTGCGATGC and
CTCATCCCGCCCCCATTC. The thermal cycling conditions consisted of an initial
incubation of 2 min at 94°C, then 9 cycles of 30 sec at 94°C and 6 min 30 sec at 68°C,
followed by 20 cycles of 20 sec at 94°C, 6 min 30 sec at 68°C with 10 seconds
increased per cycle, and followed by an final extension of 3 min at 68°C.
The primers for 3' screening PCR (4.7kb) are: GGTGGGGGTGGGGTGGGATT and
GGAGCACCACGTTCACCGGA. The thermal cycling conditions consisted of an
initial incubation of 4 min at 94°C, then 9 cycles of 30 sec at 94°C, 1 min at 55°C and
5 min at 68°C, followed by 20 cycles of 30 sec at 94°C, 1 min at 55°C and 5 min at
68°C with 10 seconds increased per cycle, and followed by an final extension of 3
min at 68°C. The PCR reactions were carried out on a Gene Engine thermocycler (MJ
Research Inc, USA). The PCR products were visualized on 1% agarose gel directly.
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CHAPTER THREE
Association study of 5' COL1A1
polymorphisms and BMD
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Abstract
Osteoporosis is a complex disease with a strong genetic component. The COL1A1 gene is
a strong functional candidate gene for susceptibility. A polymorphism affecting an Spl
binding site in the first intron of COL1A1 gene has been established as a functional
variant and associated with genetic regulation of BMD, osteoporotic fracture and other
osteoporosis-related phenotypes such as postmenopausal bone loss, bone geometry, bone
quality and bone mineralization. However, recently two promoter polymorphisms of
COL1A1 were identified and found to be in strong linkage disequilibrium (LD) with the
Spl polymorphism in a small study of Spanish post-menopausal women.
To investigate the three polymorphisms in relation to BMD in women, an association
study was performed in a large population-based cohort of 3270 Scottish women.
In this study, the polymorphisms were in strong linkage disequilibrium and three
haplotypes accounted for over 95% of alleles at the COLIA1 locus. Individual
polymorphisms were each associated with BMD, but the most consistent associations
were with haplotypes defined by all three polymorphisms. For example, homozygote
carriers of haplotype 2 (-1997G /-1663delT / +1245T) had reduced BMD at baseline
(p=0.007 for LS-BMD; p=0.008 for FN-BMD), whereas homozygotes for haplotype 3 (-
1997T / -1663insT / +1245G) had increased BMD (p=0.007 for LS-BMD). In conclusion,
haplotypes defined by polymorphisms in the 5' flank of the COLIA1 regulate BMD in a
bidirectional manner in the large cohort of Scottish perimenopausal women.
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Introduction
Osteoporosis is a common disorder characterized by low bone mass, micro-architectural
deterioration of bone tissue and enhanced bone fragility leading to an increased incidence
of fracture. Genetic factors have been recognized to play an important role in both
osteoporosis and its associated phenotypes including bone mineral density (BMD) and
fracture risk. Many candidate gene polymorphisms have been implicated in the
pathogenesis of osteoporosis but one of the most widely studied is a polymorphism that
affects an Spl binding site in the first intron of the COLIA1 gene at position +1245
relative to the transcription start site (rs 1800012). The COLIA1 Spl binding site
polymorphism has been associated with bone density, fragility fractures and other
osteoporosis-related phenotypes such as postmenopausal bone loss, bone geometry bone
quality and bone mineralization (reviewed by Ralston SH & de Crombrugghe B, 2006).
Functional analysis has shown that the osteoporosis associated T allele of the Spl
polymorphism is associated with increased DNA-protein binding, increased transcription,
abnormally increased production of the collagen type I alpha 1 mRNA and protein and
bone mineralization (Stewart TL et al, 2005 & Mann V et al, 2003). Several retrospective
meta-analyses of published studies concluded that carriage of the T allele is associated
with reduced BMD at the lumbar spine and femoral neck and with vertebral fractures
(Ralston SH et al, 2006b; Mann V et al, 2003; Efstathiadou Z et al, 2001 & Mann V et al
2003). However, two promoter polymorphisms of COL1A1 (-1997G/T; rsl 107946 and -
1663indelT; rs2412298) were recently found to be in strong LD with the Spl
polymorphism. These polymorphisms were found to interact with each other and the Spl
polymorphism to regulate BMD in a small study of Spanish post-menopausal women
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(Garcia-Giralt Net al, 2002). Also they were found to regulate reporter gene transcription
in a promoter-reporter assay (Garcia-Giralt N et al, 2005). The -1997G/T promoter
polymorphism has been studied in relation to BMD in other populations and family based
studied with mixed results although most of these studies have been of limited sample
size (Yamada Y et al, 2005 & Liu PY et al, 2004). In this study therefore, the effects of
the promoter and Spl polymorphisms of the COLIA1 gene on BMD was investigated in a
large population-based cohort of 3270 predominantly postmenopausal Scottish women.
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Methods
The subjects were taken from the Aberdeen Prospective Osteoporosis Screening Study
(APOSS) population. This was a population-based screening study for osteoporotic
fracture risk, involving 3883 women aged 45-54 years who were initially assessed over a
4 year period between 1990 and 1994 and further assessed between 1997 and 1999.
Information was collected on weight, height, menopausal status, use of hormone
replacement therapy (HRT), smoking, alcohol use and exercise at the second visit. Bone
mineral density (BMD) was measured at the femoral neck (FN-BMD) and lumbar spine
(L2-4) (LS-BMD) by dual energy x-ray absorptiometry. Rate of bone loss was calculated
as yearly percentage of change in BMD.
The participants in the present study comprised 3270 women who consented to give
blood samples for DNA extraction and were successfully genotyped for at least one of the
polymorphisms studied by PCR-sequencing. The details of the APOSS population and
the genotyping method are described in chapter 2.
Statistical analysis
Statistical analyses were performed using Minitab version 12. The chi-square test was
used to test for Hardy-Weinberg equilibrium. I used the ANOVA general linear model
(ANOVA-GLM) routine of Minitab to study differences in BMD according to genotype
and haplotype, with adjustment for age, body mass index (BMI), smoking (current
smoker or non-smoker), physical activity level (PAL) score, menopausal status
(premenopausal vs. perimenopausal and postmenopausal) and HRT use (never used HRT,
previous HRT user, current HRT user). At the baseline visit, BMD values were adjusted
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only for age, BMI, HRT and menopausal status, since information on smoking and PAL
was not available at this time point. When significant differences were detected by
ANOVA-GLM across genotype groups, the means were compared between groups using
Tukey's test. Multiple regression analysis and stepwise multiple regression analysis was
used to evaluate associations between genotypes and haplotypes and BMD and to
estimate the effect size of the genotype and haplotypes in relation to other predictors of
BMD. For this analysis, continuous variables (age, BMI and PAL) were entered into the
statistical model as covariates. For categorical variables, such as menopausal status, HRT
use, and COLIA1 genotype and haplotype, dummy variables were constructed for use in
the multiple regression analysis. Although I performed multiple statistical tests of three
polymorphisms (and haplotypes defined by these polymorphisms) in relation to BMD at
baseline and follow up at two skeletal sites, these factors were interrelated and therefore
not independent. In view of this I used a modified Bonferroni correction to adjust for the
number of independent tests performed to take account of the fact that the
polymorphisms were in linkage disequilibrium and the BMD measurements at the spine
and hip at baseline and follow up were strongly correlated. To make this correction, I
took an average of the D' values for all 3 polymorphisms (0.92) and subtracted this figure
from 1 to get an indication of the number of independent polymorphisms tested [1+2*(1-
0.92)]. According to this calculation, the number of independent polymorphisms tested
was 1.16. I analysed two skeletal sites (FN-BMD and LS-BMD) but these were
significantly correlated (r=0.668) and taking this correlation into account, I effectively
analysed 1.33 independent sites [1+ (1-0.668)]. Similarly, baseline and follow up BMD
were strongly correlated (r=0.883) and therefore the analysis of genotype in relation to
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baseline and follow-up BMD can be considered as 1.12 independent tests [1+ (1-0.883)].
In total therefore, I conducted 3.61 independent tests (1.16+1.33+1.12). Applying a
Bonferroni correction to our data using this figure gives an adjusted threshold for
significance ofp=0.014, equating to the conventional threshold for significance of p=0.05.
The sample size gave approximately 99% power of detecting a difference of 0.15* BMD
Z-score units between genotype groups assuming a population frequency of 0.20 for the
rare allele.
*: z-scores are the number of standard deviations below the average for a person of the same age, race and gender.
For example, a person with a z-score of-1 has 2.5 times the chance of a hip fracture compared to a woman with an
average bone density. The 0.15 z-score was picked based on the mean ± SD BMD values of this population (see
next page).
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Results
Characteristics of the Population
The average ± SD age of the participants at the baseline visit was 48.4 ± 2.3 years (range
44-56 years) and was 54.8 ± 2.3 years at the follow up visit. The average time between
baseline and follow-up visits was 6.3 ± 0.85 years and did not differ between genotype or
haplotype groups (data not shown). At the baseline visit, 44.9% of participants were
premenopausal and 16.9% were current users of HRT. At the follow up visit only 3.2% of
participants were premenopausal and the proportion of current HRT users had roughly
doubled to 37.5%.
The average ± SD of the lumbar spine BMD at the baseline was 1.057 ± 0.329 g/cm2and
was 1.010 ± 0.170 g/cm2at the follow up visit. For the femoral neck BMD, the baseline
value was 0.881 ±0.125 g/cm2 and the follow up visit was 0.837 ±0.122 g/cm2.
The genotype rates were 98.77%, 88.87% and 82.87% for the Spl G/T, -1997 G/T and -
1663ins/delT respectively. Genotype frequencies for all three polymorphisms were
similar to those previously reported in other Caucasian populations (Garcia-Giralt N et al,
2002 & Liu PY et al, 2004). All three polymorphisms were in strong linkage
disequilibrium (LD) and D' values ranged from 0.88-0.96 (Figure 3.1). Genotypes for the
-1997 G/T polymorphism and the Spl polymorphism were in Hardy-Weinberg
equilibrium (HWE) (p>0.05) but genotypes for the -1663indelT polymorphism deviated
significantly from HWE (p=0.002) due to over representation of homozygotes for the -
1663InsT allele and under-representation of heterozygotes. In view of this I carefully
scrutinized sequencing traces from all individuals who were heterozygous for -
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1663indelT and all -1663delT homozygotes, but no errors were identified. I also re-
sequenced from both directions (forward and reverse) for all the -1663indelT
heterozygotes and all -1663delT homozygotes, no errors were identified. Thereby
genotyping error was excluded as a cause of the HWE deviation.
Analysis of genotype data by the PHASE software program predicted the presence of all
eight possible haplotypes in the APOSS population, but five of these were very rare, and
three common haplotypes accounted for 95.4% of alleles at the 5' flank of the COLIA1
locus (Figure 3.1). These were designated haplotype 1 (-1997G / -1663InsT / +1245G),
which accounted for 65.3% of alleles; haplotype 2, which accounted for 16.8% of alleles
(-1997G / -1663DelT / +1245T) and haplotype 3, which accounted for 13.3% of alleles (-
1997T / 1663InsT / +1245G).
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Figure 3.1 Common haplotypes in the promoter and intron 1 ofCOLIA1
-1997 G/T -1663 insdelT +1245 G/T (Sp 1)
1 2 3 4 5 6
G - InsT G Haplotype 1 (65.3%)
G - DelT T Haplotype 2 (16.8%)




Common haplotypes and their frequencies at the 5' flank of the COLIA1 gene are shown
in relation to the COLIA1 gene structure. Shaded boxes represent exons. Linkage
disequilibrium values (as D') between SNP are depicted in colored triangles at the bottom
of the figure. Other haplotypes and their frequencies are shown in Table 5.4 page 202.
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Association between Individual Polymorphisms and BMP
Relevant characteristics of the APOSS population at baseline and follow-up in relation to
the individual polymorphisms are shown in Table 3.1. The BMD values shown are
adjusted for age, body mass index, HRT use, and menopausal status at the baseline
assessment and for age, body mass index, HRT use, menopausal status smoking and
physical activity score at the follow-up assessment.
There was no difference in age, BMI, menopausal status or HRT use between the
genotype groups at the baseline visit, but all three polymorphisms were associated with
adjusted BMD at either the lumbar spine and/or femoral neck at baseline. For the -
1997G/T polymorphism, there was a significant association with lumbar spine BMD
(p=0.003) and comparison between genotypes showed that BMD values were
significantly higher in homozygotes for the T allele.
For the -1663indelT, there was also a significant association with lumbar spine BMD
values (p=0.006) and for the Spl polymorphism the p-value was nominally significant
(p=0.018) but fell below the adjusted threshold for significance of p=0.012 when multiple
testing was taken into account. For both the -1663indelT and Spl polymorphisms,
comparison between genotypes showed that BMD values were significantly reduced in
rare homozygotes. Nominally significant results were obtained for baseline femoral neck
BMD in relation to the -1663indelT and Spl polymorphisms (p=0.024, p=0.048,
respectively) but these did not reach the threshold for significance when multiple testing
was considered. There was no significant association between -1997G/T and femoral
neck BMD at baseline (p=0.196). When 1 performed multiple regression analysis,
entering genotypes for all polymorphisms into the model assuming a recessive mode of
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inheritance, I found that homozygosity for the -1997T allele was an independent predictor
of baseline lumbar spine BMD (p=0.002; 0.32% of the variance), along with BMI
(p<0.001; 6.09% of the variance), age (p<0.001; 0.94% of the variance), menopausal
status (p<0.001; 3.64% of the variance) and HRT use (p=0.003; 0.25% of the variance).
Taken together, these variables explained 11.24% of the variance in lumbar spine BMD.
When I performed a similar analysis for femoral neck BMD none of the individual
genotypes was identified as an independent predictor ofBMD (data not shown).
At the follow-up visit, there was a highly significant difference in the proportion ofHRT
users in relation to the -1663indelT (p=0.02) and Spl polymorphisms (p=0.003). For
these polymorphisms, the proportion of HRT users in heterozygotes was less than in the
other genotype groups and for the Spl polymorphism, there was an excess of HRT users
among TT homozygotes. Genotype-specific associations with BMD at the follow-up visit
for the -1997G/T polymorphism were similar to the baseline visit (p=0.003), except that
the association with femoral neck BMD at follow-up was nominally significant (p=0.039).
For the -1663indelT and Spl polymorphisms, the associations with BMD at follow-up
were weaker than at baseline and nominal significance was observed only for the Spl
polymorphism in relation to lumbar spine BMD (p=0.037). When I performed multiple
regression analysis entering genotypes at all three polymorphisms into the regression
model assuming a recessive mode of inheritance, I found that homozygosity for the -
1997T allele was an independent predictor of follow-up lumbar spine BMD (p=0.001)
accounting for 0.35% of the variance and of femoral neck BMD (p=0.027) accounting for
0.21% of the variance. Other non-genetic predictors of femoral neck and lumbar spine
BMD at follow-up were similar to those at the baseline visit (data not shown).
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I also analysed the relationship between individual polymorphisms and unadjusted BMD
values at each visit by ANOVA and this yielded broadly similar results to the adjusted
BMD values (data not shown).
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Association between COLIA1 5' Haplotypes and BMP
Relevant characteristics of the APOSS population at baseline and follow-up in relation to
the three commonest haplotypes are shown in Table 3.2. There was no significant
association between any haplotype and age, BMI, menopausal status or HRT use at the
baseline visit and there was no significant difference in adjusted lumbar spine BMD or
femoral neck BMD values at baseline in relation to haplotype 1. There was a significant
association between haplotype 2 and baseline BMD at the lumbar spine (p=0.007) and
femoral neck (p=0.008) with reduced BMD values in homozygote carriers of haplotype 2.
There was also a significant association between haplotype 3 and baseline BMD at the
lumbar spine (p=0.007), but the association with baseline femoral neck BMD was not
significant (p=0.224).
Multiple regression analysis showed that haplotypes 2 and 3 were significant predictors
of lumbar spine BMD at baseline. Homozygosity for haplotype 2 accounted for 0.26% of
the variance in lumbar spine BMD (p=0.007) and homozygosity for haplotype 3
accounted for 0.19% of the variance (p=0.007). Other predictors were BMI (p<0.001;
6.43% of the variance), menopausal status (p<0.001; 3.66% of the variance), age
(p<0.001; 0.95% of the variance) and HRT use (p=0.003; 0.27% of the variance).
Together these variables predicted 11.76% of the variance in baseline lumbar spine BMD.
Homozygosity for haplotype 2 was also a significant predictor of baseline femoral neck
BMD (p=0.004) accounting for 0.25% of the variance. Other predictors were BMI
(p<0.001; 9.18% of the variance), age (p<0.001; 2.57% of the variance), menopausal
status (p<0.001; 0.64% of the variance) and HRT use (p=0.048; 0.16% of the variance).
Together these variables predicted 12.81% of the variance in baseline femoral neck BMD.
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At the follow-up visit, there was no difference in age, BMI, smoking, or physical activity
score in relation to haplotype (data not shown), but there was a significant difference in
the proportion of HRT users in relation to carriers of haplotype 2, with a reduced number
of HRT users in heterozygotes and an increased number of HRT users in haplotype 2
homozygotes (p=0.002). There was no significant difference in adjusted lumbar spine
BMD or femoral neck BMD values at follow-up in relation to haplotype 1. There was no
significant association between haplotype 2 and follow-up BMD at the lumbar spine,
contrasting with the significant association at baseline. Moreover, the association
between haplotype 2 and femoral neck BMD at follow-up was weaker than at baseline
(p=0.033). For haplotype 3, the association with lumbar spine BMD at follow-up
remained significant (p=0.004) with a similar effect size as at the baseline visit.
Haplotype 3 was associated with femoral neck BMD at follow-up with a nominally
significant pvalue of p=0.030.
Multiple regression analysis showed that haplotype 3 was a significant predictor of
lumbar spine BMD at follow-up. Homozygosity for haplotype 3 accounted for 0.50% of
the variance in BMD (p=0.004). Other predictors were BMI (p<0.001; 7.49% of the
variance), age (p<0.001; 2.563% of the variance), menopausal status (p<0.001; 1.55% of
the variance), and HRT use (p<0.001; 1.1% of the variance). Together these variables
predicted 13.2% of the variance in follow-up lumbar spine BMD. For follow-up femoral
neck BMD, multiple regression analysis showed that homozygosity for haplotype 2 was a
significant predictor of BMD (p=0.021) accounting for 0.21% of the variance. Haplotype
3 was also a significant predictor of follow-up femoral neck BMD (p=0.05) accounting
for 0.16% of the variance. Other predictors were BMI (p<0.001; 8.47% of the variance),
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age (p<0.001; 2.12% of the variance), and menopausal status (p<0.023; 0.18% of the
variance). Together these variables predicted 10.93% of the variance in follow-up
femoral neck BMD. Since haplotype 2 and haplotype 3 had opposing effects on BMD, I
stratified participants according to combinations of these two haplotypes. This showed a
striking difference in BMD between the extreme genotypes at both baseline and follow-
up as illustrated in Figure 3.2. Subjects who were homozygous for haplotype 3 had the
highest BMD and homozygous for haplotype 2 had the lowest BMD. The difference
between haplotypes was greatest for lumbar spine BMD at baseline (p=0.001) and
follow-up (p=0.008), but was also evident and statistically significant for femoral neck
BMD at baseline (p=0.02) and follow-up (p=0.012). The difference in BMD between the
extreme haplotypes (homozygotes for haplotype 2, versus homozygotes for haplotype 3)
was 0.094 g/cm at the lumbar spine which is equivalent to about 0.58 BMD Z-score
units and 0.042 g/cm2 at the femoral neck which is equivalent to about 0.33 BMD Z-score
units. At follow up, the difference in BMD between the extreme genotypes 2/2 and 3/3
was 0.010 g/cm2 at the lumbar spine which is equivalent to about 0.81 BMD Z-score and
0.061 g/cm2 at femoral neck which is equivalent to about 0.50 BMD Z-score units.
I also analysed the relationship between individual haplotypes and unadjusted BMD at
each visit by ANOVA and this yielded broadly similar results to those obtained with the
adjusted BMD values (data not shown).
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Figure 3.2 Association between COLIA1 5' haplotypes and BMD
1.10
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The BMD values shown are adjusted for confounding factors by ANOVA-GLM in
relation to carriage of haplotype 2 and 3 in the 5' flank of the COLIA1 gene. Panels a and
b show the results for lumbar spine BMD at baseline and follow up respectively, whereas
panels c and d show the results for femoral neck BMD at baseline and follow-up
respectively. Columns are least square means, and bars are standard deviation. 2/2
indicates homozygotes for haplotype 2; 2/0 indicates heterozygotes for haplotype 2 who
were not carriers of haplotype 3; 3/0 indicates heterozygotes for haplotype 3 who were
not carriers of haplotype 2; 3/3 indicates homozygotes for haplotype 3; 0/0 indicates
subject who were not carriers of either haplotype 2 or haplotype 3.
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Genotype and Haplotype Associations with Bone Loss
There was no significant association between genotype or haplotype and bone loss at
either the lumber spine or femoral neck in the APOSS population. Multiple regression
analysis showed that the major predictors of lumbar spine bone loss were HRT use
(pO.OOl; 14.59% of the variance); menopausal status (p<0.001; 4.48% of the variance);
BMI (pO.OOl; 3.04% of the variance); and age (p=0.01; 0.19% of the variance).
Together these variables accounted for 22.3% of the variance in bone loss. Similar
analysis for femoral neck bone loss showed that the major predictors were HRT use
(pO.OOl; 7.85% of the variance); menopausal status (pO.OOl; 2.17% of the variance);
BMI (p=0.01; 0.4% of the variance). Together these variables accounted for 10.4% of the
variance in femoral neck bone loss.
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Pair-wise Interactions between Polymorphisms and BMP
Pair-wise interactions among the three polymorphisms on BMD were tested in this
population. The method was developed by Bustamante M et al (2007). The interactions
between polymorphisms were tested against BMD at lumbar spine and femoral neck by
using program SPSS. The significant level is p value lower than 0.05. There were two
interactions with significantp values are showed in Figure 3.3. The heterozygote and rare
homozygote of -1663ins/delT can be divided into two groups with extreme mean BMD
values according to the genotype at -1997. A similar interaction was observed in Spl
genotypes. Significant associations between the interaction between -1997G/T and -
1663ins/delT polymorphisms with lumbar spine BMD were observed at baseline
(p=0.006) and follow-up (p=0.032) after adjusting for age, BMI, menopausal status and
HRT use. This association was also observed with femoral neck BMD with a less
significant level at only follow-up (p=0.05, data not shown). Significant associations for
the interaction between -1997G/T and Spl G/T polymorphisms with lumbar spine BMD
was detected at both baseline (p=0.005) and follow-up (p=0.02) after adjusting for age,
BMI, menopausal status and HRT use. This association was also observed with femoral
neck BMD with a less significant level only at follow-up level (p=0.046, data not shown).
However, no association between the interaction between Spl G/T and -1663ins/delT
polymorphisms with either lumbar spine BMD or femoral neck BMD was observed in
this population.
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a. Interaction between the -1997G/T and -1663ins/delT polymorphisms is associated with
adjusted lumbar spine BMD at baseline (p=0.006). b. Interaction between the -1997G/T
and SplG/T polymorphisms is associated with adjusted lumbar spine BMD at baseline
(p=0.005).
BMD values are adjusted for age, BMI, menopausal status, and HRT use. BMD values
are showed as mean ±SEM. Genotypes are indicated either below the figure or by
coloured code (right). The number of individuals per group (n) and the significance (p)
are also shown.
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Discussion
The COLIA1 gene is a strong functional candidate for the genetic regulation of bone mass
and susceptibility to fragility fractures, since it encodes the alpha 1 chain of type I
collagen, the most abundant protein in bone. Most previous studies of COLIA1 alleles in
relation to osteoporosisrelated phenotypes have focused on the intronic Spl binding site
polymorphism (Grant SFA et al, 1996). The promoter polymorphisms that I studied here
were originally identified by Garcia-Giralt and colleagues on mutation screening of the
proximal COLIA1 promoter in 265 postmenopausal Spanish women (Garcia-Giralt N et
al, 2002). In that study, the -1997G/T polymorphism was the one most strongly
associated with BMD and lumbar spine BMD values were reduced in TT homozygotes
compared with the other genotype groups (Garcia-Giralt N et al, 2002). Whilst the -
1663InsT/DelT polymorphism was not significantly associated with BMD in Spanish
women, regression analysis showed that alleles at the -1663 and Spl site interacted with
alleles at the -1997 site to regulate lumbar spine BMD. The relation between the -
1997G/T polymorphism and BMD has also been investigated in other cohorts. In a study
of 308 postmenopausal Caucasian women from the USA, haplotypes defined by the -
1997 and Spl polymorphisms were found to be associated with BMD such that higher
values were found in carriers of the G allele at both polymorphic sites (Liu PY et al,
2004). Another family based study in Chinese subjects showed evidence of an association
between the -1997G/T polymorphism and hip BMD using a quantitative TDT based
approach (Zhang YY et al, 2005), whereas a population based study of unrelated Chinese
women showed no association between -1997G/T alleles and BMD (Lau HH et al, 2005).
A further study of 1100 Japanese postmenopausal women, reported a significant
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association between -1997G/T alleles and hip BMD with lower BMD values in GG
homozygotes (Yamada Y et al, 2005).
The present study of promoter and intron 1 polymorphisms at the COLIA1 locus is the
largest and most comprehensive to be conducted so far and is the first study to examine
the role of all three polymorphisms and haplotypes in relation to BMD. In agreement with
the previous study of Spanish women (Garcia-Giralt N et al, 2002), 1 found that all three
polymorphisms were in strong linkage disequilibrium and three common haplotypes
accounted for more than 95% of alleles at the 5' flank of the COLIA1 locus. These were;
haplotype 1 (-1997G / -1666InsT / +1245G); haplotype 2 (1997G / -1663delT / +1245T)
and haplotype 3 (-1997T/ -1663InsT / +1245G). Whilst the individual polymorphisms
were associated with BMD to an extent, I observed stronger and more consistent
associations with BMD in relation to the carriage of the COLIA1 haplotypes and also
observed significant differences in the strength of association by skeletal site and the time
point at which participants were studied. For the -1997G/T polymorphism, homozygotes
for the T allele had increased lumbar spine BMD at baseline and follow-up and had
increased femoral neck BMD values at follow-up. These observations are in broad
agreement with the findings reported by Yamada and colleagues, who also reported
higher BMD values in relation to the -1997 T allele in Japanese postmenopausal women
(Yamada Y et al, 2005). Our findings differ from the results reported in Spanish and US
postmenopausal women however, where the -1997T allele was associated with reduced
BMD (Garcia-Giralt N et al, 2002 & Liu PY et al, 2004). The differences between these
studies could be due to the fact that the polymorphisms studied here are in linkage
disequilibrium with other functional polymorphisms at the COLIAl locus that regulate
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BMD and that the patterns of LD differ in these different populations. Another more
likely explanation is due to a more accurate estimate of effect size in the Yamada study
(Yamada Y et al, 2005), and in this study, which respectively, were about 3 times and 10
times larger than the studies which reported an association between the -1997T allele and
low BMD (Garcia-Giralt N et al, 2002 & Liu PY et al, 2004).
For the -1663indelT and Spl polymorphism 1 observed a strong and highly significant
association with lumbar spine BMD values at baseline, even after correction for multiple
testing, but these associations were weaker at follow-up. The difference that I observed
between baseline and follow up may have been influenced by differential use of HRT in
the different genotype groups. This was most marked and statistically significant for the -
1663indelT and Spl polymorphisms, where there was a highly significant difference
across genotype groups in terms of HRT use at follow up, compared with no difference at
baseline. This difference in HRT use may be accounted for by the fact that women in this
cohort who had BMD values in the lowest quartile at baseline were advised to take HRT
in order to protect from osteoporosis (Torgerson DJ et al, 1997). Since BMD values were
significantly lower in homozygotes for the rare allele at the -1663indelT and Spl sites at
baseline, this could have accounted for higher rates of HRT uptake at follow-up in these
genotype groups.
The association between haplotypes and BMD were stronger and more consistent across
skeletal sites than the associations with individual genotypes. Haplotypes 2 and 3 were
both strongly associated with lumbar spine BMD at baseline and haplotype 2 was also
strongly associated with femoral neck BMD at baseline. At follow-up, the association
between haplotype 3 and lumbar spine BMD was similar to the baseline visit, whereas the
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association with haplotype 2 was weaker than at baseline and was not statistically
significant. These differences were most likely due to differences in uptake of HRT in
carriers of haplotype 2, reflected by the significant difference in the proportion of HRT
users in this haplotype group at the follow-up visit as compared with baseline. As was the
case with the individual polymorphisms, I speculate that this difference may be increased
use of HRT in homozygote carriers of haplotype 2.
The p-values for significance reported here should be interpreted in light of the fact that I
studied associations between three polymorphisms and associated haplotypes in relation
to BMD at two sites, measured on two occasions. However taking into account the LD
between polymorphisms and the fact that the traits were correlated, many of the
associations I observed remained below the adjusted threshold for significance (p=0.014)
using a modified Bonferroni test to correct for the number of independent tests performed.
The haplotype associations that I report here are of interest in relation to a recent study
using promoter-reporter assays where it was shown that promoter constructs containing
the -1997GDelT allele (corresponding to haplotype 2) had higher rates of transcription
than the -1997T - 1663InsT allele (corresponding to haplotype 3) (Garcia-Giralt N et al,
2005). The effects of the COLIA1 Spl polymorphism on transcription were not
investigated in the reporter studies mentioned above. These observations suggest that
there is an association between high levels of COLIA1 transcription and reduced BMD
values, consistent with previous work which has suggested that the Spl T allele is
associated with increased COLIA1 transcription leading to an imbalance in the ratio of the
collagen type I alpha 1 and collagen type I alpha 2 chains resulting in a subtle impairment
of bone mineralization (Stewart TL et al, 2005). The present observations indicate that
152
Chapter 3: Association study of 5'COL1A1 polymorphisms and BMD
the previously reported association between the COL1A1 Spl "T" allele and increased
allele specific transcription (Mann V et al, 2001) may actually be driven by an extended
haplotype driven by both the intron 1 and promoter polymorphisms.
I also found significant associations between interactions of -1997G/T and -1663ins/delT
(or Spl G/T) with BMD. The heterozygote and rare homozygote of -1663ins/delT (or
Spl G/T) could be divided into two groups with extreme mean BMD values at lumbar
spine and femoral neck, according to the genotype at -1997. The highest mean BMD
value appeared in the group with -1997G/G homozygote and the heterozygote & rare
homozygote of -1663ins/delT (or Spl G/T), whereas the lowest mean BMD value
appeared in the group with -1997G/T & T/T and the heterozygote & rare homozygote of -
1663ins/delT (or Spl G/T). This is the same as the results reported by Garcia-Giralt N et
al, (2002). The association between -1997G/T and Spl polymorphisms with lumbar spine
BMD was also observed in a larger Spanish postmenopausal female population (p=0.01,
N=719) by Bustamante M et al, (2007).
One of the limitations of this study is that genotypes for the -1663in/delT polymorphism
deviated significantly from Hardy-Weinberg equilibrium. In view of this I carefully
scrutinized sequencing traces from all individuals who were heterozygous for -
1663indelT and all -1663delT homozygotes, but no errors were identified, thereby
excluding genotyping error as a cause of the HWE deviation. Possible explanations
include a greater proportion of failed reactions in the -1663indelT heterozygotes (Wittke-
Thompson JK et al, 2005), since this polymorphism was technically the most difficult to
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genotype and had the greatest number of dropouts; or the fact that the -1663indelT
polymorphism may actually have been a composite of two polymorphisms within the
poly-T tract on different haplotype backgrounds if the poly-T tract is viewed as "copy
number variant". This has previously been documented as a cause of HWE deviation at
other loci (Nancy Cox, personal communication) but I was unable to investigate this
possibility in the present population since the participants were unrelated Another
possible explaination is the population stratification, although it's not likely in this study
since APOSS population were tested in other association studies and no HWE deviation
was found. Therefore, the most possible explanation is the genotyping failure in this
study. In future new methodologies are needed to investigate this polymorphisms, such as
denaturing high-performance liquid chromatography (DHPLC).
It is also worth notice that the associations observed in this study might be caused by
other polymorphisms which are in linkage disequilibrium with these 5' polymorphisms. I
have checked the Hapmap database, however, no enough data suggests the existence of
other candidate polymorphism.
In summary, this study demonstrates that haplotypes, defined by the promoter and intron
1 polymorphisms of the COLIA1 gene, regulate BMD in postmenopausal women. One of
the most interesting observations to emerge from the study was the much higher uptake
of HRT in women who carried genotypes and haplotypes that were associated with low
BMD at the baseline assessment. This example of a gene-environment interaction
illustrates the challenges faced by investigators who seek to detect genetic variants that
regulate BMD in populations such as this, where systematic BMD screening has been
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followed by a specific therapeutic intervention. Whilst the mechanism by which COLIA1
variants regulate BMD remains to be fully elucidated, current evidence is consistent with
an effect of these different haplotypes on COLIA1 transcription.
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CHAPTER FOUR
FunctionalAnalysis of
5'Polymorphisms by Gel Shift
Assays and Reporter Assay
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Abstract
The previous chapter showed that 5' flank COL1A1 polymorphisms regulate BMD in
a population of perimenopausal women and showed evidence of an interaction
between the polymorphisms in regulating BMD. The underlying mechanisms of these
associations are unclear. Previous studies showed that the +1245 Spl T allele had
higher binding affinity for the transcription factor Spl than the G allele. A recent
report also found that the -1663in/delT polymorphism is located within a binding site
of Nmp4 proteins and that the -1663inT (8T) allele had greater binding affinity than
the -1663delT (7T) allele. This study also showed that haplotypes defined by the
promoter polymorphisms regulate reporter gene transcription in vitro.
In this chapter non-radioactive electrophoretic mobility shift assays (EMSAs) and
super-shift assays were used to investigate the DNA-protein binding affinities of the
regions surrounding both the -1997G/T and -1663indelT promoter polymorphisms.
The results confirmed the binding of Nmp4 proteins and Osterix to the region
surrounding the -1663in/delT polymorphism. The -1663delT allele (7T) consistently
bound nuclear proteins with greater affinity than the -1663inT (8T) allele. The region
surrounding the -1997G/T polymorphism contained a Spl binding site and the T allele
had increased binding affinity than the G allele. However, supershift assays did not
show evidence of Spl protein binding to DNA in osteoblast nuclear extracts.
1 also studied the effect of the three polymorphisms on reporter gene transcription in
osteoblast-like cells. Eight possible haplotypes defined by the three polymorphisms
comprising 2300 bp upstream of the transcriptional start site to the beginning of exon
2 were generated and inserted into a modified pGL-3 basic vector. This resulted in a
construct comprising the promoter, exonl and intronl of COL1A1, plus a small part
of exon2, which drives expression of a fusion protein comprising 55 amino acids of
COL1A1 and Firefly luciferase. These reporter constructs were then co-transfected
with the Renilla pRL-TK vector into HOS TE85 cells. For each sample, the Firefly
luciferase activity was normalized by the Renilla luciferase activity and then
compared with the mean value of the pGL3-basic vector. All reporter vectors had
significantly higher luciferase activities than the pGL3-basic vector which lacks
eukaryotic promoter and enhancer sequences (p<0.001). The pGL3-G7T vector had
the highest gene transcription and differed from all the other vectors (pO.OOl). The
luciferase activity of the pGL3-T8G vector was the second highest and also
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significantly differed from all the other vectors. The pGL3-T7G vector had the lowest
luciferase activity. The luciferase activities of different haplotypes were not clearly
related to the effects of any individual polymorphism. Therefore, these results
suggested that the COL1A1 5' flank polymorphisms interact with each other to
regulate reporter gene transcription.
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Introduction
In the previous chapter, I showed that the 5' COL1A1 polymorphisms were associated
with BMD in a population based study. Previous studies have suggested that the
+1245Spl polymorphism and other promoter polymorphisms may predispose to
osteoporosis by affecting gene transcription. For example, Mann V et al reported that
the Spl T allele within intronl had significantly increased binding affinity for the
transcription factor Spl compared with the G allele, and primary RNA transcripts
derived from the SplT allele were found to be approximately three times more
abundant than those from the G allele in heterozygotes (p<0.05, Mann V et al, 2001).
A recent functional study showed that haplotypes defined by the two promoter
polymorphisms regulated reporter gene transcription in vitro in osteoblast-like cells,
and the -1663insT allele had increased binding affinity for nuclear proteins in
osteoblasts. One of these proteins was identified by supershift assay as the nuclear
matrix protein Nmp4 (also called cas interacting zinc finger protein, CIZ), a known
inhibitor of BMP/Smad signalling (Garcia-Giralt N et al 2005). Analysis of the
sequence around the -1663insdelT polymorphism also revealed a potential Osterix
binding site located upstream of the -1663indelT polymorphism in the human
COL1A1 promoter. This makes Osterix a strong candidate for DNA-protein binding
interactions in the vicinity of -1663insdelT polymorphism. The region surrounding -
1997G/T polymorphism is also predicted to contain nuclear protein binding sites such
as a Spl binding site, but the nuclear proteins that bind to the -1997G/T region are
still unclear.
In this chapter non-radioactive electrophoretic mobility shift assays (EMSAs) and
super-shift assays were used to confirm the -1663indelT /Nmp4 binding and
determine whether two promoter polymorphisms affected binding affinity for nuclear
159
Chapter 4: Functional analysis of 5' COL1A1 polymorphisms by gel shift assays and reporter assays
proteins in osteoblasts. Reporter assays were used to investigate the transcriptional
effect of the three polymorphisms on reporter gene expression in osteoblasts.
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Methods
The binding affinities of nuclear proteins derived from human osteoblast cell lines
(MG63 & HOS TE85) to the regions surrounding the two promoter polymorphisms
were analysed by non-radioactive electrophoretic mobility shift assays (EMSAs)
using the methods described in chapter 2.
The online program Alibaba 2.1 was used to predict the possible binding sites in all
the oligonucleartides which flank the two promoter polymorphisms (http://www.gene-
reuulation.com/pub/programs/alibaba2/index.html). This type of program is based on
the potential binding sequences so it often over-predicts. Only the transcription factors
related to bone biology were analysed in this study.
The reporter vector was constructed by ligation of a PCR-amplified fragment of
human DNA sequence containing the promoter, exonl, intronl and part of exon2 (-
2316 to +1723) of COL1A1 (haplotype 1) into a modified pGL3-basic vector. The
other seven possible haplotypes were introduced into reporter vectors by Site-Directed
Mutagenesis (SDM) reactions. All the vectors were prepared by using the PureLink1 M
HiPure Plasmid DNA Purification Maxi prep Kit (Invitrogen). The concentration of
each DNA was determined by Quant-iT™ PicoGreen® dsDNA Reagent (Invitrogen).
The same amount of each reporter vector and two control vectors (pGL3-basic &
pGL3-control) were co-transfected into the osteoblast-like cell line HOS TE85 cells
with the pRL-TK vector by the Magnet Assisted Transfection (MATra) kit. Luciferase
expression was measured by plate-reader (Synergy HT, Bio-Tek). The results were
analysed by GLM-ANOVA (Minitab). All experiments were repeated four times
under similar conditions.
To check the existence of the fusion protein, total cell RNA of the pGL-3 basic vector,
pGL-3 T8G and pGL-3 G7T vectors was extracted and used as template to make
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cDNA using reverse transcriptase twenty-four hours after the transfection. A 242bp
fragment was then amplified by PCR with a forward primer in COL1A1 exon 1 and a
reverse primer in luciferase gene. The products were confirmed by sequencing
reaction. Full details of the methodology are provided in chapter 2 Material and
methods.
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Results
Nmp4 and Osterix Bind to the Region Surrounding the -1663ins/delT
Polymorphism
Several proteins were predicted to bind the DNA surrounding -1663ins/delT
polymorphism as shown in Figure 4.1.











The oligonucleotide probe used in EMSA was 5'-end labeled with biotin. Six
potential binding motifs were predicted by online program Alibaba 2.1. Three
proteins were investigated in this study (framed) were Spl, Osterix and Nmp4. The
other five binding sites for nuclear proteins (GR, NF-EMS, C/EBMPalp, FIB, ICSBP
& ISGF-3) were not investigated in this study. The -1663insT allele is indicated by
dashed line.
GR: Glucocorticoid Receptor; NF-EMS: also called IRF-4, Interferon-regulatory
factor 4; C/EBPalpha: CCAAT Enhancer Binding Protein alpha; HB: Hunchback
transcription factor; ICSBP: Interferon Consensus sequence binding protein; ISGF-3:
Transcription factor ISGF-3
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When nuclear extracts (from MG63 & HOS TE85) were used as the protein source in
EMSAs which contained biotin-labelled -1663ins/delT oligonucleotide probes, the
DNA-protein complexes were seen as several distinct bands (shifts) on the gel (Figure
4.2; lane 2). In this study only Nmp4, Spl and Osterix were investigated due to their
biological relation to bone metabolism. To confirm specific binding of Nmp4 and
Osterix to the oligonucleotide probe, antibodies to Nmp4 and Osterix were added to
the EMSA binding reaction resulting in super-shifts, which had an identical binding
pattern (blue box, Figure 4.2). Addition of an antibody to actin showed a different
pattern of binding. Although the intensity of the bands decreased, a similar pattern of
bands was observed as compared with nuclear extract alone apart from a very high
molecular weight band (lane 5, Figure 4.2).
Figure 4.2 EMSA demonstrating binding ofNmp4 and Osterix to the biotin-labelled -
1663delT oligonucleotide probe
Lane 12 345
EMSA was performed on a 6% (w/v) polyacrylamide gel with biotin-labelled -
1663delT (7T) probe (all lanes) and HOS TE85 cell nuclear extract (NE, lane 2-5).
DNA-protein complexes were seen as shifts. Addition of antibodies for Nmp4 and
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of antibody for actin caused similar shifts as the NE (lane 2) apart from a very high
molecular weight band (lane 5).
Spl Binds to the Region Surrounding -1663ins/delT Polymorphism
Since the DNA surrounding -1663insdelT polymorphism is predicted to contain an
Spl binding site, I also investigated the effect of the SNP on Spl protein binding.
When Spl protein was used in the binding reaction which contained a biotin-labeled -
1663inT (8T) oligonucleotide probe, a single shift was seen on the gel (lane 2, figure
4.3). Addition of Spl antibody together with Spl protein caused a super-shift (lane 3).
When Spl antibody was mixed with nuclear extract, the super-shift was very faint but
still visible on gel (lane 1). EMSA with biotin-labeled -1663delT (7T) probe gave the
same results (data not shown).
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Lane 1 2 3
(a) (b)
EMSA was performed with biotin-labeled -1663insT oligonucleotide probe (all lanes).
The left panel (a) shows that when Spl protein was used as sole protein source, DNA-
Spl binding complex was seen as shift (lane 2) and super-shift (lane 3) with addition
of antibody to Spl. When HOS TE85 nuclear extra was used as protein source, a very
faint super-shift was seen on the gel (lane 1). Addition of antibody to NFATcl to the
nuclear extra did not alter the DNA-protein binding pattern (lane 4).
The right panle (b) is the same image but with a less intensity.
-1663delT (7T) Allele Has Greater Affinity for Nuclear Proteins than
-1663insT (8T) Allele
The '7T' oligonucleotide consistently bound nuclear proteins with greater affinity
than the "8T' oligonucleotide when adding the same amount of nuclear protein into
166
Chapter 4: Functional analysis of 5' COLlAl polymorphisms by gel shift assays and reporter assays
the binding reactions with the same amount of probes. This is illustrated on Figure 4.4:
the bands had greater intensity with the biotin-labeled '7T' probe (lane 1-4) compared
to those with the biotin-labeled '8T' probe (lane 5-7).
Figure 4.4.
Lane 1 2 3 4 5 6 7
-1663delT probe (7T) -1663 insT probe (8T)
EMSA was performed with biotin-labeled -1663delT (7T) oligonucleotide probe (lane
1-4) and biotin-labeled -1663inT (8T) oligonucleotide probe (lane 5-7). Both probe
generated the same binding pattern. Upon incubation with nuclear proteins, the 7T
oligonucleotide consistently produced retention bands of higher intensity than the 8T
oligonucleotide, suggestive of a higher binding affinity for some of them.
NE, nuclear extracts. Experiments were repeated in triplicate under similar conditions.
167
Chapter 4: Functional analysis of 5' COL!A! polymorphisms by gel shift assays and reporter assays
To compare the difference in binding affinity of the polymorphic variants for nuclear
proteins, competition assays were performed. The biotin-labeled '7T' oligonucleotide
probe was incubated with nuclear extracts from HOS TE85 cells and with varying
concentrations of either '7T' or "8T' unlabeled competitor oligonucleotide probes.
The unlabeled '7T' probe bound nuclear proteins with greater affinity than did the
unlabeled '8T' competitor resulting in weaker intensity of DNA-protein bands with
'7T' competitor for each competitor concentrations (Figure 4.5).
Figure 4.5 Competition EMSA showed -1663delT (7T) allele has higher binding
affinity for proteins than -1663insT (8T) allele with biotin labelled 7T probe
Lane 1 2 3 4 5 6 7
EMSA was performed using 0.04pM biotin-labelled -1663delT (7T) probe (all lanes)
and HOS TE85 cell nuclear extract (all lines). The bands presenting the specific
binding of DNA-protein complex were attenuated more rapidly with increasing
concentrations of the unlabeled competitor '7T' oligonucleotide (lane 5-7) compared
with the unlabeled competitor '8T' oligonucleotide (lane 2-4). Assays were performed
in triplicate. NE: nuclear extra; competitors: 8T (-1663insT) unlabeled probe; 7T (-
1663delT) unlabeled probe.
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Identical EMSA experiments were run, in triplicate, using biotin-labeled '8T'
oligonucleotide probe instead of "7T' labelled probe (figure 4.6). Again the difference
in binding affinity was found between the two competitors with the '7T' competitor
binding with greater affinity than the '8T' competitor.
Figure 4.6 Competition EMSA showed -1663delT (7T) allele has higher binding
affinity for proteins than -1663insT (8T) allele with biotin-labeled 8T probe
EMSA was peformed using 0.04pM biotin-labelled -1663insT (8T) probe (all lanes)
and HOS TE85 cell nuclear extract (lane 2-8). The bands presenting the specific
binding of DNA-protein complex were attenuated more rapidly with increasing
concentrations of the unlabeled competitor '7T' oligonucleotide (lane 6-8) compared
with the unlabeled competitor '8T' oligonucleotide (lane 3-5). Assay was performed





Lane 1 2 3 4 5 6 7 8
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Band intensity results from three competitive EMSA experiments were quantified by
Genetools software (SynGene). These results were averaged and analyzed by
constructing a one-site competitive binding model ("Boltzman" model). As shown in
Figure 4.7, band intensities (mean ± SEM) from lanes containing three different
concentrations of competitors (lane 3-8, Figure 4.6) were expressed as a percentage of
the band intensity in the absence of competitor (control, Figure 4.6, land 2). The band
intensities of the two alleles were compared by GLM-ANOVA model (Minitab.
version 12). Competitor "7T" had significantly greater binding affinity compared with
the "8T" allele (pO.OOl).
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Figure 4.7 Competitive binding curves for -1663insT (8T) and -1663delT (7T)
unlabeled probes when competing for biotin-labled "ST1 - protein complex
% Log [competitor] (M)
Band intensities of DNA-nuclear proteins complex from three EMSA experiments
(mean ± SEM) were plotted against -1663insT (8T) and -1663delT (7T) unlabeled
competitor concentration. Band intensity (mean ± SEM) at three concentrations was
plotted as a percentage of band intensity in the absence of competitor for each
competitor concentration (Figure 4.6, lane 2).For every competitor concentration "7T'
competitor had greater binding affinity than "8T" competitor (p<0.001) and therefore
a weaker band intensity was observed.
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Spl Binds to the Region Surrounding the -1997T/G Polymorphism
Several proteins were predicted to bind the DNA surrounding -1997G/T
polymorphism as shown in Figure 4.8.
Figure 4.8 Oligonucleotide sequence of -1997G probe used in EMSA and the
potential binding motifs
( 57 Biotin J





The oligonucleotide probe used in EMSA was 5'-end labeled with biotin. Three
potential binding motifs were predicted by online program Alibaba 2.1. Two protein
bindings investigated in this study (framed) were Spl and USF. The-1997G allele was
bold Italic.
USF: Upstream Stimulatory Factor; COUP: Chicken Ovalbumin Upstream
transcription factor
Since the DNA surrounding -1997G/T polymorphism contains a Spl site, 1
investigated the effects of the SNP on Spl protein binding. When Spl protein was
used in the binding reaction which contained biotin-labeled -1997T oligonucleotide
probe, one band was seen on the gel (figure 4.9, lane 2). When nuclear extracts from
HOS TE85 cells were used as protein source in EMSA, two distinct bands were seen
on the gel (lane 4), both different from the band in lane 2 representing the DNA-Spl
complex. Addition of antibody to Spl did not change the position of DNA-nuclear
protein complex (lane 5). To investigate the potential DNA-USF binding, Usf protein
and its antibody were added into the binding reactions. As shown in Figure 4.9,
addition of Usf protein did not result in any shift (lane 3), and the addition of USF
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antibody did not further shift the DNA-nuclear protein complex, either (lane 6).
Identical results were obtained when using biotin-labeled -1997G oligonucleotide
probe (data not shown).
Figure 4.9 EMSA demonstrating binding of nuclear proteins to the biotin-labelled -
1997T oligonucleotide probe
EMSA was performed with biotin-labeled -1997T oligonucleotide probe (all lanes).
No protein was added to the control reaction (lane 1). DNA-Spl (lane 2) or DNA-
nuclear protein complex (lane 4-6) were seen as shifts on gel. Usf protein showed no
binding to the -1997T probe (lane 3). Addition of antibody of Spl and Usf did not
change the binding of DNA-protein complex (lane 5-6).
NE, nuclear extracts from HOS TE85 cells.
173
Chapter 4: Functional analysis of 5' COL1A1 polymorphisms by gel shift assays and reporter assays
-1997T Allele Had Greater Affinity for Spl than -1997G Allele
In the competition gel shift assays, biotin-labeled -1997T oligonucleotide probe was
incubated with Spl protein and varying concentrations of either -1997T or -1997G
unlabeled competitor oligonucleotides. The unlabeled -1997T competitor bound Spl
protein with greater affinity than the unlabeled -1997G competitor resulting in weaker
intensity ofDNA-Spl band with -1997T competitor for each competitor concentration
(Figure 4.10).
Figure 4.10 Competition EMSA showed -1997T allele had higher binding affinity for
Spl protein than -1997G allele
shift <—
Free probe <
Lane 1 2 3 4 5 6 7 8
EMSA was performed with 0.04pM biotin-labelled -1997T oligonucleotide probe (all
lanes) and Spl protein (lane 2-8). No addition of Spl in control reaction (lane 1). The
bands presenting the specific binding of DNA-Spl complex were attenuated more
rapidly with increasing concentrations of the unlabeled competitor 'T' oligonucleotide
(lane 3-5) compared with the unlabeled competitor 'G' oligonucleotide (lane 6-8).
Assay was performed in triplicate.
Identical EMSA experiments were run, in triplicate, using biotin-labeled -1997G
oligonucleotide probe instead of -1997T labelled probe (data not shown). Again the
difference in binding affinity for Spl protein was found between the two competitors
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such that the -1997T competitor had greater binding affinity than the -1997G
competitor.
To quantify the DNA-protein binding affinities between -1997G/T alleles, band
intensity results from three competitive EMSA experiments were quantified by
Genetools software (SynGene). These results were averaged and analyzed by
constructing a one-site competitive binding model ("Boltzman" model). As shown in
Figure 4.11, band intensities (mean ± SEM) from lanes containing three different
concentrations of competitors (Figure 4.10. lane 3-8) were expressed as a percentage
of the band intensity in the absence of competitor (control, Figure 4.10, land 2). The
band intensities of two alleles were compared by GLM-ANOVA model (Minitab,
version 12). Competitor T had significantly greater binding affinity compared with the
G allele (p=0.009).
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Figure 4.11 Competitive binding curves for -1997T and G unlabeled probes when
competing for biotin-labeled T-Spl complex
Band intensities of the DNA-Spl complex from Five EMSA experiments (mean ±
SEM) were plotted against -1997T and G unlabeled competitor concentrations. Band
intensity (mean ± SEM) at three concentrations was plotted as a percentage of band
intensity in the absence of competitor for each competitor concentration (Figure 4.10,
lane 2).For every competitor concentration T competitor had greater binding affinity
than G competitor (p=0.009) and therefore a weaker band intensity was observed.
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Unknown Nuclear Proteins Bind DNA Surrounding -1997G/T
Polymorphism
When nuclear proteins from HOS TE85 cells were used as protein source in EMSA,
two distinct bands were visualized (lane 1, Figure 4.12), which was different from the
DNA-Spl band (lane 7). Addition of Spl protein or spl antibody did not change the
binding pattern of DNA-nuclear protein complex (lane2-4). Increasing concentration
of Spl protein had no impact on the gel shift either (lane 5-6).
Experiments were performed using nuclear extracts from MG63 cells and a biotin-
labeled -1997G probe, with similar results (data not shown).
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Lane 1 2 3 4 5 6 7
When nuclear extracts from HOS TE 85 cells were used as protein source, two
distinct bands were seen on the gel (lane 1). Addition of Spl antibody did not change
the binding (lane 2). Addition of Spl with nuclear extracts produced the same shifts
as lane 1 (lane 3). Spl antibody did not shift the DNA-nuclear protein binding (lane 4).
Increased amounts of Spl protein (lane 5 & 6) did not cause any change in DNA-
nuclear protein binding. Spl protein alone caused a DNA-Spl shift (lane 7).
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Competition gel shift assays were performed to compare the difference in binding
affinity of the polymorphic variants for nuclear proteins. Biotin-labeled -1997T
oligonucleotide probe was incubated with nuclear extracts from HOS TE85 cells and
varying concentrations of either T or G unlabeled competitor (Figure 4.13). Two
bands were seen on the gel. The upper band was attenuated more rapidly with
competitor -1997G compared with -1997T and disappeared completely when the
amount of competitor was increased up to 0.12 pM (lane 2-4 & 8-9). The lower band
disappeared completely with 1.2 pM of competitor T (lanel2), but not with the same
amount of competitor G (lane 7). Assays were repeated three times, and similar
results were obtained. Identical experiments were performed using biotin-labeled -
1997G probe, and again, similar results were obtained (data not shown).




Lane 1234 5 6 7 89 10 11 12
EMSA was run with 0.04pM biotin-labeled -1997T probe (all lanes) and nuclear
extracts from HOS TE85 cells (lane 2-12). The upper band was attenuated more
rapidly with increasing concentrations of the unlabeled G competitor (lane 2-3)
compared with the unlabeled T competitor (lane 8). The lower band was attenuated
more rapidly with T competitor than the G allele. The assays were performed in
triplicate.
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To quantify the DNA-protein binding affinities between -1997G/T alleles, band
intensity results from three competitive EMSA experiments were analyzed by
Genetools software (SynGene). Band intensities from lanes containing different
concentrations of competitors were expressed as a percentage of the band intensity in
the absence of competitor (control, lane 2, Figure 4.13). The band intensities of two
alleles were compared by GLM-ANOVA model (Minitab, version 12). There was no
statistically significant different binding affinity between two alleles (p=0.3 for the
top band, p=0.8 for the bottom band).
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Generation of COL1A1-luciferase Reporter Vectors
The pGL3-basic vector was modified to generate a fusion protein in which the open
reading frame of the luciferase gene was inserted downstream of human COL1A1
exon2. This resulted in production of a fusion protein containing the first 55 amino
acids of COL1A1 and the luciferase amino acid sequence (Figure 4.14). To confirm
the presence of the COL 1A/-luciferase fusion mRNA, total cell RNA was extracted
twenty-four hours after the transfections and used as template to make cDNA by
using reverse transcriptase. Then a 242bp fragment was amplified by a PCR reaction
with a forward primer in COL1A1 exonl and a reverse primer in luciferase gene. The
PCR product was then sequenced to confirm the presence of the fusion mRNA, as
shown in Figure 4.14.
The vectors containing eight different haplotypes were generated by SDM reactions
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Figure 4.15 Sequencing reactions confirmed the Site-directed mutagenesis (SDM) at
three polymorphic sites
Three figures show base changes introduced by SDM at site -1997 (top panel), -1663
(middle panel) and +1245 Spl (bottom panel). The polymorphisms were represented
in frame.
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Luciferase Expression
The activities of Firefly luciferase (expressed from all pGL-3 reporter vectors) and
Renilla luciferase (expressed from co-transfected pRL-TK vector) were measured
sequentially from each sample by using the Dual-Luciferase® Reporter (DLR™)
Assay System with the Plate-reader (Synergy HT, Bio-Tech). For each sample, the
Firefly luciferase activity was normalized by the Renilla luciferase activity and then
compared with the mean value of the pGL3-basic vector. As shown in Figure 4.16, the
values of each vector represent the percentage of the relative activities to the pGL3-
basic vector (where activity of the pGL-3 basic was set to 100). All the reporter
vectors had significantly higher expression of luciferase than the pGL3-basic vector
which lacks eukaryotic promoter and enhancer sequences (p<0.001). The vector
containing haplotype 2 (G7T) had the highest luciferase activity, and this was
significantly different from all the other vectors (p<0.001). The vector containing
haplotype 3 (T8G) had the second highest luciferase activity, and this was
significantly different to haplotype 4 G8T (p=0.016), to haplotype 5 G7G (p=0.024)
and all the others (p<0.001). The vector containing haplotype 7 T7G had the lowest
luciferase activity when compared with the vectors containing the other seven
haplotypes. The activity of vector (haplotype7 T7G) differed significantly from those
of haplotype 2(G7T) and 3 (T8G) (p<0.001), but also from the activity of G7G
(P=0.03) and G8T (P=0.054). The rest of the vectors (G8G, G8T. G7G, T8T & T7T)
had similar luciferase activities.
183
Chapter 4: Functional analysis of 5" COL1AI polymorphisms by gel shift assays and reporter assays















basic G8G G8T G7G G7T T8G T8T T7G T7T
HI H4 H5 H2 H3 H8 H7 H6
The values represent the percentage of the relative activities to the pGL3-basic vector
(mean ± SEM). The transfection experiments were performed four times under the
similar conditions. The results were analyzed by GLM-ANOVA.
a: Luciferase expression was significantly different from all the other vectors (p<0.05).
b: Luciferase expression was significantly different from a & c (p<0.05).
The dashed line represents the expression of the wild type vector (pGL-3 G8G).
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The luciferase expressions were further analyzed by categorizing all the vectors
according to three polymorphic sites (Figure 4.17). When vectors were grouped by
Spl site, no consistent allele-specific effect on transcription was found between Spl T
and G alleles. The SplT allele had higher luciferase expression than G allele when in
context of'-1997G/-1663delT' (G7) (pO.OOl), whereas T allele had lower luciferase
when in context of M997T/-1663insT' (T8) (pO.OOl). However, the Spl G and T
allele had similar luciferase expression when in context of '-1997G/-1663insT' (G8)
and '-1997T/-1663delT' (T7).
When vectors were grouped by -1663 site, no consistent allele-specific effect on
transcription was observed, either. The -1663delT allele (7T) had higher luciferase
expression than -1663insT allele (8T) only when in context of '-1997G/SplT'
(pO.OOl), whereas 8T allele had higher expression than 7T allele when in context of
'-1997T/SplG' (pO.OOl). There was similar luciferase expression between -1663
alleles when the other two sites had the same allele, such as '-1997G/SplG' or '-
1997T/SplT'.
When vectors were grouped by -1997 site, no consistent allele-specific effect on
transcription was observed. The -1997G allele showed higher luciferase expression
than -1997T allele, when in context of M663delT', such as '-1663delT/SplG' (7G,
pO.03), '-1663delT/SplT7 (7T, pO.OOl). But -1997T allele showed higher luciferase
expression than -1997G allele when in context of '-1663insT/SplG' (8G, pO.OOl).
There was no difference between -1997G/T alleles when in context of '-
1663insT/SplT' (8T).
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The luciferase expressions were analyzed by categorizing vectors into three series
according to three polymorphic sites: Spl series (a); -1663 series (b), and -1997 series
(c). Luciferase expression was represented as mean ± SEM.
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Discussion
Previous studies showed that the +1245 SplT allele has significantly greater binding
affinity for the transcription factor Spl than the G allele, in keeping with the fact that
transcriptional efficiency of the T allele was increased compared with the G allele
(Mann V et al. 2001). Another study showed that the -1663inT (8T) allele had higher
binding affinity for nuclear proteins than the -1663delT (7T) allele and one of the
binding proteins was identified as the architectural transcription factor Nmp4 (Garcia-
Giralt N et al, 2005).
The super-shift assays performed in this study confirmed that one of the nuclear
proteins bound to the region surrounding -1663indelT polymorphism was Nmp4. I
also showed that the transcription factor Osterix bound this region by using an Osterix
antibody, which confirmed the potential Osterix binding site in this region. Since the
super-shift with antibodies to Nmp4 and Osterix was the same, it is probable those
two transcription factors bound to the same complex. However, it is not possible to
identify which band represented which binding by super-shift assays as multiple shifts
were seen on the gel and the super-shifts caused by two antibodies were identical. It is
very likely that more than two nuclear proteins (Nmp4 & Osterix) bound this region
and form DNA-multiple protein complexes. Although there are several potential
binding sites in this region, as predicted by the online program Alibaba 2.1, I only
tested a Spl binding site by using a Spl antibody. A single shift was seen when Spl
protein was used as protein source in the gel shift and a super-shift was observed with
addition of Spl antibody. The Spl antibody also resulted in a faint super-shift when
nuclear extract was used as a protein source, whereas the NFATcl antibody did not
result in a super-shift. This suggested that Spl protein can bind the region surrounding
-1663indelT polymorphism.
187
Chapter 4: Functional analysis of 5' COL1A1 polymorphisms by gel shift assays and reporter assays
The -1663delT (7T) allele showed higher binding affinity for nuclear proteins than the
-1663inT (8T) allele in competition gel shift assays with either labelled probe. By
quantification of the band intensities from competitive EMSA, I found that the -
1663delT (7T) allele had greater binding affinity than the "8T" allele. However, the
overall effects of DNA-nuclear proteins binding are not clear. Osterix is a zinc finger-
containing transcription factor encoded by the sp7 gene and expressed in osteoblasts
of all endochondral and membranous bones. Osterix contains a DNA binding domain
consisting three Cys2His2-type zinc fingers at its C terminus that share a high degree
of identity with motifs in Spl, Sp3 and Sp4 (Nakashima K et al, 2002). Osterix binds
to Spl and EKLF consensus sequences and to other G/C-rich sequences.
Osterix is required for osteoblast differentiation and bone formation since in Osterix
null mutant mice neither endochondral nor intramembranous bone formation occur
(Nakashima K et al, 2002). Osterix regulates the expression of a number of important
osteoblast genes such as osteocalcin, osteonectin, osteopontin, bone sialoprotein and
type I collagen. In Osterix null mutant mice, Collal RNA levels in the mesenchyme
were severely reduced, expressed at levels similar to those in skin fibroblasts
(Nakashima K et al, 2002). Therefore, Osterix is a stimulator of COL1A1
transcription.
On the other hand, nuclear matrix Nmp4 proteins are the only known Cys2His2 zinc
finger proteins that bind to the AT-rich minor groove of DNA. These transcription
factors regulate gene expression by virtue of their ability to bend or loop DNA, which
thus facilitates communication between cA-elements and consequently modulates
interactions between other trans-acting proteins (Wolffe AP, 1994). Some of the
isoforms of Nmp4 recently have been identified as Cas-interacting zinc finger
proteins (CIZ) that were characterized as nucleocytoplasmic shuttling proteins
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localized at cell adhesion plaques. In ClZ-deficient mice, bone volume and the rate of
bone formation were increased as well as the levels of mRNA expression of
osteoblastic differentiation markers, such as alkaline phosphatase. Moreover, BMP2-
induced bone formation on adult mouse calvariae in vivo was also enhanced by CIZ
deficiency (Morinobu M et al, 2005). This is in agreement with the observations that
Nmp4/CIZ over-expression suppressed the BMP2-enhanced expression of
osteoblastic differentiation markers such as alkaline phosphatase and type I collagen
(Shen ZJ et al, 2002). Therefore, Nmp4/CIZ is an inhibitor of the BMP signalling
pathway and COL1A1 transcription.
Two poly (dT) sequences in the rat Collal promoter region were identified as binding
sites ofNmp4 (Alvarez M et al, 1998) and mutation of either site increased promoter
activity in rat osteoblast-like cells in reporter assays (Thunyakitpisal P et al, 2001).
One of the poly (dT) site (site B) is homologous to the human COL1A1 -1663indelT
site (Garcia-Giralt N et al, 2002) and -1663inT (8T) showed increased binding
affinity compared to the 7T allele (Garcia-Giralt N et al, 2005). However our
competition analysis showed that the 7T allele had greater binding affinity than the 8T
allele. The difference between two experiments may be that double-stranded
oligonucleotides were used as probes and competitors in our experiments while
single-stranded oligonucleotides were used as probes and competitors in theirs.
Moreover, our oligonucleotides are long enough to contain the whole potential
Osterix binding site, which may have influenced the results.
Since the antibodies to Osterix and Nmp4 gave the same super-shift pattern and the
two binding sites are next to each other, it is very likely that Osterix and Nmp4
interact with each other and form a DNA-multiple protein complex. That interaction
may involve other nuclear proteins as the online program Alibaba 2.1 predicted
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multiple binding sites overlapping each other at this region. Therefore, it is very
difficult to predict how the different binding affinity for nuclear proteins between two
alleles contributes to gene transcription simply based on the EMSA results. Further
studies using reporter gene assays or CHIP assays would be of interest to explain
these issues.
There was also an unexpected band appeared on the reaction with the actin antibody,
which was very low molecular weight. Since there was no actin binding site on the
oligonucleartide probe, one of the possible explain is that actin may interact with one
of the transcription factors binding to the oligonucleartide probe. This interaction is
needed to be investigated in future.
In the case of the -1997G/T polymorphism, the Spl protein bound to the region,
because a single shift was seen on the gel when Spl protein was used as the protein
source in gel shift and Spl antibody abolished this DNA-Spl shift. The -1997T allele
showed increased binding affinity for Spl protein compared to the -1997G allele in
competition assays. This is consistent with previous results that the +1245 SplT allele
had greater binding affinity for Spl protein than the G allele (Mann V, et al, 2001).
According to the prediction of online program Alibaba 2.1, Usf protein and antibody
were also used in binding reactions. However, neither DNA-Usf shift nor super-shift
was observed by using either of the probes, which suggested no DNA-Usf binding.
Although I did not test the binding affinity of the Usf protein or Usf antibody to its
known binding site, it is very unlikely both protein and the antibody do not work
properly in this study.
Interestingly, two distinct shifts were observed when nuclear extracts from a
osteosarcoma cell line (HOS TE 85 cells) were used as protein source. The migration
190
Chapter 4: Functional analysis of 5' COL1A1 polymorphisms by gel shift assays and reporter assays
of either of these two shifts was different from the DNA-Spl shift. Moreover,
addition of Spl antibody to nuclear extracts did not change the DNA-nuclear proteins
binding pattern. It is possible that Spl protein is in competition with other nuclear
proteins and loses the binding to DNA in vivo. Allelic differences in binding nuclear
proteins were also detected by competition assays. However, the difference did not
reach statistical significance.
In summary, three nuclear proteins bound to the region surrounding -1663indelT
polymorphism were identified as Osterix, Nmp4 and Spl by super-shift assays. The -
1663delT (7T) allele had greater binding affinity for nuclear proteins than the -
1663inT (8T) allele. The -1997T allele had greater binding affinity for Spl protein
than did the G allele in vitro. To clarify the contribution of allelic binding differences
to gene transcription, more work is needed such as employment of reporter gene
assays or Hap-CHIP assays.
This is the first study to investigate the transcriptional effects of all three
polymorphisms on the COL1A1 gene by reporter assays. Previous studies have shown
that the SplT allele has increased binding affinity for Spl protein, and primary RNA
transcripts derived from the SplT allele were approximately three times more
abundant than SplG allele-derived transcripts in GT heterozygotes (Mann V et al,
2001). Collagen produced from osteoblasts cultured from Spl heterozygotes had an
increased ratio of a 1(1) protein relative to a2(I), and this was accompanied by an
increased ratio of COL1A1 mRNA relative to COL1A2 (Mann V et al, 2001). A recent
in vitro functional study showed that COL1A1 promoter sequence containing
haplotype '-1997G/-1663delT' (G7) drove luciferase activity more strongly than
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haplotype '-1997T/-1663insT' (T8) (Garcia-Giralt N et al, 2005). Moreover, this
study also found that different transcription activity between two -1663insdelT alleles
was dependent on the allele at -1997, and correlated with different binding capacities
of the corresponding oligonucleotides to osteoblast nuclear proteins. However, the
effect of the Spl polymorphism was not taken into account in this study.
Since the three polymorphisms are in high linkage disequilibrium and interact with
each other to regulate BMD, it is also possible that all three 5' polymorphisms interact
with each other to regulate gene transcription. In the current study, the luciferase
reporter vectors containing 5' COL1A1 sequence with all three polymorphisms were
used to investigate the transcriptional activity of all eight possible haplotypes. The 5'
COL1A1 sequence was inserted into a modified pGL3-basic vector to produce a
fusion protein containing the first 55 amino acids of COL1A1 fused to the luciferase
gene. The results showed that all the reporter vectors expressed significantly higher
luciferase activity levels than pGL3-basic vector which lacks eukaryotic promoter and
enhancer sequences (p<0.001). This means the COL1A/-luciferase fusion protein was
functional and was expressed properly. This was also confirmed by sequencing the
cDNA of the COL1A1 -luciferase fusion protein.
The pGL3-G7T vector had the highest transcriptional activity compared with all the
other haplotypes. This is in agreement with the results of Garcia-Giralt N et al (2005)
and Mann v et al (2001), as haplotype 'G7' and SplT allele showed higher
transcriptional activity in their studies, respectively. Given the fact that haplotype
'G7T' was associated with decreased BMD at LS & FN (chapter 3), this also supports
our hypothesis that the mechanism underlying the association of COL1A1 haplotypes
with osteoporosis is that increased transcript in the COL1A1 gene results leads to an
increased ratio of al(I) protein relative to a2(I). However, other factors may also be
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operative since the haplotype T8G which was associated with high BMD had the
second highest transcription activities of the eight vectors studied.
The transcriptional activity of vector pGL3-T7G (haplotype7) was the lowest in eight
reporter vectors, and significantly lower than those of pGL3-G7G (haplotype5,
P=0.03) and pGL3-G8T (haplotype4, p=0.054), although it did not differ significantly
from the wild type pGL3-G8G (haplotype 1). But the haplotype7 (T7G) was not
common in APOSS and was not associated with BMD. Five of the other reporter
vectors containing haplotype 1, 4, 5, 6 and 8 (G8G, G8T, G7G, T8T & T7T) had
similar transcriptional activities.
The results also suggest that the three polymorphisms interact with each other to
regulate transcription, which agrees with Garcia-Giralt N et al (2005). When the eight
reporter vectors were analyzed by categorizing into three series according to three
polymorphic sites, no consistent allele-specific effect on transcription was observed at
any polymorphic site. For example, when vectors were grouped by the Spl site, the
SplT allele had higher luciferase expression than the G allele when in context of
1997G/-1663delT' (G7) (p<0.001), whereas T allele had lower luciferase when in
context of '-1997T/-1663insT' (T8) (p<0.001). However, the Spl G and T allele had
similar luciferase expression when in context of '-1997G/-1663insT' (G8) and
1997T/-1663delT' (T7). Therefore, the haplotype effect on reporter gene transcription
could not be simply predicted by the individual effect of any polymorphism, either.
The gel shift assays showed that -1663delT allele (7T) had greater binding affinity for
nuclear proteins, such as transcription factors Nmp4 and Osterix. The -1997T and
SplT alleles had higher binding affinity for Spl protein than T allele. However,
neither -1663delT (7T), -1997T, or SplT allele showed consistent effects on reporter
gene transcription. This suggests that interactions among the three polymorphisms
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have a more important effect on reporter gene transcription than individual
polymorphisms.
However, the limitation of reporter gene assays is that chromatin structure is not taken
into account. It is known that chromatin structure has an important effect on gene
transcription. Therefore, to accurately investigate the effects of three polymorphisms
on gene transcription, further study is required such as Hap-CHIP assay.
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CHAPTER FIVE
Role of COL1A1 Variants in the
Mechanical Properties ofBone
Chapter 5: Role of COL1A1 variants in the mechanical properties of bone
Abstract
In chapter 3, I analyzed the relation between two COL1A1 promoter polymorphisms
and the Spl polymorphism and showed that they interacted to regulate BMD. In
chapter 4, I showed that the regions surrounding both promoter polymorphisms were
able to recognise nuclear proteins in gel shift assays and different alleles influenced
DNA -protein binding affinities. The promoter polymorphisms interacted with the
Spl polymorphism to affect reporter gene transcription in vitro. The Spl
polymorphism of the COL1A1 gene has been previously associated with reduced bone
strength and abnormalities of bone mineralization in vitro and in vivo. In view of this,
I sought to determine if haplotypes at the 5' flank of COL1A1 were associated with
the mechanical properties of bone.
Biomechanical tests were performed on trabecular bone samples from femoral heads
obtained from 23 male and 71 female hip fracture patients. The stiffness and yield
strength were determined from the stress-strain curve using standard techniques
described previously. DNA was extracted from each bone sample and the genotypes
at all three polymorphic sites were determined by PCR and DNA-sequencing analysis.
Haplotypes were constructed using the 'PHASE' program. Statistical analysis (GLM-
ANOVA) was used to compare bone volume, density, stiffness and yield strength
according to genotypes and haplotypes. Bone cores derived from common
homozygotes (-1997G/G, -1663delT/delT and SplG/G) had significantly increased
bone volume, yield strength and stiffness compared with the cores derived from
heterozygotes and rare homozygotes (p<0.05). The second most common haplotype 6
(-1997T/-1663delT/SplT, 12.24%) was associated with reduced bone volume, yield
strength and stiffness (p<0.05). Interestingly, this haplotype was very rare in the
general population and its frequency in the bone cores from the hip fracture patients
was 401 times greater than in the APOSS population (0.03%) described in chapter 3.
The associations remained significant after adjusting for gender, age, bone volume
and the density of bone core. Therefore, the three common variants in 5' COL1A1
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gene may predispose to osteoporosis by complex mechanisms involving a reduction
in bone quality.
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Introduction
Previous studies showed that the COL1A1 Spl polymorphism acts as a predictor of the
reduced BMD and increased risk of fragility fractures in several populations
(Efstathiadou Z et al, 2001; Mann V et al, 2003). In a small study of 17 patients,
mechanical tests also showed that the yield strength of bone derived from Spl G/T
heterozygotes was reduced when compared with bone derived from Spl G/G
homozygotes (Mann V et al, 2001). Subsequent studies showed that carriage of the
COLIA1 Spl T allele is associated with an impaired ability of osteoblast-like cells to
form mineralized bone nodules in vitro and with abnormalities of bone mineralization in
vivo (Stewart TL, et al, 2005). It is already known that specific abnormalities of
collagen structure or quantity due to mutations in the COL1A1 or COL1A2 gene can
cause osteogenesis imperfecta, a disease characterized by impaired material properties
of bone and increased bone fragility. Some mutations that change the amino acid
sequence can result in formation of branched fibers leading to brittle bone and abnormal
mineralization (Baum J and Brodsky B, 1999). Therefore, the increased bone fragility in
carriers of the SplT allele may result in part from defects in bone mineralization.
The effects of the promoter polymorphisms on biomechanical properties of bone have
not yet been studied. In view of this, biomechanical properties of bone were studied
according to genotypes and haplotypes defined by the 5' flank polymorphisms of the
COL1A1 gene on trabecular bone cores derived from femoral heads removed from hip
fracture patients.
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Methods
The biomechanical studies were performed on trabecular bone samples from femoral
heads obtained from 23 male and 71 female patients undergoing hip replacement
surgery as a result of osteoporotic hip fracture. The age at fracture ranges from 58 to
101 years with a average age of 81.6 ± 9.0 years.
Cylindrical cores of bone were removed from the superior in the femoral head and then
subjected to an unconstrained compression test using an Instron 5564 materials testing
machine (Instron, High Wycombe, UK), as shown in figure 5.1. The apparent density of
washed and defatted bone samples was calculated by dividing the total mass by the
sample volume. The stiffness and yield strength were determined from the
characteristics of the stress-strain curve using standard techniques described previously
(Li B and Aspden RM, 1997).
DNA was extracted from bone cores and the genotypes were determined by PCR
followed by sequencing analysis as described in chapter 2. Haplotypes were constructed
by the program 'PHASE'. Genotype and haplotype differences in bone volume, density
of bone core, yield strength and stiffness were analyzed by comparing the common
homozygotes with the heterozygotes and the rare homozygotes. GLM-ANOVA was
used to adjust the effect of gender, age and density of bone core on bone volume, yield
strength and stiffness by entering "gender", "age", "density of the bone core" and
"genotype/ haplotype" into the "model". Multiple regression analysis and best subsets
multiple regression analysis were used to evaluate associations between genotype,
haplotype and bone volume, yield strength and stiffness.
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Dean et al 1998
The top panel shows that trabecular bone cores were taken out from femoral head and
subjected to mechanical testing. The bottom panel shows the stress-strain curve from
which the "stiffness" and the "yield strength" were determined.
Mpa, megapascals.
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Results
Characteristics of the Subjects
The average age at fracture of all subjects was 81.6±9.0 years. The average age at
fracture was 82.5±9.3 years for 69 female, and 79.0±7.5 years for 23 males. There was
no difference in genotype distribution according to age or gender (p>0.05, Table 5.1).
The genotype frequencies for all three polymorphisms were in Hardy-Weinberg
equilibrium. Genotype frequencies of common homozygotes (-1997G/G, -1663 In/In &
SplG/G) were similar to those in younger individuals from the general population
(APOSS) (p>0.05, Table 5.2). Eight possible haplotypes were predicted by the
'PHASE' program. Two common haplotypes accounted for 88% of alleles at the 5'
flank of the COL1A1 locus (Table 5.3). Haplotypel (-1997G/ -1663InT/ +1245G, G8G)
accounted for 76.53% of alleles, which is similar to its frequency in the general APOSS
population (67.05%). But haplotype 2 and 3 were very rare in bone core subjects
(1.53% and 1.02%, respectively), which were the second and third common haplotypes
in the general population APOSS (17% and 12.21%, respectively). Conversely,
haplotype 6 (-1997T/ -1663delT/ +1245G, T7T) had the second highest frequency in
bone core subjects (12.24%), which was 400 times more common in this population
than in the general APOSS population (0.03%). The other four haplotypes were equally
rare in bone core subjects and the general population (<3%). The difference between
haplotype distribution in bone core subjects and the APOSS population was highly
significant (p<0.001, %2 test).
201
Chapter 5: Role of COL1A1 variants in the mechanical properties of bone










G/G 16(69.57) 50 (72.46) 66 (71.74) 81.37±8.97
G/T 7(30.43) 18 (26.09) 25 (27.17) 82.58±9.54 0.86 0.57
-1997G/T
T/T 0 3 (4.35) 3 (3.26) 81.50±6.56
Ins/InsT 18 (78.26) 49 (71.01) 67 (72.83) 81.34±8.90
Ins/DelT 5 (21.74) 17(24.64) 22 (23.91) 82.14±9.99 0.76 0.40
-1663In/DelT
Del/DelT 0 5 (7.25) 5 (5.43) 84.00±6.42
G/G 18 (78.26) 46 (66.67) 64 (69.57) 81.18±9.29
splG/T G/T 5 (21.74) 22 (31.88) 27 (29.35) 83.04±8.60 0.67 0.39
T/T 0 3 (4.35) 3 (3.26) 81,00±6.68
pa, ANOVA test of genotype frequencies in gender; pb, ANOVA test of genotype
frequencies in age. Age*, age at fracture.
Table 5.2 Comparison of genotype frequencies in bone core samples and APOSS
population
Bone core (%) APOSS (%)
Genotype N=92 N=3011 p
Age=81.6±9.0 Age=48.4±2.3


















G/G 64 (69.57) 2145 (66.51)
splG/T G/T 27 (29.35) 963 (29.86) 0.94
T/T 3 (3.26) 117(3.63)
p, ANOVA test of genotype frequencies in bone core subjects and APOSS.
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Table 5.3 Comparison of haplotype frequencies in bone core samples and APOSS
population




G8G (1) 150 (76.53) 4396 (67.05)
G7T (2) 3 (1.53) 1114(17.00)
T8G (3) 2(1.02) 800(12.21)
G8T (4) 4 (2.04) 102 (1.56)
G7G (5) 5 (2.55) 135 (2.06)
T7T (6) 24(12.24) 2 (0.03)
T7G (7) 3 (1.53) 3 (0.05)
T8T (8) 5 (2.55) 2 (0.03)
The haplotype frequencies in bone core samples are significantly different from those in
APOSS population (p<0.001, x2"test)- N: the number of chromosome, calculated by
multiplying the total number of the subjects by 2.
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Effects of Individual Polymorphisms on Biomechanical Properties of
Bone
The relationship between COL1A1 genotypes and biomechanical properties of bone is
shown in Table 5.4. When three genotypes at each polymorphism were compared, the
common homozygotes (-1997G/G, -1663in/inT, & SplG/G) were associated with
increased yield strength and stiffness when compared with carriers of the less common
allele (pa <0.05). The SplG/G genotype was also associated with increased bone
volume (pa =0.017). There was no difference of genotype distribution in length of bone
core or density of bone core (pb >0.05), but all three polymorphisms were associated
with bone volume, yield strength and stiffness in unadjusted and adjusted models. The -
1997G/G genotype was associated with significantly increased bone volume, yield
strength and stiffness (pb=0.028, pb<0.001, pb<0.001, respectively). Similar associations
were observed for the -1663in/delT and the SplG/T polymorphisms. The -1663in/inT
and the SplG/G genotypes were associated with increased bone volume, yield strength
and stiffness. After the adjustment for gender, age and "density of bone core", the
associations remained significant (padj<0.05). These associations were similar when
females (N=71) were analyzed separately, but no comparison was conducted in male
group due to the small number (N=23).
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length of core (mm) 9.29+1.23 9.19+1.45 8.56+1.80 0.55 0.78
density of bone core (g/mm3) 1.41 + 0.13 1.37+ 0.10 1.30+ 0.18 0.09 0.089
bone volume (mm3) 0.30+0.10 0.26+0.07 0.24±0.10 0.10 0.028 0.001
yield strength (MPa) 32.16+ 8.98§ 25.35 + 7.267 26.25 + 8.77 0.002 <0.001 0.001








length of core (mm) 9.28+1.17 9.13+1.65 9.10+1.63 0.86 0.88
density of bone core (g/mm3) 1.40+ 0.12 1.40+ 0.13 1.35 + 0.17 0.65 0.86
bone volume (mm) 0.30+ 0.09 0.26+ 0.08 0.25 + 0.08 0.07 0.017 0.017
yield strength (MPa) 32.14+ 8.86§ 24.3 + 7.19+ 29.00+ 8.17 0.001 <0.001 <0.001








length of core (mm) 9.34+1.23 9.00+1.51 9.15+1.07 0.53 0.46
density of bone core (g/mm3) 1.41 + 0.12 1.37+ 0.12 1.28 + 0.16 0.08 0.16
bone volume (mm) 0.31+0.10§ 0.25 + 0.07+ 0.27 + 0.07 0.017 0.003 <0.001
yield strength (MPa) 32.85 + 8.85 § 24.82±6.48+ 22+ 6.22+ <0.001 <0.001 <0.001
Stiffness (MPa) 264.84+ 67.24§ 208.66±52.86+ 199.4 ±41.7 <0.001 <0.001 <0.001
pa: GLM-ANOVA among three different genotype groups for each polymorphism; pb:
student t test between the common homozygotes and other genotype groups for each
polymorphism; pa J: adjusted for density of bone core & gender in GLM-ANOVA
model.
§: significantly different from t group.
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Regression analysis was used to investigate the relationship between the response (yield
strength & stiffness) and the predictors by entering genotypes, gender, age at fracture,
density of bone core, and bone volume into the model as predictors (Minitab). This
regression model showed that three genotypes, density of bone core and bone volume
predicted yield strength independently (p<0.05, Table5.5). The density of bone core and
bone volume predicted stiffness independently (p<0.001 for both). The three
polymorphisms did not predict stiffness significantly in the multiple regression model
including gender, age at fracture, density of bone core, and bone volume.
Table 5.5 Multiple linear regression analysis of yield strength for the 5' flank COL1A1
genotypes
Independent predictor R2 p
Bone density (g/mm3) 13 <0.05
Bone volume (mm3) 3.9 <0.05
-1997 genotypes 10.2 0.051
-1663 genotypes 7.5 0.038
Spl genotypes 19.9 0.001
R2 value is the percentage of variance explained.
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Effects ofHaplotypes on Biomechanical Properties of Bone
Relevant characteristics of the bone cores in relation to the two common haplotypes are
shown in Table 5.6. There was no significant association between any haplotype and
age at fracture or v. Homozygotes for haplotype 1 had significantly increased bone
volume (p=0.001), yield strength (pO.OOl) and stiffness (p=0.002). Conversely,
carriers of haplotype 6 had significantly reduced bone volume (p=0.001), yield strength
(pO.OOl) and stiffness (p=0.001). Because the homozygotes of haplotype 6 were very
rare (n=2), they were combined with heterozygotes when analysis was carried out (pb,
Table 5.6).
Table 5.6 Biomechanical properties of bone according to two COL1A1 haplotypes
haplotype 1 0 copy 1 copy 2copies Pa p"di
(G8G) N=6 N=29 N=56
Age at op (yrs) 82.2±5.9 83.3 + 9.3 80.6+ 9.1 0.42
Density ofBone core (g/mm3) 1.387+ 0.139 1.390+ 0.128 1.414+ 0.122 0.649
Bone volume (mm) 0.257+ 0.076 0.262+ 0.073 § 0.312 + 0.0971 0.028 0.001
Yield strength (MPa) 28 + 9.08 25.03 +6.80§ 33.35±8.92f <0.001 <0.001
Stiffness (MPa) 231.7+ 44.9 221.3 + 56.1 § 267.43 + 67.971 0.003 0.002
haplotype 6 0 copy 1 copy 2copies Pb padi
(T7T) N=75 N=17 N=2
Age at op (yrs) 81.70+ 9.1 81.88+ 9.15 77.50+ 4.95 0.92
Density of Bone core (g/mm3) 1.41+0.13 1.38 + 0.10 1.31+0.24 0.15
Bone volume (mm) 0.30+ 0.09 0.25 + 0.09 0.30+ 0.11 0.034 0.001
Yield strength (MPa) 32.05 + 8.79 23.35 + 6.45 22.00+ 9.90 <0.001 <0.001
Stiffness (MPa) 259.60 + 65.1 203.60+ 0.10 227.10 + 0.24 0.001 0.001
pa: GLM-ANOVA model for three groups of haplotypel; pb: student Mest for "0 copy"
and "1 copy+2copies" of haplotype6; padh adjusted for density of bone core & gender in
GLM-ANOVA model by entering density of bone core, gender and the haplotypes into
the model.
§: significantly different from f group.
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Multiple regression analysis showed that haplotype 1 & 6 were also independent
predictors of yield strength (p=0.023 & 0.007, respectively). In best subsets regression
analysis, haplotype 1 accounted for 12.3% of the variance in yield strength, and
haplotype 6 accounted for 13.6% of the variance in yield strength. However, neither of
these haplotypes predicted stiffness significantly.
Since haplotype 1 and 6 had opposing effects on material properties of bone, all the
samples were stratified according to combinations of these two haplotypes. This also
showed significant differences in bone volume, yield strength and stiffness between the
extreme haplotypes (Figure 5.1). Subjects who were homozygous for haplotype 1 had
the highest bone volume, yield strength and stiffness, and carriers of haplotype 6
(homozygotes & heterozygotes) had the lowest bone volume, yield strength and
stiffness. The difference between haplotypes was greatest for bone volume (p=0.017),
but was also significant for yield strength (p=0.027) and stiffness (p=0.025). The
difference in bone volume between the extreme haplotypes (homozygotes for haplotype
1, versus heterozgotes & homozygotes for haplotype 6) was 0.05 mm"3 (about 0. 6 SD).
The difference between the extreme haplotypes was 7.15 MPa (about 0.8 SD) in yield
strength, and 62.83 MPa (about 0.9 SD) in stiffness.
The relationships between individual haplotypes and unadjusted bone volume, yield
strength and stiffness were also analyzed as illustrated in Figure 5.1. These also gave
the similar results to those obtained with the adjusted values.
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Discussion
So far only one study was performed to study the relationship between the Spl
polymorphism and bone quality (Mann V et al, 2001). In that study, the Spl "Ss"
genotype (G/T heterozygote) was associated with reduced yield strength in a small
study of 23 patients (p=0.031), but no association was found between genotype and
stiffness (p=0.22) or density of the bone core (p=0.45). Bone cores derived from the Spl
heterozygotes also had significantly reduced inorganic content (p=0.001) when
compared with common homozygotes. A significant effect of density of bone core on
yield strength was also reported in this study (p<0.0001).
This study is the first to examine the role of all three COL1A1 polymorphisms and
haplotypes in relation to bone mechanical properties including yield strength and
stiffness. The Spl T allele ("s" allele) was associated with reduced yield strength
(p<0.001), which is consistent with the results of a previous study (Mann V et al, 2001),
but the association repeated here was stronger due to the larger sample size (n=94). No
association between genotypes and density of bone core was observed in agreement
with Mann's study. A possible explanation is that the density of the bone core in both
studies is the density of the cancellous structure itself calculated by dividing the mass
by the gross sample volume, which differs from the bone mineral density (BMD) that is
used in most genetic association studies. In contrast to Mann's study, bone cores
derived from the Spl G/G homozygotes ("SS") showed significantly increased bone
volume and stiffness (p<0.001 for both) when compared with heterozygotes and rare
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homozygotes. These differences could be due to the smaller sample size (17 females
and 6 males) in the previous study.
For the two promoter polymorphisms, significant associations between genotypes and
yield strength and stiffness were observed in present study. The -1997G/G homozygotes
had increased yield strength and stiffness when compared with -1997G/T heterozygotes
and -1997T/T homozygotes. There were also significant associations between the -
1663insT/insT genotype and increased yield strength (p<0.001) and stiffness (p=0.02)
compared with heterozygotes and rare homozygotes.
The associations between haplotypes defined by all three polymorphisms and bone
quality were also very strong. Homozygotes of haplotype 1 containing three common
alleles (-1997G/ -1663InT/ SplG) had significantly increased yield strength and
stiffness when compared with carriers of haplotype 6 containing the three rare alleles (-
1997T/ -1663DelT/ SplT). All three polymorphisms and haplotypes 1 & 6 were
identified as independent predictors for yield strength.
Interestingly, the frequencies of some haplotypes were dramatically different from those
in the general population (APOSS), although the genotype frequencies of all three
polymorphisms did not show any difference between the two populations. For example,
haplotype2 (-1997G/ -1663DelT/ Spl T, G7T) was the second common in APOSS
(17%), but was very rare in bone cores samples (1.53%). The frequency of haplotype 3
(G8T) was 12.21% in APOSS but 1.02% in bone core samples. In contrast, haplotype 6
(T7T) was the second common in the bone core subjects (12.24%), which is 401 times
more frequent than APOSS (0.03%). This is probably because the bone cores were
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derived from a highly selected group (patients suffering from osteoporotic hip fractures
that underwent hip replacement surgery) whereas the APOSS population comprised
younger, normal healthy women of average age 48.4±2.3. Therefore the APOSS
population is not the ideal control group for this fracture group, an age-matched control
group is needed to confirm if the difference is due to age or fracture prevalence.
In summary, all three polymorphisms and haplotypes (1 & 6) were associated with yield
strength and stiffness, and predicted yield strength significantly. This study therefore
provides evidence to suggest that three COL1A1 common variants that predispose to
osteoporosis do so at least in part by determining bone quality and bone strength.
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CHAPTER SIX
Association between COL1A1 5'
Flank Polymorphisms and Fractures
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Abstract
Previous studies have indicated that the 5' flank COL1A1 polymorphisms are
functional variants that influence BMD at the lumbar spine and the femoral neck,
DNA protein binding, reporter gene expression and bone strength. The Spl
polymorphism has been previously reported to be associated with osteoporotic
fractures, particularly vertebral fracture, in several meta-analyse. However, there is no
report about the association between the promoter polymorphisms, or haplotypes and
fractures. Considering the fact that the three polymorphisms are in high linkage
disequilibrium and interact with each other to regulate BMD, the aim of this chapter
was to investigate the association of the three COL1A1 5'flank polymorphisms,
haplotypes and osteoporotic fractures. The fracture groups comprised 303 female hip
fracture patients and 151 female vertebral fracture patients, and 145 controls for hip
fracture patients and 143 controls for vertebral fracture patients. There was no
association between any of the individual SNP or haplotypes and vertebral fracture or
hip fracture. Another interesting finding to emerge from this study was that allele
frequencies and haplotype frequencies of COL1A1 5' flank polymorphisms altered
with age and morbidity, which indicated that they are associated with mortality.
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Introduction
The major clinical importance of osteoporosis is due to the fact that it is associated
with an increased risk of fractures, most commonly affecting the hip, spine, and distal
forearm. In the UK, the lifetime risk of symptomatic fracture for a 50 year old white
woman has been estimated as 13% for the forearm, 11% for the vertebrae and 14% for
the femoral neck. Fracture is a very complex phenotype which depends not only on
fall-related factors but also on factors which influence bone-strength. Skeletal
determinants of fracture risk include BMD, bone geometry, microarchitecture, bone
turnover and the material properties of bone. Most of these factors are subject to
strong genetic influences. For example, twin studies have suggested that 60-85% of
the variance in BMD is genetically determined (Pocock NA et al, 1987 & Krall EA
1993). The genetic contribution to osteoporotic fracture risk has also been studied.
Family history of hip fracture has consistently been shown to be a risk factor for
fracture, independent of BMD in population-based studies (Seeman E et al, 1994;
Cummings SR et al, 1995). Some family and twin studies showed the heritability of
fracture was largely independent of BMD (Deng HW et al, 2000a; Andrew T et al,
2005). This indicated that predisposition may have been mediated through genetic
influences on bone turnover, and bone geometry or other factors such as the risk of
falling. Moreover, environmental factors become more important with age. For
example, the study on a large cohort of 6021 Swedish twins has shown that the
heritability of overall age-adjusted fracture was greater for first hip fractures before
the age of 69 years (0.68; 95% CI, 0.41-0.78) and between 69 and 79 years (0.47;
95% CI, 0.04-0.62), but it dropped off rapidly with age to almost zero after 79 years
old (0.03; 95% CI, 0.00-0.26) (Michaelsson K et al, 2005).
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Among all candidate gene polymorphisms investigated in relation to osteoporosis so
far, the COL1A1 Spl polymorphism affecting a Spl binding site in the first intron is
one of few validated functional polymorphisms which have been associated with
BMD and fractures. In chapter 3, I found that two promoter polymorphisms were in
strong linkage disequilibrium with the Spl polymorphism, and the COL1A1 5'flank
haplotypes had stronger effects on BMD. The haplotypes were also found to influence
reporter gene transcription (chapter 4) and bone strength in samples derived from hip
fracture patients ex vivo (chapter 5). Therefore, the aim of this chapter is to study the
associations of the three COL1A1 5'flank polymorphisms and haplotypes with
fragility fracture.
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Methods
There were two study groups in this chapter: one comprised 303 female hip fracture
patients (average age 75.4±7.4 years) who were admitted to Aberdeen Royal
Infirmary with osteoporotic hip fracture resulting from low-energy trauma and
matched 145 female controls (average age 78.8 ± 8.6 years) recruited from patients
admitted the same hospital who had fallen but not sustained a hip fracture. The other
group comprised 151 female clinical vertebral fracture patients (average age 72.5 ±
6.5 years) and matched 143 controls (average age 71.1±5.6 years) also from the north
east Scotland who had responded to an advertisement for volunteers to take part in a
study of treatment for osteoporosis.
DNA was extracted and the genotypes for the three polymorphisms were determined
by PCR and DNA sequencing methods. Haplotypes were constructed by the 'PHASE'
program, as described in chapter 2. The probability threshold at which haplotype
phases are called as "correct" is 90%.
This study had 80% power to detect a 10% difference in allele proportions (OR=1.5)
in hip fracture (N=303) and control groups (N=145) based on the allele frequencies of
the -1663delT and the SplT in normal Scottish women (20%, chapter 3). The power
to detect the same effect in vertebral fracture (N=151) and control groups (N=143)
was less than 60% (Minitab).
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Results
Genotype Frequencies in Hip Fracture-control Groups
Genotypes for the -1997 G/T polymorphism and the Spl polymorphism were in
Hardy-Weinberg equilibrium (HWE) in both hip fracture and control groups, but
genotypes for the -1663in/delT polymorphism deviated significantly from HWE
(p=0.03) due to under-representation of homozygotes for the -1663delT allele and
over representation of heterozygotes in the hip fracture group. But HWE of -
1663in/delT genotypes was observed in the combined samples (hip fracture and
control groups). As shown in Table 6.1, there was no significant association of any
genotype with hip fracture.







G/G 242 (79.87) 123 (84.8)
-1997G/T G/T 59 (19.47) 22(15.2) 0.18
T/T 2 (0.66) 0
In/inT 179 (59.08) 83 (57.2)
-1663In/delT In/delT 116 (38.28) 52 (35.9) 0.31
Del/delT 8 (2.64) 10(6.9)
G/G 192 (63.37) 85 (58.6)
SplG/T G/T 98 (32.34) 57 (39.3) 0.67
T/T 13 (4.29) 3(2.1)
P: x2 test of allele frequencies between hip fracture and control groups
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Association of Haplotype Frequencies in Hip Fracture-Control
Groups
Five haplotypes with minor-allele frequency (MAF) >1% were observed and these
accounted for more than 90% of alleles in the hip fracture and control groups. As
shown in Figure 6.1, the most common haplotype 1 (-1997G/-1663InT/splG, 'G8G')
accounted for more than 45% in both groups. There was no significant difference in
• 2
haplotype frequencies between hip fracture and control groups (% =2.87, p=0.58).
Figure 6.1 Common haplotypes and frequencies in hip fracture-control group
-1997 G/T -1663 In/delT +1245 G/T (Spl)
II n I n





G - InsT G HI (G8G) 299 (49.34) 136 (46.9)
G - DelT T H2 (G7T) 8(1.32) 3 (1.03)
T - InsT G H3(T8G) 59 (9.74) 22 (7.59)
G - InsT T H4 (G8T) 112(18.48) 60 (20.69)
G - DelT G H5 (G7G) 124 (20.46) 69 (23.79)
Common haplotypes at the 5' flank of the COLIA1 gene and their frequencies in hip
fracture-control groups are shown in relation to the COLIA1 gene structure. Shaded
boxes represent exons. N represents the copy number of chromosomes, calculated by
multiplying the total number of the population by 2.
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Genotype Frequencies in Vertebral Fracture-Control Groups
The genotypes for all three polymorphisms were in Hardy-Weinberg Equilibrium
(p>0.05). As shown in Table 6.2, there was no significant association between any
genotype and vertebral fracture.






G/G 114(75.50) 106 (74.13)
-1997G/T G/T 32 (21.19) 35 (24.48) 0.47
T/T 5 (3.31) 2(1.40)
In/inT 95 (62.91) 95 (66.43)
-1663indelT In/delT 52 (34.44) 43 (30.07) 0.69
Del/delT 4 (2.65) 5 (3.50)
G/G 101 (66.89) 95 (66.43)
SplG/T G/T 46 (30.46) 44 (30.77) 0.99
tts—t~.—:
T/T 4 (2.65) 4 (2.80)
P*: X2 test.
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Haplotype Frequencies in Vertebral Fracture and Control Groups
Four haplotypes with minor-allele frequency (MAF) >1% were observed, and they
accounted for more than 99% of alleles in the vertebral fracture and control groups.
As shown in table 6.3, the most common haplotype 1 (-1997G/-1663/«77splG, 'G8G')
accounted for more than 65% of both groups. There was no significant difference in
haplotype frequencies between vertebral fracture and control groups (%2=2.23,
p=0.53).





HI (G8G) 198 (65.56) 194 (67.83)
H2 (G7T) 52 (17.22) 50 (17.48)
H3(T8G) 42(13.91) 37 (12.94)
H5 (G7G) 8 (2.65) 3 (1.05)
N, copy number of the chromosomes, calculated by multiplying the total number of
the population by 2.
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Allele and Haplotype Frequencies Change with Age
The frequency of the -1997G allele was increased from 86.23% in the APOSS
population (average age =48.5 ± 2.4 years) to 92.4% in the hip fracture controls
(average age=78.8 ± 8.6 years). The frequency of -1997T allele was correspondingly
reduced in elderly hip fracture controls, compared with APOSS (p=0.003). The
frequency of the -1663inT allele was decreased from 80.4% in the APOSS population
to 75.2% in the hip fracture controls, and the -1663delT allele was correspondingly
enriched in the hip fracture controls compared with APOSS (p=0.029). The frequency
of the Spl genotype showed a similar change as the -1663in/delT genotype, but it did
not reach statistical significance (p=0.176).










-1997G 5193 (86.23) 247 (86.37) 268 (92.4) 0.003
-1997T 829(13.77) 39(13.64) 22 (7.6)
-1663InT 4803 (80.40) 233 (81.47) 218 (75.2) 0.029
-1663DelT 1171 (19.60) 53 (18.53) 72 (24.8)
SplG 5253 (81.44) 234 (81.82) 227 (78.3) 0.176
SplT 1197 (18.56) 52(18.18) 63 (21.7)
P, %2 -test between APOSS and hip control
When haplotype frequencies were compared among the hip fracture controls, the
vertebral fracture controls and the general population (APOSS), I found that the
frequencies for some haplotypes differed significantly in hip fracture controls and
APOSS (Figure 6.2). Two haplotypes (4 & 5) had higher frequencies in the hip
fracture controls than the APOSS population (P<0.001). Instead, the other three
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haplotypes (1-3) were less common in hip fracture controls compared with APOSS.
However, there was no significant difference in haplotype frequencies between
vertebral fracture controls and APOSS (x2=1.53, p=0.68).









G8G(1) 4396 (67.05) 194 (67.83) 136 (46.9)
G7T(2) 1114(17) 50 (17.48) 3 (1.03)
T8G(3) 800 (12.21) 37 (12.94) 22 (7.59)
G8T(4) 102 (1.56) 0 60 (20.69)

























The frequencies of haplotypes 1-3 (HI, H2 & H3) were decreased in elderly controls
(hip control). In particular, the frequency of haplotype 2 dropped from 17% in
APOSS to 1.03% in hip controls. Conversely, the frequencies of haplotypes 4-5 were
increased from ~2% in APOSS to more than 20% in the hip fracture controls.
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Discussion
The COL1A1 gene is one of the most important functional candidate genes for
osteoporosis due to the fact that type I collagen is the most abundant protein of bone.
The Spl polymorphism of the COL1A1 gene has been widely studied in relation to
BMD and fractures. It has been considered a functional polymorphism because in
vitro studies suggested that the rare 'T' allele is associated with more COL1A1
transcript and protein product (Mann V et al, 2001). Two promoter polymorphisms (-
1663In/delT & -1997G/T) were first identified in a Spanish population and have been
associated with BMD in several other populations (Garcia-Giralt N et al, 2002; Liu
PY et al, 2004; Yamada Y et al, 2005; Zhang YY et al, 2005 & Stewart TL et al,
2006). More recently, the Rotterdam study showed that the SplT allele was associated
with a 2.3 times increased risk of fragility fracture (95%CI 1.4-3.9, P=0.001), and
haplotype2 (-1997G/SplT) was associated with a 2.1 fold increased risk of fragility
fracture in women (95%CI 1.2-3.7, P=0.001) (Yazdanpanah N et al, 2007). However,
two promoter polymorphisms and the Spl polymorphism have not been studied
together in the form of haplotypes in relation to osteoporotic fractures.
The present study of two promoter polymorphisms in relation to osteoporotic
fractures is the first to be performed and also the first to report the results of haplotype
analysis taking into account alleles at the Spl polymorphic site. In chapter 5, by
performing biomechanical studies ex vivo in bone samples from hip fracture patients,
I found that alleles -1997T, -1663delT and SplT were associated with reduced bone
strength. Moreover, strong associations were found when subjects were categorised
by haplotypes. The rare haplotype 6 '-1997T/-1663delT/SplT' was dramatically
enriched in bone samples from hip fracture patients (12.24%), and was 401 more
frequent than the general population (APOSS, 0.03%). This rare haplotype was
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associated with reduced bone strength in hip fracture bone samples (pO.OOl), but it
was totally absent in the present study of fracture and control subjects. One of the
poassible explanations is that the bone samples used in biomechanical test were
removed from the patients who were admitted to Aberdeen Royal Infirmary and
underwent hip replacement surgery as a result of osteoporotic hip fracture. This is a
highly selected group with the age at fracture ranges from 58 to 101 years old with an
average of 81.7 years, which is different from the hip fracture patients used in this
association study.
In this case control study, the genotype frequency of the heterozygote -1663in/delT
was significantly different between the hip fracture group and APOSS study
(p=0.017). This was mainly due to a departure from Hardy-Weinberg Equilibrium
caused by an over representation of the heterozygote -1663in/delT genotype in the hip
fracture group. Possible reasons for the apparent HWE deviation include: genotyping
error, random sampling error and because one genotype is predisposing to disease and
therefore will be more frequent in subjects ascertained for that disease. To exclude the
genotyping error, all the genotypes of three polymorphisms were repeated in duplicate.
Since the genotype frequencies of the other two polymorphisms were not out ofHWE
and all the subjects were recruited from North East Scotland, random sampling error
is not likely. Considering that only the hip fracture group showed a departure from
HWE of the -1663ins/delT genotype, it may indicate an effect of the genotypic
disease association or the functional nature of this polymorphism.
However, none of the genotypes or haplotypes was associated with increased risk of
vertebral fracture or hip fracture in this study. It may be under-powered to detect the
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modest effects that are expected from individual polymorphism on a complex disorder
such as osteoporotic fracture in light of the fact that fracture is a very complex
phenotype involving many risk factors and determined by multiple genes with minor
effects. For example, the most recent meta-analysis involving 20,786 individuals from
several European countries reported a non-significant trend for association of the Spl
genotypes with vertebral fracture and a nominally significant association with incident
vertebral fractures in females (OR=1.33 [95% CI, 1.00 to 1.77]; p=0.05). The study
presented here only had about 50% power to detect the same effect of the SplT allele
on hip fracture (N=303) and 30% on vertebral fracture (N=151) based on the
frequency of SplT allele in the general population (20%, APOSS). Power was also
low to detect similar effects of the -1997G/T and the -1663in/delT polymorphisms.
Therefore, further studies in larger populations are required to detect the subtle effects
of individual polymorphism on fracture.
Another interesting finding to emerge from this study was that the frequencies of
genotypes and haplotypes differed markedly with age. For example, the frequencies
of -1997G and -1663delT alleles were significantly increased in elderly hip fracture
controls compared with those in the general population APOSS. The frequencies of
haplotypes 4 & 5 were also significantly increased in elderly hip controls compared
with those in APOSS. Conversely, the frequencies of haplotypes 1-3 were less
common in elderly hip fracture controls. There was also a marked difference in
haplotype frequencies in the bone core samples (chapter 5) compared with the general
population.
Taken together, these observations suggest that COL1A1 haplotypes might be
associated with morbidity or mortality in the general population. There is evidence
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that the SplT allele is associated with lower arterial compliance which may reflect the
effects of the polymorphism on collagen type I composition of blood vessels (Brull
DJ et al, 2001b).. Reduced arterial compliance precedes the development of
hypertension which in turn is associated with the development and progression of
atherosclerosis and increased cardiovascular risk (Noma T et al, 1999).
Another possible explanation is that the elderly controls for hip fracture were
recruited from patients admitted to Aberdeen Royal Infirmary (ARI) with a fall who
had not sustained a hip fracture, whereas the controls for vertebral fractures and
APOSS population were randomly selected populations of normal healthy women.
In summary, there was no association of any genotype or haplotype with osteoporotic
fracture in this study. But the frequencies of 5' flank COL1A1 genotypes and
haplotypes vary among populations, raising the possibility that COL1A1 alleles are
associated with morbidity or longevity, although further study will be needed to
investigate this.
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CHAPTER SEVEN
Towards Generation ofAn Animal
Model for Osteoporosis Mediated
by COL1A1 Alleles
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Abstract
The previous chapters have already revealed the possible mechanisms by which the
three polymorphisms at 5' flank of COL1A1 gene predispose to osteoporosis
including regulating BMD and bone strength. I also found these polymorphisms have
functional effects on gene transcription using promoter-reporter assays and affect
DNA-nuclear protein binding in gel shift assays. To further investigate the function of
these polymorphisms in vivo, the aim of the present study was to create an animal
model of osteoporosis associated with the COL1A1 haplotypes by gene targeting. Two
targeting constructs containing 17.7 kb humanized mouse Collal sequence were
generated by cloning and were transfected into mouse 129 embryo stem cells (ES) by
electroporation. Recombination events were detected by long-PCR amplification of
DNA extracted from ES cells which survived the G418 seletion. After three targeting
attempts, 45 ES cell clones survived but none had the correct homologous
recombination.
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Introduction
In the previous chapters, I found that three polymorphisms at 5' flank of COL1A1
gene interacted with each other to regulate BMD at lumbar spine and femoral neck in
a peri-menopausal Scottish women population. The haplotypes defined by these
polymorphisms also have strong effects on BMD: haplotype 2 (-1997G/-
1663delT/SplT, "G7T") was associated with reduced BMD (p=0.007 at lumbar spine
& p=0.008 at femoral neck) while haplotype 3 (-1997T/-1663inT/SplG, "T8G") was
associated with increased BMD (p=0.007 at lumbar spine). The mechanisms of these
associations are still not clear. The biomechanical tests in chapter 5 showed that the -
1997 T, -1663 delT (7T) and Spl T alleles were associated with reduced bone
strength (p<0.001), and haplotype 6 (T7T) was also associated with reduced bone
strength ex vivo bone samples from hip fracture patients (p<0.001) with 401 times
enrichment of its frequency in these bone samples. The -1663delT and -1997T alleles
were found to have greater binding affinity for nuclear proteins of osteoblasts
compared to their common alleles in gel shift assays (chapter 4). Furthermore,
promoter-reporter assays in chapter 4 showed that haplotype 2 and 3 had higher
transcriptional activities than other haplotypes for reporter gene (p<0.001).
Therefore, three 5' flank polymorphisms predispose to osteoporosis by the regulation
of BMD and bone quality. Previous studies suggested that the Spl polymorphism
predisposes to osteoporosis by increasing the ratio of collagen a 1(1) to a2(I) mRNA in
"Ss" heterozygotes (2.3 to 1), leading to abnormal protein production (homotrimer
[a 1(1)3]). This hypothesis is supported by the previous studies which have shown
homotrimer [a 1(1)3] is found in mouse fetal tissues and material derived from tumors
and chronic fibrotic conditions and associated with impaired mechanical strength of
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bone (Chipman SD et al, 1993 & McBride DJ et al, 1998). However, its presence has
not been observed yet in human tissue due to the limited amounts of patient material
available. The aim of this chapter was to investigate the molecular mechanisms by
which the COL1A1 haplotypes affect bone metabolism in vivo by generating a mouse
model of osteoporosis associated with the polymorphisms by gene targeting.
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Methods
Construction of Targeting Vectors
Targeting constructs containing 4.6kb of human COL1A1 5' sequence (-2104 to
+1537; promoter, exonl and intronl) were used to replace the proximal mouse
Collal 5' sequence since the three polymorphisms of interest are absent from the
mouse Collal gene. A neomycin-resistance gene (neo) was flanked by two loxp sites
and the whole loxp-neo-loxp cassette was inserted into intron 5 of the mouse Collal
gene (Figure 7.1).
Two targeting constructs were made corresponding to haplotypes 2 & 3. The base
changes at each of the three polymorphic sites were introduced by a Pfu DNA
polymerase-based mutagenesis with the Quick-Change site-directed mutagenesis kit
(Strategene, UK). The same method was used to create restriction sites for cloning
and to correct the PCR errors in the targeting constructs. The desired changes were
confirmed by DNA sequence analysis.
To screen the recombination events at both 5' and 3' ends after targeting experiments,
a control vector (18.4kb) was also constructed with the extended upstream sequence
on mouse Collal 5' homologous sequence (-5320 to -1352) and extended
downstream sequence on 3' homologous sequence (+1573 to +7590) (Figure 7.1).
All the details were described in chapter 2.
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Figure 7.1 Schematic representation of endogenous mouse Collal gene, targeting
vector and control vector.
Endogenous
mouse collal
1 2 3 4 5 6 ... 22 23
I I I II I Fl
Mouse promoter Human 5' sequence mouse exons 2-22
Targeting vector (17.7kb)





l . III! It
P3
Control vector (18.4kb)












This targeting event will replace the proximal promoter of the mouse Collal gene
with the human COL1A1 promoter, exonl and intronl. Loxp-Neo-loxp cassette serves
as a positive selection marker. A control vector with two extended homologous ends
was generated to screen recombination events at both homologous ends using long-
PCR reactions. The black boxes represent mouse Collal exons. The gold box
represents human COL1A1 promoter and intronl. The purple box represents human
COL1A1 exonl. PI, P2 & P3 represent three polymorphisms: -1997G/T, -
1663ins/delT & splG/T, respectively. Notl and Nsil site were used to linearize the
targeting for the targeting experiments.
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ES cell Targeting Method
The two targeting vectors were purified and lineared using the restriction enzymes
Notl and Nsil. The linear DNA (16.6 kb) was then extracted using Elutrap Electro-
seperation system (Schleicher & Schuell), and 100 pg purified linear DNA was used
for electroporation. After the electroporation, ES cells were seeded at 106 per
gelatinised petri plate (10 plates for targeted cells and 4 plates for control cells) and
incubated at 37°C overnight before adding G418 (175pg/ml) for selection of
recombinant colonies. The targeting was repeated three times under similar conditions
by Fiona Kilanowski in Human Genetic Unit, MRC.. G418 resistant clones were
picked, DNA was extracted and screened by myself using two long-PCR reactions to
detect the recombinant integrations at both 5' and 3' end. The PCR conditions were
optimized using the 18.4 kb control vector at different concentrations prior to the
targeting. Details were described in chapter 2.
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Results
Generation of Targeting Vectors by Long-PCR
Four PCR reactions were optimized to produce strong signals of 2.3 kb human
COL1A1 promoter and exonl, 1.3 kb human COL1A1 intronl, 3.9 kb mouse Collal
promoter and 2 kb loxp-neo-loxp cassette, respectively (Figure 7.2).












Lane M 1 M
The top panel shows the targeting construct and the sizes of the fragments. The
bottom panel shows the PCR products electrophoresed on a 1% agarose gel along
with two lkb DNA ladders on both sides.
Lane 1: 2.3 kb of human COL1A1 promoter; lane 2: 1.3 kb of human intronl; lane 3:
3.9 kb of mouse promoter; lane 4: 2 kb of Loxp-Neo-Loxp cassette; M: 1 kb DNA
ladder.
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All these PCR fragments were subcloned into the pBLuescript SK (-) vector, and all
ligations of the subclonings were checked by restriction digestions. After the sequence
of each subclone was confirmed by sequencing reactions, DNA fragments were then
ligated together to assemble the targeting vector as shown in Figure 7.3.









© i iiiiiiw S E E/Hl H2
23456 22
dl.8kb
2 3 4 5 6 22
© i hfh iS S E E/Hl H2
« ~15.7kb ►
1 2345 6 22
iJ i i i i
E E/Hl A M H2
- ~17.7kb ►
a: 8.2kb mouse Collal exon2-22 subclone; b: 10.5kb vector made by ligation of a &
5'human COL1A1; c: 11.8kb vector made by ligation of b & human COL1A1 intronl;
d: 15.7kb vector made by ligation of c & mouse Collal promoter; e: 17.7kb targeting
vector made by ligation of d & Loxp-neo-loxp cassette.
Restriction enzymes used in each ligation: S, SpeI; E, EcoRl; A, A/Ill; M, MfeI; HI,
Hindlll; H2, Hincll.
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Sequencing Results
Two haplotypes created by three Site-directed mutagenesis (SDM) reactions at the
human COL1A1 -1663, -1997 and +2145 polymorphic sites were confirmed by DNA
sequence analysis. The completed targeting vectors were sequenced successfully
using primers covering the entire vector sequence at least twice. This revealed several
base changes relative to the published sequence. A silent point mutation creating an
Xho\ site in mouse Collal exon7 was confirmed by both forward and reverse
sequence reactions, which was introduced by Hormuzdi SG et al (1999) for
quantification of allele-specific transcripts in vivo (Figure 7.4)
Figure 7.4 A Xho\
Forward sequence
Reverse sequence
site was introduced in mouse Collal exon7
690 700 710 720 730












This T-*A substitution in exon7 resulted in a silent mutation, which would be used
for quantification of allele-specific transcripts in vivo.
The Xho\ site is represented in frame (top); T—A substitution is in red (bottom);
amino acids are in bold Italic (bottom); the silent mutation is underlined.
GPSGPRGLPGPPGAP
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The second base change was detected within the human COL1A1 promoter. It was
identified as a G/C SNP (rs2269336) with the G allele present in both targeting
vectors (Figure 7.5). This is a validated SNP with an allele frequency of 0.838 for "C"
and 0.164 for "G" in Central European population (CEU), according to the HapMap
genotyping results.
Figure 7.5 A G/C SNP was detected within human COL1A1 promoter
This is a G/C SNP (rs2269336) with rare G allele present in both targeting vectors.
The SNP is underlined.
238
Chapter 7: Generating an animal model for osteoporosis by gene targeting
The third base change (a "G" insertion) was detected at position -1545 of the mouse
Collal promoter (Figure 7.6). It was confirmed as a SDM error after comparing with
the SDM template sequence. To correct this error, another SDM was performed with
new primers on plasmid DNA without human homologous sequence (chapter 2,
Material and methods).




Mouse (129/ola) Collal promoter
Homologous human sequence
A "G" insertion at position -1545 of mouse Collal promoter (top) was found in the
sequence reactions. This position is highly homologous to human COL1A1 promoter
(-1660 to -1670; bottom).
Finally, the sequencing reactions revealed that there were 21 extra bases of plasmid
vector inserted into the human promoter which might be introduced by subcloning. To
excise the extra 21 bp sequence, the pBlueScript SK (-) vector was first modified to
introduce NheI and AfeI restriction sites by inserting 20 base oligonucleotides
containing both restriction sites into the multiple cloning site (Figure 7.7).
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Secondly, the targeting vector was digested by enzymes Nhel and AfeI to release two
fragments: a 5.1 kb fragment containing the 21 extra bases and a 12.6kb fragment.
Both fragments were purified from gel and quantified. The 5.1 kb fragment was then
ligated with the modified pBlueScript SK (-) vector to make a new vector of about
8kb (Figure 7.7).
Figure 7.7 Modification of pBluescript SK(-) vector and generation of a new 8kb























5'COL1A1 sequence (5.1 kb)
From targeting vector
r
HindlU Nhel EcoRl BsrGl Afel Eagl
5' atcgataAGCTTGCTAGC . GAATTC.... . TGTACA.... . AGCGCTCggccg3'
3' tagctattcgaACGATCG.... . CTTAAG.... . ACAGTG.... . TCGCGAGCCGGc5'
A A
a: double-stranded oligonucleotides containing Nhel and Afe I sites, b: pBluescript
SK(-) vector was modified by cloning the double-stranded oligos into the multiple
cloning site (MCS) by Hindlll and Eagl digestion, c: a new 8kb vector was made by
Nhel and Afel digestion of targeting vector and modified pBluescript SK(-) vector,
which contains 5.1 kb 5* COL1A1 sequence including the extra 21 bases.
Restriction sites are underlined.
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Then a SDM reaction was carried out on a "human promoter' subclone to create an
extra HindIII restriction site at the first extra base (Figure 7.8). After SDM reaction,
the extra 21 bases were removed by HindlU digestion, which was confirmed by
sequencing reaction. After that a 1,5kb fragment containing the correct sequence was
released from the 'human promoter' subclone by BsrGl and EcoRl digestion followed
by ligation with the 8kb new plasmid digested by BsrGl and EcoRl. Finally the 5.1 kb
fragment with correct sequence was released from this 8kb new plasmid and cloned
into the 12.6kb fragment digested by AfeI and Nhel to make targeting vector.





5' GAATTC AAAGCTTTcgcgagctcgagatcagctttGGT TGTACA 3'












EcoRl Hindi II Hindlll
5' GAATTC AAAGCTTTcgcgagctcgagatAagctttGGT TGTACA 3'
3' CTTAAG TTTCGAAAgcgctcgagctctaTtcg^aaCCA ACAGCG 5'
©
pUC ori
EcoRl Hindll 1 BsrGl
ffl (-) ori
ompicillin i
5' ... GAATTC.... . AAagctttGGT.... . TGTACA . ....3'





a: "huamn promoter' subclone with extra 21 bases (in bold blue low case), b: another
Hindlll site was created by SDM (c—-A substitution), c: 'huamn promoter' subclone
with extra sequence removed by a HindlU digestion. Restriction site are underlined.
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Generation of a control vector for PCR screening
A control construct with extended 3' homologous sequence was made for long PCR
screening of homologous recombinant events after targeting. A 2838bp DNA
fragment of mouse Collal intron 12-26 was amplified by long PCR and used to
replace the mouse Collal intron 12-22 in the targeting vector. The extended 3'
sequence was then inserted into a 13.2kb vector which was derived from the 17.7kb
targeting vector by BsrGI digestion. Finally, this vector was ligated with the BsrGI
digested fragment to generate the 18.4kb control vector, as shown in Figure 7.9.
Figure 7.9 Schematic representation of the strategy to make control vector
2 3 4 5 6...22
4 i III in l »
AN B B H
« 4.5kb —*
•* 17.7kb >
\±) 2 3 4 5 6. ..22 23 24 25 13 14. ..23 24 25"
HHbHI
AH A E A E
* 13'2kb
<*—760bp—► « 2.8kb ►
A+E digest Long PCR product
ci) 2 3 4 5 6...2223 24 25
N B A H/E
■* - 14 kb ►
© 2 3 4 5 6. ..22 23 24 25
I lll-vjH-ll I I I
N B B A II/E
« 4.5kb ►
•* I8.4kb ►
a: 17.7kb targeting vector; b: 13.2kb vector made by BsrG\ digestion; c: 760bp insert
made by AatW + EcoRV digestion of 2.8kb long PCR product; d: 14kb vector made
by ligation of b & c; e: 18.4kb control vector made by ligation of 4.5kb BsrGI
fragment & d.
Restriction enzymes: N, Not I; B, BsrGI: A, AatW: H. Hincll: E, EcoRV.
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The completion of the targeting vectors and control vector were also confirmed by
restriction digestions prior sequencing reactions. The digestion products were loaded
on gel and shown in Figure 7.10.
Figure 7.10 Restriction digest products of targeting and control vectors
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Lane M: 1 kb DNA ladder
Lane 1: Aatll digest to control vector
(13.4 kb + 5 kb)
Lane 2: Aatll digest to targeting vector
(13.4 kb + 4.3 kb)
Lane 3: Notl + Nsil digest to linearize
targeting vector (16.5 kb +1.2 kb)
The top two panels show the restriction maps of the targeting vector and the control
vector. The bottom panel shows the restriction products on gel along with lkb DNA
ladder (M). Restriction enzymes: Nl, Notl; N2, Nsil; A. Aatll. PSKII, pBluescripti SK
(-) vector.
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Long PCR reactions for screening the recombination events
Two PCR reactions for screening the recombinant integrations at 5' and 3' ends were
also optimized with control vector at different concentrations. In this project, 5'
screening PCR was optimized to give a 6330 bp band and 3' screening PCR still
produced an unspecific amplification about 2000 bp apart from 4705 bp product after
optimization (Figure 7.11).
244
Chapter 7: Generating an animal model for osteoporosis by gene targeting
Figure 7.11 Screening for recombination events by long PCR










a. PCR screen for 5' integration
3' screening PCR
(4.7kb)
Lane 1: 80ng mouse 129/ola DNA
Lane 2: 129/ola +10copies control vector
Lane 3: 129/ola +lcopy control vector
Lane 4: 129/ola +0.01 copy control vector
b. PCR screening for 3' integration
The top panel shows that long PCR reactions were designed to detect the recombinant
events at both 5* and 3' end. a: 5' screening PCR with forward primer locating
extended homologous mouse promoter and reverse primer binding within human
COL1AI intronl. The expected product is 6330bp. b: 3' screening PCR with forward
primer binding within loxp-neo-loxp cassette and reverse primer located downstream
of the targeting vector homology sequence (exon23). The expected product is 4705bp.
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Gene Targeting Results
After the G418 selection, 45 resistant clones were picked of which 32 were from the
first two targeting attempts and 13 from the third targeting. The quality and quantity
of all 45 DNA samples extracted from the ES cells were confirmed by a PCR reaction
which was designed to amplify a 300bp fragment of the mouse Sqstml gene (not
shown). Two screening PCR reactions were then carried out to screen the homologous
recombination events at the 3' and the 5' arms on the ES cell DNA. However, only
the control vector was amplified successfully, whereas none of the ES cell DNA
samples gave the positive amplification signal (Figure 7.12).





Lane 1: 129/ola+0.01 ng control vector
Lane 2: lOng control vector
Lane 3: 129/ola mouse DNA
Lane 4: ES DNA





Lane 1: 129/ola mouse DNA
Lane 2 & 3: ES DNA
Lane 4: 129/ola +0.0 lng control vector
M: lkb DNA ladder
The 5' and 3' screening PCR products (top and bottom, respectively). The ES cell
DNA extracted from G418 resistant ES cell clones did not give any band at either
ends (lane 4 on the top and lane 2&3 on the bottom).
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Discussion
The development of gene-targeting technology combined with the sequencing of
mouse genome has dramatically increased our ability to create mouse models in
which the functional significance of genes, gene variants, and quantitative trait loci
(QTL) can be determined. This can be achieved in a number of ways: microinjection
of DNA into the pronucleus, embryonic stem cell transfer, retroviral transfer or the
nuclear transfer. Embryonic stem cell (ES cells) transfer is based on homologous
recombination at the both arms of interest. Embryonic stem cells are derived from the
inner cell mass of a blastocyst, which is an early stage embryo. Embryonic stem cell
transfer involves isolation of stem cells from a blastocyst, transfection of the
transgene (by electroporation), selection of the stem cells in which the transgene has
undergone homologous recombination at the desired locus, and injection of the
selected stem cells into a host blastocyst-stage embryo. The resulting chimera will
undergo further selective breeding for homozygous expression of the desired gene.
This is also called gene-targeting.
To study the functions of the three 5' flank COL1A1 polymorphisms in vivo, targeting
vectors were designed to contain two haplotypes ("G7T" & "T8G"), which have been
associated with BMD in the general population (chapter 3) and regulate reporter gene
transcription (chapter 4). Since the three polymorphisms of interest are absent from
the mouse Collal gene, the human COL1A1 5' sequence (-2104 to +1537) containing
part of promoter, exonl and intronl were inserted in the targeting vector to replace
the relevant mouse Collal gene sequence. A control vector was also created by
cloning, which contained the same targeting gene but with extended 5' and 3'
homologous mouse sequence used to screen the recombination events on both ends.
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The targeting and control vectors were successfully completed and confirmed by
restriction digestions and DNA sequence analysis. There were several base changes
found by DNA sequencing. A "G" insertion at position -1545 of the mouse Collal
promoter was introduced during SDM-PCR amplification, because the forward SDM
primer bound human sequence as well as this highly homologous mouse sequence
during the SDM-PCR amplification. This highly-conserved sequence may contain
potential binding site of nuclear matrix protein 4 (Nmp4) because the binding site was
already identified in homologous rat and human sequences (Alvarez M et al, 1998 &
GARCIA-GIRALT N et al, 2005). Therefore, this error was corrected by performing
SDM to the mouse sequence only. The DNA sequencing also revealed there were 21
extra bases in the human COL1A1 promoter region, which derived from the multiple
cloning sites of the pUC19 vector. These extra bases were excised successfully by
SDM-ligation methods. Another G/C SNP (rs2269336) in human promoter sequence
was also detected by sequencing reactions. The frequency is 0.836 for "C" allele and
0.164 for "G" allele in CEU population according to HapMap genotyping results.
Although the "G" allele is rare, it was kept in both targeting vectors due to the same
DNA template used in the initial PCR amplification. Finally there was a silent
mutation in mouse Collal exon7, which was designed to create an Xho\ site for
quantification of allele-specific transcripts in vivo.
Two long-PCR reactions were optimized to detect the recombinant integrations at
both 5' and 3' ends with 18.4 kb control vector which contains extended 5' upstream
of homologous mouse promoter sequence and extended 3' homologous sequence
downstream of the targeting vector (exon25). Because one primer was located in the
human COL1A1 intronl and another was located in the loxp-neo-loxp cassette, PCR
reactions should only give positive products when the homologous recombination has
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occurred. Although the 3' screening PCR has a non-specific amplification about 2000
bp, both 5' and 3' screening PCR reactions were optimized to be able to amplify as
little as 0.01 copy of control vector mixed with 80 ng mouse 129/ola genomic DNA.
Therefore, this is a quick and sensitive method to screen for recombination, although
southern blot would still be required to confirm homologous recombination after PCR
screening. However, none of the 45 ES clones tested gave positive band in the 5' and
3' screening PCR reactions. The quality and quantity of these DNAs were checked by
another PCR. It appears that no homologous recombination occurred in these 45 ES
cell clones.
Technical errors in DNA purification, targeting process or ES cell culturing are
excluded because the targeting was repeated three times by the same person with the
same procedure. Some other targeting vectors which were purified and electroporated
into ES cells in parallel were all successfully recombined into the mouse genome.
Considering the very low survival of clones from G418 selection (average 13 clones
out of 10 plates), it is possible that the loxp-neo-loxp selectable marker cassette did
not function properly. This DNA cassette contains two loxp sites, the PGK promoter
and neomycin resistance gene. In this project, DNA was amplified from a loxp-PGL-
neo-loxp plasmid (gift from Omar Albagha) by PCR reaction with two primers
containing MfeI and ft/711 restriction sites. However, the function of this PGK-
neomycin resistant gene was not tested prior to targeting, although it worked properly
in another project and the sequence was confirmed by sequencing reactions. To
address this issue, the function of this selectable cassette needs be tested in ES cells in
the future. Another possible explanation is that for some reason, the mouse genome
does not favour the human COL1A1 targeting construct. There is no relevant literature
on this so far. Many foreign genes have been introduced into the mouse genome by
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targeting including human Apolipoprotein E4 (cDNA) (Hamanaka H et al, 2000),
human rhodopsin-GFP fusion gene (7.4kb DNA) (Chan F et al, 2004). Moreover, the
part of human COL1A1 sequence in the targeting vector is highly homologous to
mouse Collal sequence. To make the human sequence more homologous to mouse
sequence, some mouse sequences were inserted into the boundary of human
promoter-exonl-intronl to mimic the splicing procedure in the mouse genome
(Appendix 2). Therefore, it is unlikely that the mouse genome rejects human COL1A1
sequence during the targeting process.
In summary, two targeting vectors containing two haplotypes of 5' flanking human
COL1A1 gene and a control vector were successfully constructed. Three targeting
attempts were performed to introduce targeting vectors into mouse 129/ola ES cells
by electroporation. 45 neomycin resistant clones were picked. All extracted DNA was
confirmed to have high quality and quantity by a PCR reaction, but none of them
exhibited homologous recombination. Further study is in progress to try and repeat ES







SUMMARY and Future Work
Osteoporosis is a multifactorial disease with a strong genetic component. Approaches
such as linkage analysis, candidate gene association study and genetic analysis of
mice have been successfully used in the identification of genes that are implicated in
the pathogenesis of osteoporosis. Many candidate gene polymorphisms have been
implicated in the pathogenesis of osteoporosis but one of the most widely studied is a
polymorphism that affects a Spl binding site in the first intron of the COLIA1 gene at
position +1245. Type I collagen is the major protein of bone. Mutations within the
exons of COL1A1 and COL1A2 genes, which code for procollagen a 1 (I) and a2(I)
polypeptides, result in the abnormal bone quality and increased fragility which is
associated with osteogenesis imperfecta. The Spl polymorphism has been associated
with bone density, fragility fractures and other osteoporosis-related phenotypes such
as postmenopausal bone loss, bone geometry, bone quality and bone mineralization.
Functional analysis has shown that the osteoporosis-associated T allele of the Spl
polymorphism is associated with increased DNA-protein binding, increased
transcription, abnormally increased production of the collagen type I alpha 1 mRNA
and bone mineralization (Stewart TL et al, 2005 & Mann V et al, 2003). Several
retrospective meta-analyses of published studies concluded that carriage of the T
allele is associated with reduced BMD at the lumbar spine and femoral neck and with
vertebral fractures (Ralston SH et al, 2006b; Mann V et al, 2003; Efstathiadou Z et al,
2001 & Mann V et al 2003). However, two promoter polymorphisms of COL1A1 (-
1997G/T; rsl 107946 and -1663indelT; rs2412298) were recently found to be in strong
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LD with the Spl polymorphism. These polymorphisms were found to interact with
each other and with the Spl polymorphism to regulate BMD in a small study of
Spanish post-menopausal women (Garcia-Giralt N et al, 2002). Also they were found
to regulate reporter gene transcription in a promoter-reporter assay (Garcia-Giralt N et
al, 2005). The -1997G/T promoter polymorphism has been studied in relation to BMD
in other populations and family based studied with mixed results although most of
these studies have been of limited sample size (Yamada Y et al, 2005 & Liu PY et al,
2004).
In this study therefore, I examined the roles of all three polymorphisms of the 5' flank
of COL1A1 and their haplotypes in the determination of BMD and fracture, the roles
of two promoter polymorphisms in DNA-protein binding and gene transcription and
the roles of three polymorphisms and their haplotypes in mechanical properties of
bone.
In chapter 3, I demonstrated that all three polymorphisms at 5' flank of COL1A1 gene
were associated with BMD at lumbar spine and femoral neck, and the haplotypes
defined by them had stronger effects on BMD in a large cohort of Scottish
perimenopausal women (N=3225). Homozygote carriers of haplotype 2 (-1997G /-
1663delT / +1245T, "G7T") had reduced BMD at baseline (p=0.007 for LS-BMD;
p=0.008 for FN-BMD), whereas homozygotes for haplotype 3 (-1997T / -1663insT /
+ 1245G, "T8G") had increased BMD (p=0.007 for LS-BMD). I also found that the
three polymorphisms were in strong linkage disequilibrium and the interactions
between the -1997 and -1663 (or Spl) polymorphisms with BMD, which is in
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agreement with Garcia-Giralt N et al (2002) and Bustamante M et al (2007).
Therefore, these 5' flank polymorphisms interact to regulate BMD in this population.
There was no association between any individual polymorphism or haplotype and
fractures (hip / vertebral) probably due to lack of power of the study. Another
interesting finding was that frequencies of some of COL1A1 genotypes and
haplotypes altered with age. This suggests that COL1A1 alleles may be associated
with longevity, but this requires further study.
The possible mechanisms by which these polymorphisms regulate BMD have also
been studied in this thesis. The gel shift and the super-shift assays in chapter 4 showed
that the transcription factors Spl, Nmp4 and Osterix bind to the DNA surrounding -
1663ins/delT polymorphism. The "delT" (7T) allele had greater binding affinity for
nuclear proteins of osteoblasts than "insT" (8T) allele. Since the antibodies to Osterix
and Nmp4 gave the same super-shift pattern and the two binding sites are next to each
other, it is very likely that Osterix and Nmp4 interact with each other and form a
DNA-protein complex.
The Spl protein also bound to the -1997G/T probe, and the "T" allele showed greater
binding affinity than the "G" allele. However, when nuclear extracts from osteoblasts
were used as a protein source, there was no evidence of Spl binding. It is possible that
other GC-box trans-acting proteins in nuclear extracts are in competition with Spl to
bind the cis-acing element. For the -1997 G/T site, allelic differences in binding




To further clarify the contribution of allelic binding differences to gene transcription,
luciferase reporter assays were performed. Eight reporter vectors containing different
haplotypes and a negative control vector (pGL-3 basic) were con-transfected with
pRL-TK vector into osteoblast-like cells (HOS TE85). These reporter vectors were
engineered to produce fused COZ/yli-luciferase protein. All reporter vectors had
significantly higher luciferase activities than pGL3-basic which lacks eukaryotic
promoter and enhancer sequences (p<0.001). The pGL3-G7T (haplotype 2) vector had
the highest gene transcription and differed from all the other vectors (p<0.001). The
luciferase activity of pGL3-T8G (haplotype 3) was the second highest and also
significantly differed from all the other vectors. The pGL3-T7G vector had the lowest
luciferase activity. The luciferase activity of different haplotypes was not mediated by
any individual polymorphism. Therefore, these results suggested that the COL1A1 5'
flank polymorphisms interact with each other to regulate reporter gene transcription.
I also demonstrated that these polymorphisms were associated with reduced bone
quality ex vivo by performing biomechanical tests on trabecular bone samples from
femoral heads obtained from hip fracture patients. Not only the individual
polymorphisms but also haplotype 6 (T7T) were associated with bone strength
(p<0.05). Haplotype 6 was the second most common allele in these bone samples
(12.24%), but very rare in the general population (0.03%). This is probably because
the bone samples were derived from a highly selected group who had suffered from
osteoporotic hip fractures and underwent hip replacement surgery, whereas the
APOSS population is a randomly selected population of normal healthy women.
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In summary, the studies suggest that haplotypes, rather than individual
polymorphisms in the 5' flank of COL1A1 predispose to osteoporosis, by affecting
DNA protein interactions, gene expression and bone strength. Future work is required
including repeating the gene targeting and the subsequent work on animals, further
analyzing of COL1A1 gene transcription by CHIP assays and studying the 5' flank
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Appendix 1 Primers Used for Sequencing of Targeting Vectors
1.1 Primers Located in Mouse collal Promoter Region













MouProSeql 1R TCCAATCACTCTCTCCAT 3687
MouProSeql2R TAGTACTGAAGGTGAGCT 4306
MouProSeql 3R AACTCAGAGCTCAGCACT 4802
MouProSeql 4R CAATCACCAGTTCATACC 5394
MouProSeql 5R TGGGATAATTGATGAAGT 5822
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1.2 Primers Located in 5' Flank ofHuman COL1A1 Gene



















1.3 Primers Located in Mouse Exons (2-22)












MouExSeql 1R TGTGACTTCCCGTTTTGT 10645
MouExSeql2R CCTGGCTTTCAATTTACC 13186
MouExSeql 3R CTGGTGAACCTGGCGAGC 13785
MouExSeql 4R TGTAGGGGGAAGCTGGCA 14396
MouExSeql 5R TGAATGACCTGTGCCCAA 15034
MouExSeql 6R CATCC-ACAGGGTCCCACC 15575
MouExSeql 7R CCTTGGGCTAAAATGTCT 16164
MouExSeql 8R AGGAGCCCGTGGTGAGCC 16704
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1.4 Primers Located in pBlueScript II (-) Plasmid
Name Sequence (5'—>3') Position in targeting vector
M13F GTAAAACGACGGCCAGT 17000
M13R GGAAACAGCTATGACCAT 2136
1.5 Primers Located in Loxp-neo-loxp Cassette







Appendix 2 The Full Sequence of Targeting Vector
1 GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG TTTATTTTTC TAAATACATT
61 CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT GCTTCAATAA TATTGAAAAA
121 GGAAGAGTAT GAGTATTCAA CATTTCCGTG TCGCCCTTAT TCCCTTTTTT GCGGCATTTT
181 GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT AAAAGATGCT GAAGATCAGT
241 TGGGTGCACG AGTGGGTTAC ATCGAACTGG ATCTCAACAG CGGTAAGATC CTTGAGAGTT
301 TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA AGTTCTGCTA TGTGGCGCGG
361 TATTATCCCG TATTGACGCC GGGCAAGAGC AACTCGGTCG CCGCATACAC TATTCTCAGA
421 ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT TACGGATGGC ATGACAGTAA
481 GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC TGCGGCCAAC TTACTTCTGA
541 CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA CAACATGGGG GATCATGTAA
601 CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT ACCAAACGAC GAGCGTGACA
661 CCACGATGCC TGTAGCAATG GCAACAACGT TGCGCAAACT ATTAACTGGC GAACTACTTA
721 CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC GGATAAAGTT GCAGGACCAC
781 TTCTGCGCTC GGCCCTTCCG GCTGGCTGGT TTATTGCTGA TAAATCTGGA GCCGGTGAGC
841 GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG TAAGCCCTCC CGTATCGTAG
901 TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG AAATAGACAG ATCGCTGAGA
961 TAGGTGCCTC ACTGATTAAG CATTGGTAAC TGTCAGACCA AGTTTACTCA TATATACTTT
1021 AGATTGATTT AAAACTTCAT TTTTAATTTA AAAGGATCTA GGTGAAGATC CTTTTTGATA
1081 ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTCGTTCCA CTGAGCGTCA GACCCCGTAG
1141 AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTTCTGCG CGTAATCTGC TGCTTGCAAA
1201 CAAAAAAACC ACCGCTACCA GCGGTGGTTT GTTTGCCGGA TCAAGAGCTA CCAACTCTTT
1261 TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA TACTGTCCTT CTAGTGTAGC
1321 CGTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACCGCC TACATACCTC GCTCTGCTAA
1381 TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG TCTTACCGGG TTGGACTCAA
1441 GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC GGGGGGTTCG TGCACACAGC
1501 CCAGCTTGGA GCGAACGACC TAGACCGAAC TGAGATACCT ACAGCGTGAG CTATGAGAAA
1561 GCGCCACGCT TCCCGAAGGG AGAAAGGCGG ACAGGTATCC GGTAAGCGGC AGGGTCGGAA
1621 CAGGAGAGCG CACGAGGGAG CTTCCAGGGG GAAACGCCTG GTATCTTTAT AGTCCTGTCG
1681 GGTTTCGCCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG CTCGTCAGGG GGGCGGAGCC
1741 TATGGAAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT GGCCTTTTGC TGGCCTTTTG
1801 CTCACATGTT CTTTCCTGCG TTATCCCCTG ATTCTGTGGA TAACCGTATT ACCGCCTTTG
1861 AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG CAGCGAGTCA GTGAGCGAGG
1921 AAGCGGAAGA GCGCCCAATA CGCAAACCGC CTCTCCCCGC GCGTTGGCCG ATTCATTAAT
1981 GCAGCTGGCA CGACAGGTTT CCCGACTGGA AAGCGGGCAG TGAGCGCAAC GCAATTAATG
2041 TGAGTTAGCT CACTCATTAG GCACCCCAGG CTTTACACTT TATGCTTCCG GCTCGTATGT
2101 TGTGTGGAAT TGTGAGCGGA TAACAATTTC ACACAGGAAA CAGCTATGAC CATGATTACG
2161 CCAAGCGCGC AATTAACCCT CACTAAAGGG AACAAAAGCT GGAGCTCCAC CGCGGTGGCG
2221 GCCGCTCTAG AACTAGtGGA TCCCAAGATT AGGGCAGACC CTCATTCACA ACCCGGTCTG
2281 TTGCAGTCTT TGGTTATGAG GTTTATTTCC GTCTCTTTAT CAGATGTGGG AATCCACAGG
2341 GTCTCTGCAG CTCGCTGAAT CCCAAGAGGA CCAAGAGGAT GAACCCTTGA TGTTTAAGCA
2401 CTGTGGGGTG ACTACAACAG AAGTGAACCC TAACTTCTCA GTAGAGGAAG CCGGGGCAGG
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2461 GGGGGGGCAA AAACCCTGTG GGGAAGAACA TGGGACCATC ATATCCTCCT TTATACTGGA
2521 TTCTTTTTTT TTTTAAGATT TATTTATTTA TTTTATGTAT ATGAGTACAC TGGAGCTGTA
2581 CAGATGGCTG TGAGCCTTTA TGTGGTCATT GGGAATTGAA TTTTTAGGAC CTCTGGTTGC
2641 TCTGGTCAAC CCTGCTCCCT CCAGTCAGCC CTGCTCGCTC AGGCCCAAAG ATGTATTTAA
2701 TATTATACGT AAATACACTA TAGCTGACTT CAGACCCACC AGAAGAGGGC ATAGGATCTC
2761 ATTACAGGTG GTTGTGAGCC ACCATGTGGT TGCTGGGATT TGAACTCAGG ACCTTCAGAA
2821 GAACAATCAG CGTCTCTTAC CCGCTGAGCC ATCTCACCAG CCCTATACTG GATTTTTTCT
2881 GCTGCAAGCC ACATTCTGTT CAGCCAGACC CCTAAGGAGG GATCAAAGGA GGCTGGTACA
2941 TAAGTGTAAG ATTGAAGGCA TCTGTGGCTG AGGCTTACCT GGAGAATGGA GACAATATCT
3001 GGATAGAGCC CCTGACTCAA ACACCATCTC CTCACCCAGC TCTACATAGA CACACTCTAA
3061 AACTTGAAAA TCAAGCTTCA TTGGATTCTC TGCATTTATA TCCTTGTAGT TCAAGCTGGA
3121 ATCTGGTGGT GATACAGGAC CCTTAGGCCT CTTCCCCTCC CGAAGGCAAC TGGACATCCT
3181 TCTCTTGCTG AGAAAGGATG CAGATACTGG AGAACTGGAG ACTTGGGAGC TGCGATGCCA
3241 AGCAAGGATG TTAGAAGAGA AGACAAAGGG GAAAACACTG CATGGGTGGA GGGGTGGGGC
3301 AATGGACAGA GGGAAAGAGA GGACACTGTG AAAAATGCAT GAAAAGGAGA CTTCGAGGGA
3361 GAGGAGCAGA AGGGCAGGGG GAAGAGAAGT GCAAAGCAAA GGGGGGGGGG CGGAGAAAGG
3421 TGAAGCTAGG GAGGAATGAG CGAGTCCCTT AGGGACTAAA TGAAGGTCCA GGCACTTGAT
3481 GCCTCCAGAA TTCAGATAAC AGGAAGGAGG GGTCTGACGT CTCCTCTAAA GAGGAGTAAA
3541 GAAGAGCAGG AGTTTTCCTT CAGAACCTCC CCTCCGTCCT TTTGACATAC CTGTATCCCC
3601 ACTCACTTTA TGGCTGAAGG CTTTCTTTGC CCGCCATGTT TTACTGAGCT CTGCAGTTCT
3661 CTTTGGAGCA CCCACCTCTT CCTATTTCCA ATCACTCTCT CCATCCCTCT CTTCCTTCCC
3721 TTCTCCCTCA ATAGGCCATT CTTGTCCCAT CTCCTGTGTG TGGTCCTCTT CTCCCAAATC
3781 CTTCACTCTG AGGTGGCTCG AGACTTGGCT CTAGCCCTCA GCTCCCCCGC CCCCATGCTT
3841 TCTCTGGGGA CAACTACACA CACACACACA CACACACACA CACACACACA CACACAGCTT
3901 CAGTCTCCAT GTTCCTGCGG TCCCCCCCCC CATGTTTCTT CTCTAAAATC TAGAATGCAG
3961 AAGCCAAGGA. TTTCCTTTTC TCTCTTCTCT TTCTTTTTTC CTTTTTCTCT TTCCTCCCCC
4021 CCCCCCAAGA TGGAGTTTCT C'TGTGTAGCC CTGGCTGTCC TGGAACTCAC TCTATAGACC
4081 AGGTTAGCCT CAAACTTAGA GATCTGCCTG CCTCTGGCTC TTGAGTGCTT AGAATTGAAG
4141 GTGTAAACCA CTGCTACCTG ACAGAGGATT TCTTACACAT GTCTGACTGG AGCGCTAAGA
4201 GGCATCAAAC TCAGCATAAG CAGACCTGAA CTTGTTGGCT TTCCCTTTAA ATCAGCCAGG
4261 AAAGGAGGGA TGGGGAGAGG AAGGAAATGC TCAGAAGGAA AGGAG'TAGTA CTGAAGGTGA
4 321 GCTGGAGGAA CCCAGATCGG GCCATACAGA AGAAAAAGGA GAAGCAACGC ACCCACACAC
4381 CTAGGCTCCA CCCACAGATG TTGCTCTGGG TACCTCTGTC TGAAGACTGT AGGGCTTTGT
4441 GATGGAGGGT GGGGTATGCT TCATGCCCAT GGCCTTTACT CCAGACCTAA ATGCCCACCC
4501 CCACATACAG CTGCTCTTTT TCCCTGCCCT TCTCCCGAGA GACCAGCTCT CCATCCCTGG
4561 TCTGCAGCCA AGGCTGGGGG CAGAAGAACT TTCTGGAGGA TCTGAGTGAG AAAAGCAAGA
4621 GAGCCTCGAA TAGGGACTAG AACCACTGGG GCGGCAAGTG CAGAGGAGAC CGGGTGTGTG
4681 CCCTACCTGC TACATTTATA CCTAGGCTGC CTCTGCTTCT GTTCCACACC GTAGAGTCCA
4741 GACGGGTCTT CTCCCTCCCT CGTGGGGGGG GAAACATTTG GGAAAATTTG GAGAGAGACA
4801 GAACTCAGAG CTCAGCACTT TCCTCTTTCT GTTTTTCTTC TTGAGGAATT TTTTTCCCCC
4861 AACGGCTGAT GACTTTACCA TTCTTGGGGG TGGGGGGGGG TGGAGATTCT GGCTTTTGCT
4921 CTCCCTACAC TCCAAGTGCC TGACAAAGCC CTACATTCCT CAAAAAGCCA GAGCTTTAGA
4981 GTTTCCTAAA GATGAGGTGG CGTGGCGTGG CGTGGCGTTC TCCTCCCTTC CCAGCTCCAA
5041 CTCCCCCTCC CCCAGTCTCC AGCCCTCAGC CCAGCCAGGG AGGCCCCGCC AGGCTGGGAG
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5101 GAGACCCCAA GCACATTCTT CCTCTCTCTG TCATGCTGCA GAAATTAAAG ACACATCTCT
5161 GAGCTGGGCA CCCGCCAATC GTTTCAAGTA GAGAGTGGCA GAGGAGGTCC TGAGCTGCAG
5221 CTCCATGCCA CGTGTAAAGG AAGCTTGGAA CCCATTGCCT TCAACTCCTG GGGCAAAGGC
5281 CTGGAAATCA GACACAGGGT GACGGCTGTC ACTGAATGCA CACACACCAA TCTCCCCCAC
5341 ACCCATTCTA GTGGTCTCCA AGTTTCCATC AGAACCTCAG GCCCTTAATG TAGCAATCAC
5401 CAGTTCATAC CTGTTAGGCT CTTGTCTCTT CTTCCAGGTG AGCCTTGGGG ATGCTAGATT
5461 GGGAGCAGGG AAAGGGAGCT TTGGATAAGT GCTTTTCTGA TACAAAACCC AACAAAGGGT
5521 GAGCAGATCA CACCGCGCGC GCGCGTGTGT GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT
5581 GTGCGCACGC TTCGTGGCAT TCTACCCTGG ACACAGCCAC CTCAAACACC TGTTCCCTCT
5641 GAGGTACACC ATCCTTGTCC ACTGTTGGGG AGTGGGGCAT CCTTTGGAAC TGACCACAGT
5701 GGAAGGCAGG ACTTTGGTGA GTTCCGGAAC TACCATCTCA GCATCTCAGC CCCAGCCTTG
5761 CCCTACAGGC ACTGGCATTA GGCGGGGGCA GATCCTGGGC CACAAGTTAC TGCCACATGG
5821 TTGGGATAAT TGATGAAGTC CTGTCCTTCC ATTGCTGTCT CCAGCTCTGC TTCTCTGGAA
5881 ACTCTATATT TTCCCTTTAA TTATAGCCCC TGCAGTCTCC CTCCGCCACC CCACCCGCAC
5941 TGCTCGGCCT AGCTGCCCAC GGCCAGCGAC GTGGCTCCCT CCCCTTCTGT TCCCTTGGTC
6001 tttttttttt ttccctttgc cttcgttgca caaaactagc tcagggaggg cgtgaagggg
6061 GGGGGGGGAG CAATGGAATC TTGGATGGTT TGGAGGAGGC GGGACTCCCT GCTTCCACGT
6121 TTACAGCTCT AAAGAAGCCG GTGGGGGAAG TGATACAGGA TGTCTATGGG CCCTGCAAGG
6181 AGACCCCAGT GCCTTCCCAC ACCACCacta gTCACTAACC CTCATACTAC CAAGCCCTGC
6241 GGCACCCTGC CCTAGACCAC CACTCTAAAT GTCTGTTCCC TCCAAAAACA GGACCCCTGT
6301 CGCCTATTAG GGAGGGGTTC TCTTGGAACT GACCCACAGT AGGGGGCAGG ACTTTGGTGG
6361 gttcaagaac tgccatctca gcacctcagc cccctagtcc tgccctgcag tcgctggcac
6421 taggcggggg cagaccctgg gccacaagtt gctgccacat ggtcgggata attgatgaag
6481 gtccatccct ccattgctgt ctccagccct gcctctctgg aaactctata ttttcccttt
6541 aattatagcc cctgcagtct ccctctgctg ccccacccgc accgctcatc ctggctgccc
6601 ACGGCCAGCC GGCCAGCCGA cgtggctccc tccccttctg ttcctttttt ttcccctttg
6661 CCTTCGTTGC ACAAAACCAG CTGGGGGAGG GCGTGGAGAG GGGCGGGGGG AGGCAATGGA
6721 ATCTTGGATG GTTTGGGGGA GGCGGGACTC CCCGCTTCCA CGTTTGCAGC TCTGGAGCAC
67 81 CCGGGGTGGG GAGCTGCACA GGAGGGAGAG aaatgAACAG GGCACTGCAA GGAGACCCCC
6841 AGGCCTTCTC TCAGCCCTAC AGAGTTTCTC AGGACGAGGT AGATTGGGGT TGAGGCAGAG
6901 CCTTGTTGGG GGAATGGGAC ATGGAGGAAG AAAGGACGTG GAGTTCTAGA GCCATCTTCC
6961 TTAGATATAG CCTGCTGTCC TTCGGGTCCC CAGACCCTTT CAGAGTGTAC AGATGATTCT
7021 CTCTGGTTCC TAAGGCATAG AGCAATGACC GGGATTTTCA AGAAAGAGAT GAGGCAGTGG
7081 GAAGTAGCCC CTAAAACAAA GTCAATCATC CTCTGCAGCC CATCCCACAC CCCCAAAGGA
7141 AAGTTTCACC CAGACACCCA AAATATCCCA TACATCCCCA ACACTGAGTC CAGGTACAAC
7201 TGGAGAAGGG GCTTTATGCA GCTCCCAGAA AGACACCCCT TTAGCTAAGT GCCCTCCCTC
7261 CACCCAGGTT CTCTCTGGTT TGACTGTGCT GGGAAGGAGG GTCTCTAAGC AGCCCCTGGC
7321 CACAGCCATG GCAAACAAAA CTCTTCTCTA AGTCACCAAT GATCACAGGC CTCCCACTAA
7381 AAATACTTCC CAACTCTGGG GTGGAAGAGT TTGGGGGATG AATTTTTAGG GGATTGCAAG
7441 CCCCAATCCC CACCTCTGTG TCCCTAGAAT CCCCCACCCC TACCTTGGCT GCTCCATCAC
7501 CCAACCACCA AAGCTTTCTT CTGCAGAGGC CACCTAGTCA TGTTTCTCAC CCTGCACCTC
7561 AGCCTCCCCA CTCCATCTCT CAATCATGCC TAGGGTTTGG AGGAAGGCAT TTGATTCTGT
7621 TCTGGAGCAC AGCAGAAGAA TTGACATCCT CAAAATTAAA ACTCCCTTGC CTGCACCCCT
7681 CCCTCAGATA TCTGATTCTT AATGTCTAGA AAGGAATCTG TAAATTGTTC CCCAAATATT
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7741 CCTAAGCTCC ATCCCCTAGC CACACCAGAA
7801 TCCCAGCTTC CTCTGTTTTG GAGAGGTCCT
7861 TCTTGCCAGG ATATCAGAGG GTGACTGGGG
7921 CCCAACCCTT CCACCTTTGG AAGTCTCCCC
7981 CTTCTAGATT GGAGGTCCCA GGAAGAGAGC
8041 ACGCCATTCT GAGGACCCAG CTGCACCCCT
8101 GGGGGCTGGG GAGGCAGAGC TGCGAAGAGG
8161 CCTCCCCCTC TCCATTCCAA CTCCCAAATT
8221 GGGGCACGGG CGGCCGGCTC CCCCTCTCCG
8281 GGACAGTATA AAAGGGGCCC GGGCCAGTCG
8341 CGGAGCAGGA GGCACGCGGA GTGTGAGGCC
8401 GCCACAAAGA GTCTACATGT CTAGGGTCTA
8461 CTGCTCCTCT TAGCGGCCAC CGCCCTCCTG
8521 actctgggGA ATTCGGGAGT GCAAGGATAC
8 581 GGCCGCGGCT TAAAACGAGA CGTGGATGAT
8641 GAGGGCTCTT CCTCGGCGCC CTGAGACAGG
8701 TGAACGCGCC CCGGGAGCGG GAGGTGAGGG
8761 AATCCCGAGC GCGCAACCGG GGAAGTGGGG
8821 AAGATGGGAT GGGGGCGCCG AGCGGGGCAT
8881 AGGCCGTGGG ATGATTCATA AGGAAAGATT
8941 GCCGTGGGGG TGCTGGGCAG CCGCGGAGGG
9001 AAACTTTGGC GCGGACTCGG CGGGGCGGGG
9061 CACTGCGTCT CCCGGTCCAA CGCTTACTGG
9121 ATTGCTGGGT GCGGACCCCC ACCTCTAGAT
9181 CAAGCCTCTT AAAGAGGTAG TCGGGCCGGT
9241 AGCGTTGCCC GACACCTAGT GGCCGTCTGG
9301 TAACTTCTGG ACTATTTGCG GACTTTTTGG
9361 GGCTGGCTTT GGGGGACTGG GGATGGCCCC
9421 GGAGGTTAGG GTGTCTCCTA ATTTTGAGGT
9481 CAATCAGCCG CTCCCATTCT CCTAGCCCCG
9541 GGGCGGGATG AGGGCTGGAC CTCCCTTCTC
9601 CGCAAGCCAC TCCCCACGAG CCTGCCCTCC
9661 CTCCCCCTCT CACCCTGTGG TTTTTATTTC
9721 GGAGTTGGAA GCCACCGCGG ACTAAAGCTT
9781 ACAGCCTCCC TGGCCAGGCG CCTCGGCGCT
9841 TATCAAGCTT ATCGATCCCT GGTGCTCCGG
9901 GTCTCTTCCC ATTTGCTCAG TCCCTGAAGT
9961 CAATGGTGAG ACGTGGAAAC CCGAGGTATG
10021 TGTGTGCGAT GACGTGCAAT GCAATGAAGA
10081 GGGCGAGTGC TGTGCTTTCT GCCCGGAAGA
10141 GGAGGTTGGA GTCCCTCCCT CGCCTATGTC
10201 AGTAAATTTA CTTCTAACTG AACGTTTTTC
10261 GGAGTCGAGG TAATAATCTG CTCCCTACTT















































10381 CCCCACAGGG ACCCAAGGGA GACCCTGGCC CCCAAGGCCC AAGGGTAAGC ATCGTATTCT
10441 AAATGAGCTG GGAAACTGGA GGGGGCGTGG CTCTGATTTG TGCTCATAGC AGCCCCCTCC
10501 GTCTCTTGGT GCAGGGACCC GTTGGCCCCC CTGGACGAGA TGGCATCCCT GGACAGCCTG
10561 GACTTCCTGG TCCTCCTGGT CCCCCTGGGC CCCCCGGACC CCCTGGCCTT GGAGGAGTAA
10621 GTAGATCTTG GAGACCCCAG AGGGGTGTGA CTTCCCGTTT TGTTTGTTTG TTTGTCTGTC
10681 TGTTTGTTTG TTTTTCTTTG CTTTGGTTTT GTCAGACATA GTTTTCTATT TTAAAATAAT
10741 TATAAACTTA CAGAAAATAG AATAGAATAG AACTTCTATA CACTCTTCAA CACAACCGCT
10801 TTGCCACTTT CTGGGCACCC AGTTCTCTAT GTCGCTGTAT GTCCTGGACC ATTTGAGACA
10861 TAAGTTGCCA AGAACGTGCC CGTGACTTAC GATCTTAAgG ATCAATTCCG ATCATATTCA
10921 ATAACCCTTA ATATAACTTC GTATAATGTA TGCTATACGA AGTTATTAGG TCTGAAGAGG
10981 AGTTTACGTC CAGCCAAGCT TGATATCGAG GGCCCCTGCA GGTCAATTCT ACCGGGTAGG
11041 GGAGGCGCTT TTCCCAAGGC AGTCTGGAGC ATGCGCTTTA GCAGCCCCGC TGGGCACTTG
11101 GCGCTACACA AGTGGCCTCT GGCCTCGCAC ACATTCCACA TCCACCGGTA GGCGCCAACC
11161 GGCTCCGTTC TTTGGTGGCC CCTTCGCGCC ACCTTCTACT CCTCCCCTAG TCAGGAAGTT
11221 CCCCCCCGCC CCGCAGCTCG CGTCGTGCAG GACGTGACAA ATGGAAGTAG CACGTCTCAC
11281 TAGTCTCGTG CAGATGGACA GCACCGCTGA GCAATGGAAG CGGGTAGGCC TTTGGGGCAG
11341 CGGCCAATAG CAGCTTTGCT CCTTCGCTTT CTGGGCTCAG AGGCTGGGAA GGGGTGGGTC
11401 CGGGGGCGGG CTCAGGGGCG GGCTCAGGGG CGGGGCGGGC GCCCGAAGGT CCTCCGGAGG
11461 CCCGGCATTC TGCACGCTTC AAAAGCGCAC GTCTGCCGCG CTGTTCTCCT CTTCCTCATC
11521 TCCGGGCCTT TCGACCTGCA GCCAATATGG GATCGGCCAT TGAACAAGAT GGATTGCACG
11581 CAGGTTCTCC, GGCCGCTTGG GTGGAGAGGC TATTCGGCTA TGACTGGGCA CAACAGACAA
11641 TCGGCTGCTC TGATGCCGCC GTGTTCCGGC TGTCAGCGCA GGGGCGCCCG GTTCTTTTTG
11701 TCAAGACCGA CCTGTCCGGT GCCCTGAATG AACTGCAGGA CGAGGCAGCG CGGCTATCGT
11761 GGCTGGCCAC GACGGGCGTT CCTTGCGCAG CTGTGCTCGA CGTTGTCACT GAAGCgGGAA
11821 GGGACTGGCT GCTATTGGGC GAAGTGCCGG GGCAGGATCT CCTGTCATCT CACCTTGCTC
11881 CTGCCGAGAA AGTATCCATC ATGGCTGATG CAATGCGGCG GCTGCATACG CTTGATCCGG
11941 CTACCTGCCC ATTCGACCAC CAAGCGAAAC ATCGCATCGA GCGAGCACGT ACTCGGATGG
12001 AAGCCGGTCT TGTCGATCAG GATGATCTGG ACGAAGAGCA TCAGGGGCTC GCGCCAGCCG
12061 AACTGTTCGC CAGGCTCAAG GCGCGCATGC CCGACGGCGA TGATCTCGTC GTGACCCATG
12121 GCGATGCCTG CTTGCCGAAT ATCATGGTGG AAAATGGCCG CTTTTCTGGA TTCATCGACT
12181 GTGGCCGGCT GGGTGTGGCG GACCGCTATC AGGACATAGC GTTGGCTACC CGTGATATTG
12241 CTGAAGAGCT TGGCGGCGAA TGGGCTGACC GCTTCCTCGT GCTTTACGGT ATCGCCGCTC
12301 CCGATTCGCA GCGCATCGCC TTCTATCGCC TTCTTGACGA GTTCTTCTGA GGGGATCGAT
12361 CCGCTGTAAG TCTGCAGAAA TTGATGATCT ATTAAACAAT AAAGATGTCC ACTAAAATGG
12421 AAGTTTTTCC TGTCATACTT TGTTAAGAAG GGTGAGAACA GAGTACCTAC ATTTTGAATG
12481 GAAGGATTGG AGCTACGGGG GTGGGGGTGG GGTGGGATTA GATAAATGCC TGCTCTTTAC
12541 TGAAGGCTCT TTACTATTGC TTTATGATAA TGTTTCATAG TTGGATATCA TAATTTAAAC
12601 AAGCAAAACC AAATTAAGGG CCAGCTCATT CCTCCCACTC ATGATCTATA GATCTATAGA
12661 TCTCTCGTGG GATCATTGTT TTTCTCTTGA TTCCCACTTT GTGGTTCTAA GTACTGTGGT
12721 TTCCAAATGT GTCAGTTTCA TAGCCTGAAG AACGAGATCA GCAGCCTCTG TTCCACATAC
12781 ACTTCATTCT CAGTATTGTT TTGCCAAGTT CTAATTCCAT CAGAAGCTGA CTCTAGAGCT
12841 TGCGGAACCC TTAATATAAC TTCGTATAAT GTATGCTATA CGAAGTTATT AGGTCCCTCG
12901 AAGCTTATCG AcaattGCAT TCCATTGTCT CATTCCTTTG GTTCCCACAA ATGTAGACTG
12961 TTTCTGAGAC TCTATGTCAT CCTTGACTTG GGAAGGTTTT GAAGAGTCTG GCTGTTGGGC
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13021 AGAGGGTGTT ATTTTATAGG TTCTTCTGTA GTTTGGGATT GTCTGGTTAG ATTAAATTCA
13081 GTCGAGGTGT CTGGTACAGG AATATCTTAC AGGCTATATT GCTGTCTCCC TGAGTTAATT
13141 ACTTCCGGAA GCCTACATCC GTTTGTCCCA TTACTGCTAA TGCCTCCTGG CTTTCAATTT
13201 ACCATCCAGA GTCCAATTTC TCACACATTC TCTCTTGTTT TTCTAGAACT TTGCTTCCCA
13261 GATGTCCTAT GGCTATGATG AAAAATCAGC TGGAGTTTCC GTGCCTGGCC CCATGGTGAG
13321 CCACCAGGGG GAGCAGTGAC CACACAGAGG ATAGGCATCC CGAAGAGAAA GGCCAATGAT
13381 GTCCTGCAAG GGGGTGGTAC AGATAGCTTG GGAGGTAAAG GCCACCTTAG GGACTTGAGA
13441 TCTACAGTAG ATGCAAGTCA GACAGTGATC CCCACAGGAA GAGGTAGAAA CAGATTTCTG
13501 CCATACTGCC TTTATTCACA GATATCAAAA GCCCCTCTTT TTCCTTCTGT AGGGTCCTTC
13561 TGGTCCTCGT GGTCTCCCTG GCCCCCCTGG TGCACCTGTA CGTATCTAAG GGTCTTCATG
13621 GATCATTTTG GGCATGTACT GTTGCGGGGG TGGGGGAGAT GGGGATGAGG GCAGAAGGCT
13681 GGTAGACATC TCTTGTAAGA GGGAGACAGC CCGGGAGGAA CCTGCCTTTC TGAGCCTATC
13741 CTTCTCTCGT GTTCTTCAGG GTCCACAAGG TTTCCAAGGC CCCCCTGGTG AACCTGGCGA
13801 GCCTGGCGGT TCAGTAAGTT AGTCCTCCAT GCCGACACAC CTCCATCTCC ACAAATTCTC
13861 CTATGGAAAG TCACCTGTAC TGAGAGAGGG GTAGCTTGTC ACCTCCTCGC TCCAGTCTTC
13921 CTCCTTATTG TCTCTCATCT AAGAGTTCTA AATGCTTCTC CTGTCCCCTC TAGGGTCCAA
13981 TGGGTCCCCG AGGTCCCCCT GGCCCTCCTG GCAAGAATGG AGATGATGTA AGTACCCCTG
14041 GGGAAAGACA CTATCAAATC CTGTGGCCTT CTCTATGTGG GTCCTGAAAT CTTCCCAGCA
14101 GGGTCTCAGC ACCAATAACC AGGAGAAGTC AAGATGACCC TTGGCAGTCA TCTTTCCACT
14161 GAATAGAATG TTTTAGTGAG GCAGCCTCCA TCCCCACTTG CATCCTCACC CCCATCCATC
14221 TCCATCCCTT GGAGTAATCC AGGTTTAAGA GTTCTGGGTG AGCAGATGTG GAAATGAATA
14281 CACCACTGTA GATATAAACT GAGTTTTAGG TTAGAAGTTA GATTTGGTCC CTTAAACTGA
14341 ATCCACCCTT C.AATGGGGGA TAGAGGAGCA TTGCCATAAT GGGCTTTTCT CTCTCTGTAG
14401 GGGGAAGCTG GCAAGCCCGG CCGTCCTGGT GAGCGTGGAC CTCCTGGACC TCAGGTGAGC
14461 AGGATGTGAG GGTGGGCCCA GGGCTTACTG CACTGGGGAT ACATTTAGGA GCAATAGTCA
14521 CAGAGCCCTT CCTTCTGACA CCCTTCCAAG TCCTCATTTG CCTTTCTCTC CAGGGTGCTC
14581 GTGGATTGCC TGGAACAGCT GGCCTCCCTG GAATGAAGGG ACACCGAGTA AGTCTCTTTG
14641 GAGTCACTGA AGCTCCCAAA GCCCCAAGTC ACCATTCTCT CCCCTTCCCT AAGAGATCCT
14701 GTTGTGAATC ATGTTAGATG GTAGCTAGAG ATATCTCAAA GGTCATAGGT TAGACATCTG
14761 AAAGGACTTC CTTTTGTGGG GGAAGAAGTC CCAATAAAGA GACTGGCTGG ATGATAGGTG
14821 AATTGGGATC TACTTTAGCT CAGAGACAGA GAGATGGCTG GAGATCTTCC AAAAATTATT
14881 GTCAAATCCA TGTGGGTGTC AAAGTGGTAT ACTCCCCCAA CAGGGGTCTT ACTTCATCTC
14941 TTTTCCCCCC CATTAAGGGC TTCAGTGGTT TGGATGGTGC CAAAGGAGAT GCTGGTCCTG
15001 CTGGTCCTAA GGTAAGATAC TGATGAGAGG TCCTGAATGA CCTGTGCCCA ACAGTCCTAC
15061 TATGAATGCT TCACTCTGTT CTCTGTTCCT AGGGAGAGCC CGGCAGTCCT GGTGAAAACG
15121 GAGCTCCTGG CCAGATGGTA AGTAGGCCAG CTTGAGTGAC AGGGGGCGCT CCAAGAGGGA
15181 GGCTGCAGAA GAGGGTGTCT CCATCTCATT CGACCTCCCT TGGTTTCGTT TTTAGGGTCC
15241 CCGAGGTCTG CCCGGTGAGA GAGGTCGCCC TGGACCTCCT GGCACTGCTG TAAGTACTCC
15301 TGCCCCCCTT GGATGCCCCG GGCTCTGGTT GCAGTTCCCT GGGGACTAAG GGTACTGGCC
15361 ACTGCTCAGG GGACATAATT GGGCTTCCCC TCTCTCTTAC AGGGTGCTCG CGGTAACGAT
15421 GGTGCTGTTG GTGCTGCTGG ACCCCCTGTA AGTATGGCCT TGACTTTGAG TATGGGAGTA
15481 GGGTGAGACC TCAGGGTCAG CTCTTGGGGC TGACATCAAC TTTTGAAACT TAGAAGCTCT
15541 TAGTCTCCTC CACCTTGTAG CTAAACTTCC ATTTCATCCA CAGGGTCCCA CCGGCCCCAC
15601 TGGCCCTCCT GGCTTCCCTG GTGCAGTTGG TGCTAAGGTG AGGCACGTTC TTTCTTTGAA
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15661 CATGATTGTC ATAGGCAATG GGCTAGGCAT CACCCAGATC AGAGAAGCCC AGGGTGGCAA
15721 GAATGAAGCA CACTCTACAA TCCTGGACTC AATCCTGGTG TCCCCTTCCT AGCTCTCAAA
15781 GTCCTCGTCC TTGCTCCCCC GCCCTCCAAC ACCTGACATA CAGAAGTAAT GCTGGCTGCC
15841 CCAATCTGAT TTGTCCTTTC CTCCGATCTA GGGTGAAGCT GGTCCCCAAG GAGCTAGAGG
15901 CTCTGAAGGT CCCCAGGGTG TGCGTGGTGA GCCCGGACCC CCTGGCCCTG CTGGTGCTGC
15961 CGGCCCTGCT GTGAGTGTCC TTCCTGCTGC TGACCCCTGT GCTACCCGCC AACTTCACAG
16021 TTCTAGGCTT TCACTCACCC TCCTTTCTCT ATGTGACAGG GAAACCCTGG TGCTGATGGA
16081 CAACCTGGCG CTAAAGGTGC CAATGTAAGT CTCTAGCAGC CCTCCTCCCA TGAGCCACCT
16141 GCCACCTGCC CCATGCCCTC CACCCTTGGG CTAAAATGTC TGTCCTGACT CCTGCAGGGT
16201 GCTCCTGGTA TTGCTGGTGC TCCTGGCTTC CCTGGTGCCC GAGGCCCCTC TGGACCCCAG
16261 GGCCCCAGCG GCCCTCCAGG TCCCAAGGGT AACAGTGTAA GTATAAGACT CTCCCTTCTG
16321 CCTCGCTTGT TCATGAGCTC CAGGGTGCCC CCTTCTGGAG AAACATACAC TTGCGAGCCA
16381 ACAGAGCAAC TTACCCTCTT TCTCTCCCTA CACAGGGTGA ACCTGGTGCT CCTGGCAACA
16441 AAGGAGACAC TGGTGCCAAA GGAGAACCCG TAAGTCACAC ATCACCCCTT CTCCCCCTCT
16501 GCCCCCAGGG TCAGGAAGCC TCAACGGGGA GCTCCAGGGA GGAAGGGAGC CCCCTCCTCA
16561 TACCCAGAAG TCCTATTACT AGAGGCCAGC ATCATAGGCT CCTGGGCTTG TACTCCCTCA
16621 CCAAGGCTAC TCCCTCTCTG CCCACTCCAG GGTGCTACTG GAGTTCAAGG TCCCCCAGGC
16681 CCTGCCGGAG AAGAAGGAAA ACGAGGAGCC CGTGGTGAGC CTGGACCTTC CGGACTGCCT
16741 GGACCTCCTG GCGAGCGTGT AAGTGTCCCC TGTCCCCTGT GTCTCTCCTC ATTTGCTCTT
16801 AGTGCTTGCC CAGTGCTGTG ATGGTAATAG GCTCACTGGC CTTTTTTCCT TCTCCCTGCA
16861 GGGTGGACCT GGTAGCCGTG GTTTCCCTGG TGCTGATGGT GTTGCTGGCC CCAAGGTAAT
16921 CTCTCTTCCT GGCAGAGAAG CTGACTCCCC CAGCTGCCCG ACGTCACTTC CCTGACAGTA
16981 CGGTTGACCT CGAGGGGGGG CCCGGTACCC AATTCGCCCT ATAGTGAGTC GTATTACGCG
17041 CGCTCACTGG CCGTCGTTTT ACAACGTCGT GACTGGGAAA ACCCTGGCGT TACCCAACTT
17101 AATCGCCTTG CAGCACATCC CCCTTTCGCC AGCTGGCGTA ATAGCGAAGA GGCCCGCACC
17161 GATCGCCCTT CCCAACAGTT GCGCAGCCTG AATGGCGAAT GGGACGCGCC CTGTAGCGGC
17221 GCATTAAGCG CGGCGGGTGT GGTGGTTACG CGCAGCGTGA CCGCTACACT TGCCAGCGCC
17281 CTAGCGCCCG CTCCTTTCGC TTTCTTCCCT TCCTTTCTCG CCACGTTCGC CGGCTTTCCC
17341 CGTCAAGCTC TAAATCGGGG GCTCCCTTTA GGGTTCCGAT TTAGTGCTTT ACGGCACCTC
17401 GACCCCAAAA AACTTGATTA GGGTGATGGT TCACGTAGTG GGCCATCGCC CTGATAGACG
17461 GTTTTTCGCC CTTTGACGTT GGAGTCCACG TTCTTTAATA GTGGACTCTT GTTCCAAACT
17521 GGAACAACAC TCAACCCTAT CTCGGTCTAT TCTTTTGATT TATAAGGGAT TTTGCCGATT
17581 TCGGCCTATT GGTTAAAAAA TGAGCTGATT TAACAAAAAT TTAACGCGAA TTTTAACAAA
17641 ATATTAACGC TTACAATTTA G
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